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Abstract 
Tryptophan 2,3-dioxygenase (TDO) from Xanthomonas campestris (xcTDO) is a 
highly specific heme-containing enzyme from a small family of homologous 
enzymes, that includes indoleamine 2,3-dioxygenase (DO). Both enzymes catalyse 
the dioxygenation of L-tryptophan (L-Trp) to N-formylkynurenine, in the first step of 
the kynurenine pathway and play a central role in the physiological regulation of 
tryptophan flux in the human body 
The structure of catalytically active, ferrous xcTDO in complex with L-Trp has been 
determined to 1.6 A. In addition, the structure of the catalytically inactive, substrate-
free xcTDO has been determined to 2.7 A. These structures show the substrate 
binding interactions at the active-site and reveal that TDO is an induced-fit enzyme, 
with significant reorganisation of the active-site upon substrate binding. A thousand 
fold increase in the L-Trp binding affinity is observed upon heme reduction (Kd 
Fe(Ill) = 3800 tM, Kd Fe(II) = 4tM), disfavouring the mechanistically unproductive 
binding of L-Trp to the oxidized enzyme (1). 
The catalytic mechanisms employed by TDO and DO have not yet been fully 
elucidated and a number of mechanisms for tryptophan dioxygenation have been 
proposed. One proposed mechanism of dioxygen activation suggests that the base-
catalysed deprotonation of the indole nitrogen of the substrate is necessary for 
catalysis, and the crystal structure of xcTDO has revealed a histidine residue 
(histidine 55) in the active site. Histidine 55 hydrogen bonds to the indole nitrogen 
atom of L-Trp, and could function as an active site base. However, on comparison of 
the active sites of TDO and DO it can be seen that DO contains a serine residue 
(serine 167) in the analogous position to histidine 55 in TDO. This serine residue is 
unlikely to act as an active site base, suggesting the possibility that a base may not be 
needed. In this study we attempt to resolve the question of whether an active site base 
is necessary for catalytic activity. 
Active-site mutants where histidine 55 was replaced by alanine or serine (H55A and 
H5 5 S) were created and crystal structures of the H5 5 A and H5 5 S mutant forms in 
complex with L-Trp were determined to 2.15 A and 1.90 A resolution respectively 
(2). Only a small change in the L-Trp binding affinity is observed upon enzyme 
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reduction for H55A (Ks, Fe(III) = 12.tM, Kd Fe(11) = 4p.M) and H55S (Kd, Fe(ffl) = 
181.xM, Kd Fe(II) = 51.iM)), allowing unproductive binding of L-Trp to the oxidized 
enzyme. These data, in conjunction with structural, potentiometric and kinetic studies, 
revealed that histidine 55 was not essential for turnover, but greatly disfavoured the 
mechanistically unproductive binding of L-Trp to the oxidized enzyme, allowing 
control of catalysis. 
1-Methyl-tryptophan was also studied as a possible substrate or inhibitor of xcTDO 
activity. This study reveals that whilst 1-methyl-tryptophan is not a substrate for 
TDO, and is not an inhibitor of its action, the active site mutants H55A and H55S can 
dioxygenate 1 -methyl-tryptophan. These catalytic differences are explained by 
comparison of the active sites of the enzymes, and support the proposal that a 
catalytic base is not necessary for enzymatic activity. In addition, these data provide 
new insight into the future of 1 -methyl-tryptophan as an inhibitor of DO activity in 
cancer treatments. 
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DMSO Dimethyl sulfoxide 
E° Standard reduction potential 
EPR Electron paramagnetic resonance 
EDTA Ethylene diamine tetra-acetic acid 
AGO Standard Gibb's free energy change 
DO Indoleamine 2,3-dioxygenase 
IPTG Isopropyl-f3-D-thiogalactopyrano side 
hIDO Homo sapiens indoleamine 2,3-dioxygenase 
hTDO Homo sapiens tryptophan 2,3-dioxygenase 
H55A Histidine 55 to alanine mutant 
H55S Histidine 55 to serine mutant 
DO Indoleamine 2,3-dioxygenase 
k Rate constant at substrate saturation 
Kd Dissociation constant 
Ki Inhibition constant 
Km Michaelis constant 
kobs Rate constant observed at a specified substrate concentration 
L-Trp L-tryptophan 
LC-MS Liquid chromatography- mass spectrometry 
LB Luria Bertani 
MCD Magnetic circular dicroism 
MS-MS Mass spectrometry - mass spectrometry 
NMR Nuclear magnetic resonance 
OTTLE Optically transparent thin layer electrochemistry 
PAGE Polyacrylamide gel electrophoresis 
PEG Polyethylene glycol 
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P1 4-Phenylimidazole 
PrnB Pyrrolnitrin biosynthetic enzyme 
SDS Sodium dodecyl sulfate 
SHE Standard hydrogen electrode 
sIDO Shewanella oneidensis indoleamine 2,3-dioxygenase 
TDO Tryptophan 2,3-dioxygenase 
UV Ultraviolet 
Vis Visible 
wtTDO Wild-type tryptophan 2,3-dioxygenase 
xcTDO Xanlhomonas campestris tryptophan 2,3-dioxygenase 
1 -Me-L-Trp 1 -methyl -L-tryptophan 
1 -Me-D-Trp 1 -methyl-D-tryptophan 
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Standard Symbols 
m 	metre 	 M 	molar 
g 	gram 	 °C 	degree Ceicius 
litre 	 V 	volt 
S 	 second 	 A 	Angstrom 
Amino Acids 
A Ala Alanine M Met Methionine 
C Cys Cysteine N Asn Asparagine 
D Asp Aspartic acid P Pro Proline 
E Glu Glutamic acid Q Gin Giutamine 
F Phe Phenylalanine R Arg Arginine 
G Giy Glycine S Ser Serine 
H His Histidine T Thr Threonine 
I lie Isoleucine V Val Valine 
K Lys Lysine W Trp Tryptophan 





Heme is a versatile cofactor in biology and heme-containing proteins have a wide 
variety of functions, ranging from oxygen transport to single-electron transfers (3, 4). 
Many biological oxidation reactions are catalysed by oxygen-binding heme proteins 
and they are specific and powerful oxidation catalysts. Classic examples include: the 
cytochromes P450 (4), which catalyse the monoxygenation of a range of inert 
substrates, and heme oxygenases which catalyse the first step in heme catabolism, 
the oxidative degradation of heme to biliverdin and carbon monoxide (5). A wide 
variety of mechanisms are employed by heme enzymes to accomplish such 
oxygenation reactions, and our understanding of how protein structure relates to the 
catalytic mechanism is of intense interest. 
Dioxygen serves two essential functions in aerobic life. It is both a terminal electron 
acceptor and a biosynthetic reagent. It is this latter role for dioxygen that will be the 
focus of this thesis: the incorporation of both of the oxygen atoms of dioxygen into 
the amino acid L-tryptophan (L-Trp). 
Tryptophan 2,3-dioxygenase, E.C. 1.13.11.11 (TDO) and indoleamine 2,3-
dioxygenase, E.C. 1.13.11.52 (IDO) are members of a small family of heme enzymes 
that includes PrnB, the second enzyme in the pyrrolnitrin biosynthesis pathway from 
Pseudomonas fluorescens (6) and S04144, a bacterial IDO-like protein from 
Shewanella oneidensis (sIDO) (1). TDO and DO catalyse the dioxygenation of L-
Trp to N-formyl-L-kynurenine in the first and rate-limiting step of the kynureriine 
pathway. This is achieved by the activation of molecular oxygen, and the insertion of 
both atoms into the pyrrole ring of L-Trp (Figure 1.1). TDO activity is highly 
specific, and is limited to L-Trp, and a few derivatives substituted in the 5- and 6- 
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positions of the indole ring (4). In comparison, IDO exhibits broader substrate 
specificity, also catalysing the dioxygenation of D-tryptophan, 5-hydroxy-tryptophan, 
serotonin and tryptamine. As yet, the precise catalytic mechanism employed has not 
been fully elucidated. 
L-Trp is the least abundant of the essential amino acids, accounting for -1% of the 
total amino acids in cellular proteins. L-Trp is up taken by the body, as it cannot be 
efficiently synthesized by cells. The L-kynurenine pathway is the major catabolic 
route for L-Trp metabolism in the body and ultimately leads to the formation of 
nicotinamide adenine dinucleotide (NAD), an essential energy source (7). IDO and 
TDO therefore play a central role in the physiological regulation of tryptophan flux 
in the human body, controlling the kynurenine and serotogenic pathways (8, 9). TDO 
and DO are currently of intense scientific interest due to their roles in many diverse 
physiological and immunological diseases, in particular the role of DO in tumour 
induced tolerance (10, 11). Recently DO-initiated immune tolerance has attracted 
interest because of its great potential for understanding, treating, and preventing 
human diseases. Investigation of the protein structure and catalytic mechanism 
employed by TDO and DO would greatly aid our understanding of these important 






IDO/TDO 	1 &CH0 
11 
L-Trp 	 N-Formyl kynurenine 
Figure 1.1 Reaction catalysed by TDO and IDO. 
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1.2 	Discovery and Occurrence 
TDO was first called "tryptophan pyrrolase" when initially isolated by Kotake and 
Masayama in 1936 (12) and is a soluble homotetrameric protein. It is found in both 
eukaryotes and prokaryotes, and in mammals its expression is normally restricted to 
the liver. However, TDO expression has been discovered in the brain and epididymis 
of some species (13) and in some tissues TDO production can be induced in response 
to stimuli such as glucocorticoids and heme (14). It is currently unknown as to why 
this clear compartmentalisation of TDO expression exists, or its role in biological 
tryptophan regulation. TDO is homotetrameric, and eukaryotic TDOs contain around 
400 amino acids whilst prokaryotic TDOs contain approximately 300 amino acids. 
Sequence identities between prokaryotic and eukaryotic TDOs are around 20-40%. A 
sequence alignment between different TDO species is displayed in Figure 1.2. 
IDO was first identified in 1967 (15) and first purified in 1978 (16), and is found in 
many eukaryotes where it is expressed ubiquitously throughout the body, except for 
in the liver. DO expression is induced in several tissues by a number of pro-
inflammatory mediators, such as endotoxin and interferon-7 (17). In addition, DO is 
up-regulated by the immune system in response to specific stimuli, and performs a 
number of roles in the body's immune response (17). Mammalian DO is monomeric 
and contains approximately 400 amino acids, displaying high sequence identity 
between eukaryotic species, at around 20-30%. Bacteria are also believed to use 
members of this family for the aerobic metabolism of L-Trp via the kynurenine 
pathway, and some prokaryotic DO-like proteins, such as sIDO have been identified 
(1). Bacterial DOs display high sequence similarity between species, although they 
bear little sequence similarity to eukaryotic DO proteins, and homology is based on 
their predicted 3-1) structures. The recent 3-1) structure of sIDO has confirmed its 
high structural homology to DO, but as yet little is known about the function or 
expression of these proteins. 
Recently a new enzyme with the ability to catalyse L-Trp dioxygenation known as 
INDOL1 or D02, has been identified (18, 19). It is encoded by a gene adjacent to 
3 
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that for DO in many eukaryotes and is predicted to be closely related to DO in 
terms of its structure and function. However, it is thought that biological expression 
of 1D02 in the human body is different to that of DO, and it is unknown what role 
this differential expression may play physiologically. DO plays an active role in the 
body's immune response, and it is currently of interest as to what role 1D02 may 
also play in this process. Further study is needed to discover the differences between 
these two proteins and their physiological roles. 
PrnB was first isolated and studied in Pseudomonas species and catalyses the second 
step in the pyrrolnitrin biosynthetic pathway, the conversion of 7-chlorotryptophan 
(7-Cl-trp) to monodechloro-aminopyrrolnitrin. This biosynthetic pathway is common 
to many organisms such as Myxococcus fulnus (2 1) and Aspergillus nidulans (22) 
and a number of PrnB enzymes have been identified. Pyrrolnitrin itself is a potent 
anti-fungal agent used to treat skin infections, and is proposed to operate via the 
inhibition of the fungal respiratory electron transport system (21, 23). 
Sequence identity between members of this family of proteins is low and homology 
is generally only apparent from their 3-D structures and the conservation of certain 
amino acids in their active sites. 
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Figure 1.2 Amino acids sequence alignment of X campestris TDO (xcTDO) (top 
line) and a range of eukaryotic TDOs. X campestris TDO shares 34% sequence 
identity with H. sapiens TDO. Conserved residues are highlighted in red (20). 
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1.3 	Biological Function 
DO and TDO both play a central role in the physiological regulation of tryptophan 
flux in the human body, controlling the kynurenine pathway and influencing 
serotogenic regulation. Studies have implicated these proteins in many wide-ranging 
and seemingly unconnected physiological and patho-physiological conditions, as 
discussed below. Although both enzymes catalyse the same reaction, the 
compartmentalisation of DO and TDO expression is thought to reflect their differing 
biological roles. DO and TDO production can be induced in certain tissues in 
response to specific stimuli, this specificity of cellular induction suggests little 
crossover of function. DO plays an active role in the human body's immune 
response, but there is little evidence to suggest that TDO plays a part in this process. 
1.3.1 The Kynurenine Pathway 
The kynurenine pathway accounts for the processing of over 90 % of L-Trp utilised 
by humans, leading ultimately to the formation of NAD, an essential coenzyme, as 
shown in Figure 1.3 (8). 
The kynurenine pathway is important as a source of metabolites, and the build up of 
pathway metabolites can lead to numerous physiological conditions. Some of these 
metabolites are neuroactive and one such example is quinolinic acid. Quinolinic acid 
causes neural death when injected into the brain, or when applied to neurons in vitro 
(24). Up-regulation of TDO or DO activity in the brain may result in the 
accumulation of quinolinic acid and the accumulation of quinolinic acid in 
cerebrospinal fluid may be involved in various neurological disorders, including 
cerebral malaria (25), Alzheimer's disease (24), multiple sclerosis (26) and AIDS 
related dementia (27). Kynurenine pathway metabolites have also been implicated in 
cataract formation (28). The kynurenine pathway metabolites 3-hydroxyanthranilic 
acid and 3-hydroxykynurenine are UV filters found in the lens of the eye which 
protect the retina from UV light (29). These filters are synthesised from tryptophan 
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in the lens, and with increasing age, less turnover of metabolites occur. 3-
hydroxyanthranillic acid and 3-hydroxykynurenine accumulate in the lens and 
"kynurenilation" occurs, causing the lens to turn opaque (30). In addition, some 
kynurenine pathway metabolites are immunomodulatory and can consequently 
contribute to immunosuppressive pathways and suppress proliferation (or cause 
apoptosis) of T-cells (31, 32) however the mechanisms of such metabolites are 
currently unknown. 
The kynurenine pathway is important not only as a source of metabolites, but also 
due to the effect of 1DO or TDO on the local tryptophan concentration. The 
antimicrobial response to intracellular bacteria is part of the innate host defence 
against certain pathogens, as some microorganisms cannot synthesise their own 
tryptophan, and depend upon its uptake (33). The local depletion of tryptophan in a 
specific tissue by enzymatic action is mainly associated with an antimicrobial 
response by IDO or TDO, or immune regulation by DO, which is discussed below. 
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Figure 1.3 	Schematic representation of the kynurenine pathway. Greater than 
90% of L-Trp is metabolised via the kynurenine pathway in mammals (7). 
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1.3.2 Immune Regulation 
Simply put, the immune system exists to discriminate between self and non-self. The 
mechanisms which exist to regulate the many differing and sometimes 
complementary processes that make up the immune system are currently very poorly 
understood and extremely complicated. DO plays an active role in the human body's 
immune response, but there is little evidence to suggest that TDO plays a part in this 
process. Although TDO is induced in response to some stimuli in confined locations 
(34-36), it is not induced or regulated by the immune system. In contrast, DO is 
subject to complex regulation by a number of immunoregulatory stimuli, and 100-
expressing cells are found in many tissues throughout the body, including dendric 
cells (17) and human fibroblasts (37). The evolutionarily ancient structural gene that 
encodes DO pre-dates adaptive immunity, even though the promoter is easily 
regulated by the immune system (38). This suggests that IDOs initial, tryptophan 
degrading function has been re-used in regulatory mechanisms as the immune system 
evolved. The regulation of DO can be influenced by many factors including 
tryptophan depletion, the accumulation of immunosuppressive metabolites, and 
interactions with signalling or immunoregulatory pathways (10, 17, 24). 
100 is a normal effector of peripheral tolerance in the immunoregulatory pathway of 
tryptophan metabolism and helps create a balanced immune response between 
inflammation and tolerance, suppressing excessive immune activation (17). Initially, 
DO was associated with peripheral tolerance and immunosupression by the immune 
system, such as that displayed by the immune activated anti-microbial response. 
During the immune activated anti-microbial response, specific and local activation of 
dendric cells induces inferon-y production, which in turn induces 100 production, 
which depletes L-Trp levels (17, 24). As some pathogens such as viruses (Herpes 
viruses), intracellular bacteria (Chiamydia and Rickettsia) and extracellular bacteria 
(Staphylococci) are sensitive to L-Trp depletion this may be an effective mechanism 
for controlling their ability to proliferate. As an example of this behaviour, L-Trp 
depletion is an effective mechanism against Toxoplasma gondii in human fibroblasts 
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(33, 37). However, the delicate balance between suppression and activation of the 
immune response by the body is not well understood, and over-induction of DO by 
inferonj' outside of a specific location can cause detrimental effects to the host (39). 
Side effects include depression, anxiety and diarrhoea, limiting the possible 
therapeutic applications of inferon-y in humans. 
DO is now also thought to play an essential role in acquired immune tolerance. 
During pregnancy, the immune system does not reject the genetically different 
(allogenic) foetus as non-self (40). Maternal tolerance towards the allogenic foetus is 
not fully understood, but it is thought that cells expressing DO in the placenta can 
suppress T-cell responses that mediate rejection, and this induces tolerance towards 
the foetus (40). Inhibition of DO activity in mice has been shown to lead to 
allogenic fetal rejection, displaying the delicate balance between tolerance and 
rejection, which may be controlled by only one enzyme (41). If this adaptive 
immunity is caused solely by DO regulation of T-cells, DO can be targeted as a 
potent regulator of adaptive immune responses in immune therapy. Other examples 
of this adaptive immune regulation include renal allograft failure, where increased 
DO activity induces acceptance of the allograft (40, 42). 
It has also been discovered that DO is involved in the proliferation of numerous 
cancers in the human body (10, 43, 44). DO expression allows tumours to induce 
tolerance from the host's immune system by interacting with T-cells and depleting L-
Trp levels. This is crucial for tumour progression, and certain cancers can be 
highlighted due to their DO expression. In recent studies it has been suggested that 
monitoring DO concentrations in these cancers may be an effective system for 
developing prognosis reports, as the most aggressive forms of these cancers show a 
high level of DO expression (Figure 1.4) (10, 44). It is unknown exactly how 
tumours evade local immune destruction from tumour-reactive T-cells, but in 
consequence DO has emerged as an attractive drug target in cancer treatments (45-
47). 
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(33, 37). However, the delicate balance between suppression and activation of the 
immune response by the body is not well understood, and over-induction of IDO by 
inferon-T outside of a specific location can cause detrimental effects to the host (39). 
Side effects include depression, anxiety and diarrhoea, limiting the possible 
therapeutic applications of inleron-y in humans. 
IDO is now also thought to play an essential role in acquired immune tolerance. 
During pregnancy, the immune system does not reject the genetically different 
(allogenic) foetus as non-self (40). Maternal tolerance towards the allogenic foetus is 
not fully understood, but it is thought that cells expressing IDO in the placenta can 
suppress T-cell responses that mediate rejection, and this induces tolerance towards 
the foetus (40). Inhibition of IDO activity in mice has been shown to lead to 
allogenic fetal rejection, displaying the delicate balance between tolerance and 
rejection, which may be controlled by only one enzyme (41). If this adaptive 
immunity is caused solely by IDO regulation of T-cells, IDO can be targeted as a 
potent regulator of adaptive immune responses in immune therapy. Other examples 
of this adaptive immune regulation include renal allograft failure, where increased 
IDO activity induces acceptance of the allograft (40, 42). 
It has also been discovered that IDO is involved in the proliferation of numerous 
cancers in the human body (10, 43, 44). IDO expression allows tumours to induce 
tolerance from the host's immune system by interacting with T-cells and depleting L-
Trp levels. This is crucial for tumour progression, and certain cancers can be 
highlighted due to their IDO expression. In recent studies it has been suggested that 
monitoring IDO concentrations in these cancers may be an effective system for 
developing prognosis reports, as the most aggressive forms of these cancers show a 
high level of IDO expression (Figure 1.4) (10, 44). It is unknown exactly how 
tumours evade local immune destruction from tumour-reactive T-cells, but in 




Figure 1.4 	Representative immunological staining for IDO expression in 
endometrical cancer tissues, where IDO expression is often up-regulated. (A) IDO-
(negative), (B) IDOl + (sporadic/weak), (C) 1D02+ (focal/moderate), (D-F) (dffuse/ 
strong), (G) negative control, (H) positive control (normal placenta) (48). 
1.3.3 TDO and IDO inhibition 
IDO is a therapeutic target for the development of new anticancer drugs and 
importance has been given to the design of new inhibitors of its action (43, 49). Most 
strategies targeting the inhibition of IDO activity have utilised the indole ring 
structure of tryptophan as a base, and most known inhibitors are based around this 
structure (50, 51). Some known inhibitors of DO activity are shown in Figure 1.5 
(49, 52, 53). The most-studied inhibitor of IDO is 1-methyl-tryptophan (l-Me-Trp), a 
competitive inhibitor. Recently it was shown that the combination of 1 -Me-Trp with 
a number of clinically relevant chemotherapeutic agents was able to cause regression 
of established tumours in murine breast cancers (45). However, 1 -Me-Trp exists as 
two stereoisomers with potentially different biological properties, and it is unclear 
which isomer affects the greatest inhibitory response in vitro (45, 51). Most studies 
have employed a racemic mixture of 1 -Me-Trp, leaving unanswered the question of 
which stereoisomer to employ in human trials. Recent studies have showed that 
whilst 1 -Me-L-Trp is a more potent inhibitor of purified IDO than in cell—based 
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assays (45), 1-Me-D-Trp is more effective than 1-Me-L-Trp as an anticancer agent 
when tested in mouse cancer cells. These findings supported the suitability of 1-Me-
D-Trp for human cancer trials, which have since commenced (54). However, since 
these reports it has been suggested that 1 -Me-D-Trp may be inhibiting INDOL 1 
activity, rather than the activity of IDO (51, 55). Considering the importance of 
developing new cancer treatments, clearly more information is needed on both IDO 
and 1NDOL 1, and the effects of L-and D-Me-Trp upon their enzymatic activity. 
In comparison 1 -Me-Trp is ineffective against TDO activity (56). However, a few 
potent inhibitors of TDO have been discovered, including norharman (57), a 13-
carboline derivative. In addition, a number of 2-(2-pyridylethenyl) indole derivatives 











Phcnyl-imidazole 	 Brassilexin 
Figure 1.5 	L-Trp is a substrate for TDO and IDO. D-Trp is a weak inhibitor of 
TDO and a substrate for some IDOs. 1-methyl-L-tryptophan, 1-methyl-D-tryptophan, 
phenyl imidazole and brassilexin are all IDO inhibitors. 
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1.4 	The Role of Dioxygen 
1.4.1 Chemical Properties of Dioxygen 
Dioxygen is essential to aerobic life, and it is now known to play a role in a wide 
variety of biological processes. Oxygen is a powerful oxidising agent, due to its high 
electronegativity and thermodynamically favourable reactivity. Molecular dioxygen 
is primarily used in biological reactions for its oxidising capabilities, whereby it is 
reduced to water. 
Oxygenase reactions involve the cleavage of the oxygen-oxygen bond, which is a 
thermodynamically favourable reaction (61). However, the chemical reactivity of 
dioxygen with organic molecules under standard conditions is very low. Indeed if 
this were not the case, dioxygen would be harmful rather than useful for living 
organisms. This low reactivity is due to the ground state of molecular oxygen. It is a 
triplet, diradical in the ground state with two unpaired electrons residing in 
antibonding 11*  orbitals, Figure 1.6. The molecular orbital energy level configuration 
of triplet dioxygen is (1 so)2 (1 sa*)2  (2sa)2 (2so.*)2  (2po)2 (2p7i)4  (2p7rx*)' (2p7ry*)l 
This unusual paramagnetic ground state arises from two electrons residing in the 
antibonding 2p7tx*  and 2plty*  orbitals, resulting in dioxygen having a formal bond 
order of two. 
Singlet oxygen is more readily reactive than triplet dioxygen, and two singlet states 
exist (Figure 1.6). Nearly all stable organic compounds are singlets with paired 
electrons, and direct reactions between singlet and triplet species are spin forbidden 
because chemical reaction rates are much faster than spin inversion rates. Therefore 
the reaction of triplet dioxygen with these compounds under standard conditions can 
only proceed via the spin-allowed, high energy formation of an unstable triplet 
intermediate by the organic molecule. This undergoes reaction with triplet dioxygen, 
followed by slow spin inversion to form a singlet product. In addition triplet 
dioxygen will react readily with organic radicals. Non-enzymatic conversion of 
triplet to singlet dioxygen requires photolysis or an external energy source to 
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overcome the high kinetic barrier inherent to reactivity. Both singlet states of 
dioxygen are higher in energy than the triplet state, and 22.5 kcal mol' is required to 
convert triplet dioxygen to the lower energy singlet state. 
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Figure 1.6 	Molecular orbital diagrams for the triplet and singlet states of 
dioxygen, (a) 02, (b) '02  ('s) and (c) '02 (A). 
1.4.2 Enzymatic Oxygen Activation 
Nature has devised a large number of redox active groups, utilising transition metal 
ions, heme porphyrins and organic cofactors to mediate dioxygen activation. 
Oxygenases catalyse the enzymatic addition of oxygen to substrates, and utilise all of 
these different redox strategies to promote their reactions. The most commonly used 
metals in oxygenases are iron and copper, and they are employed because in their 
lower oxidation states these metals can form complexes with dioxygen, organic 
substrates, or both, and affect the electronic structure of the bound compound to alter 
its reactivity. They achieve this by promoting the reaction between dioxygen and an 
organic substrate in two main ways. Firstly, they can activate triplet dioxygen to 
attack organic substrates. Secondly, they can activate organic substrates to attack 
triplet dioxygen. Easily oxidisable singlet organic molecules can react by first 
forming resonance-stabilised, (one-electron oxidised) radicals, which then react with 
14 
Enzymatic and Mechanistic Studies into Taptophan 2,3-Dio.vigcnasc 
triplet dioxygen. This is obviously a simplification and in reality an enzyme may 
utilize a combination of these approaches, either in synergy or sequentially. 
Cofactor-less oxygenases also activate dioxygen, but the reactions catalyzed by these 
enzymes are poorly understood in mechanistic terms (62). Catalysis is thought to 
proceed via a radical mechanism, and the enzymes are thought to stabilise anionic 
intermediates in the catalytic cycle. 
1.4.3 Oxygen Activation by Heme 
The heme system consists of an iron atom coordinated in a square-planar 
arrangement by four nitrogen atoms, provided by pyrrole groups. The axial ligands to 
the heme iron are provided by either one or two amino acid side-chains or exogenous 
ligands. The most common heme prosthetic group is iron protoporphyrin 1X, heme b 
(Figure 1.7 (b)). There are a number of naturally occurring variations to the 
protoporphyrin IX system giving rise to the classes of heme a, b, c, and d (Figure 
1.7). 
Heme is generally a one-electron cofactor, with the iron atom accessing the two most 
stable oxidation states available; the ferrous (Fe 2-) and ferric (Fe 3)forms. However, 
some systems, e.g. the P450 enzymes and the heme-copper oxidases, are known to 
utilise the ferryl (Fe'') oxidation state of the iron (63, 64). The conjugated heme 
governs the activation of dioxygen, allowing the formation of low-spin states, 
stabilising highly oxidised iron intermediates that can undergo reactions. 
The mechanism of dioxygen activation by heme iron enzymes involves an initial 
reversible, complex formation between the ferrous high-spin (d6, S = 2) heme iron 
and triplet dioxygen. This yields a low-spin complex that is generally described as 
either Fe 2+_02 or Fe3tOf or a resonance hybrid of these two forms because the 
actual electronic structure may involve partial electron transfer between iron and 
bound dioxygen. For the Fe 2+_02  structure, a bond formation occurs via back 
donation from a ferrous ion orbital (e.g., d,) to the empty c702*  orbital. Transfer of 
one electron from iron to the bound dioxygen yields the ferric superoxide structure, 
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Fe3 -O2 . An unpaired electron on the superoxide resides in its antibonding a orbital 
(y02*), while a second unpaired electron resides in a nonbonding iron orbital (dv). 
In either the ferrous dioxygen or ferric superoxide configuration, the complex is 
diamagnetic. 
Substrate activation by heme enzymes involves initial complex formation between 
the (singlet) substrate and the ferric or ferrous heme iron, such as that catalysed by 
the extradiol dioxygenases (65). 
For TDO and IDO, the ferrous dioxygen structure is the best model of the electron 
configuration, as further reduction of the heme-bound dioxygen is not required in its 
mechanistic cycle (see "Catalytic Mechanism"). However, the complex formed 
between ferrous heme iron and triplet 02 must be a singlet for the reaction to 
proceed. The bound dioxygen is not singlet 02,  but can react by either an ionic or a 
radical mechanism to give products that are similar to those that would be produced 
by the reaction of singlet 02. 
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Figure 1.7 	Structures of some of the naturally occurring heme groups. The 
heme groups a, b, c, and d1 are represented. The protoporphyrin IX system is the 
heme b. 
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1.5 	Oxygenases 
Early biochemical studies assumed that the oxygen found in organic substrates came 
from water and that dioxygen was only utilised by the body in some oxidase and 
dehydrogenase reactions. Then in 1955 Hayaishi and Mason unambiguously 
demonstrated that isotopically labelled dioxygen could be incorporated into organic 
compounds directly, and designated the enzymes which catalyse such reactions 
oxygenases (66, 67). Hayaishi and Mason demonstrated that these oxygenases can 
catalyse the incorporation of one or both atoms of molecular oxygen into organic 
substrates - by processes of monooxygenation or dioxygenation. We now know that 
monooxygenases insert an atom of molecular oxygen into the substrate of interest 
and reduce the other atom of dioxygen to water, whilst dioxygenases are either 
intermolecular or intramolecular, incorporating oxygen into separate substrates or 
into a single substrate. Oxygenases may be enantio-, chemo-, or regioselective and 
can produce optically pure products when traditional chemical reactions are 
unspecific, consequently they are becoming widely exploited in industrial processes 
(68). Monooxygenases and dioxygenases may employ transition metal ions, heme 
porphyrins and inorganic cofactors in their catalytic reactions. Described below are 
some examples of monooxygenase and dioxygenase enzymes. 
1.5.1 Monooxygenases 
Monooxygenases require two electrons to reduce the unincorporated oxygen atom of 
02 to water. The two electrons may be obtained from a reducing agent or agents, or 
from the substrate itself Monooxygenases can utilise inorganic compounds, 
transition metal ions or heme porphyrins to activate the reaction, and often also 
contain non-metal cofactors such as flavins or tetrahydrobiopterin as an electron 
source to reduce the second atom of 02 to water (69). 
Heme-containing monooxygenases include cytochrome P450's (4), secondary amine 
monooxygenase (4) and heme oxygenase (70). The cytochromes P450 are perhaps 
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the most well known monooxygenases, catalysing the oxidation of a huge variety of 
organic compounds. The most common function of the P450 enzymes is the catalysis 
of regio- and stereo-specific hydroxylation reactions on non-activated hydrocarbons 
under physiological conditions. These properties have recently lead to the 
investigation of P45 Os as potential biocatalysts since uncatalysed reactions require 
high temperatures and are non-specific (71). All P450s contain a b-type heme 
coordinated to the enzyme via a cysteine ligand in the fifth ligation site (72). It has 
been proposed that the strong electron donating character of the cysteine thiolate 
provides an 'electron push' onto the heme allowing it to achieve reduction potentials 
necessary to stabilise the oxygen species required in the catalytic mechanism. 
Non-heme iron monooxygenases include tryptophan hydroxylase which catalyses the 
hydroxylation of L-Trp to 5-hydroxy-tryptophan (73), and methane monooxygenase 
(70, 74), which is found in methanotropic bacteria. Methanotropic bacteria respire on 
methane and catalyse the oxidation of methane to methanol, in the first step of the 
conversion of methane to carbon dioxide. There are many different forms of 
methane monooxygenase, including both membrane bound and soluble forms, and 
these are thought to contain copper and iron centres, although this remains a widely 
debated issue. One soluble form (soluble methane monooxygenase) is known to 
contain only iron centres, and in this enzyme dioxygen is activated at a di-iron cluster 
by a reductive process that results in the formation of a high valency iron-oxo species 
prior to substrate binding (74). 
Quinone-forming monooxygenases are cofactor-less oxygenases involved in 
polyketide tailoring (62). They catalyse the synthesis of a number of aromatic 
polyketides by the oxidation of naphthacenone- and anthrone-type precursors of 
polyketides to form the corresponding quinine derivatives. Polyketides are of 
enormous therapeutic and commercial importance, since they exhibit antibiotic, 
antitumour and immunosuppressive activities. The quinone-forming monooxygenase 
requires only dioxygen for activity and uses its substrate as a reducing equivalent for 
the reduction of dioxygen to water, making it an internal monooxygenase. 
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1.5.2 Dioxygenases 
Non-heme iron oxygenases include the Rieske cis-dihydrodiol-forming dioxygenases 
(75) and the extradiol aromatic ring cleaving dioxygenases (65, 75). The extradiol 
aromatic ring cleaving dioxygenases convert complex aromatic compounds to single 
or double-ring compounds in bacteria. The rings of these molecules are opened by 
dioxygenases that usually contain Fe 2+  or Fe 3+  at their active-sites. The active metal 
centre in most of these extradiol dioxygenases contains a ferrous iron ion bound by 
two histidine residues, and a glutamate or aspartate side chain, whilst the other three 
positions can contain up to three solvent molecules. Whilst the reactions catalysed 
can vary greatly, the initial oxygen activation mechanism is often similar between 
enzymes. Substrate coordinates to the metal first concurrently displacing two solvent 
molecules from the metal centre. Dioxygen then coordinates to the iron centre in site 
adjacent to the substrate, and the reaction between the two is facilitated by the iron 
atom allowing electron transfer between them. This is thought to induce radical 
character, allowing the otherwise spin-forbidden reaction to proceed 
Heme-containing dioxygenases include TDO and [DO, where the heme porphyrin 
coordinates and activates dioxygen whilst in the ferrous state (4). This is similar to 
the phenol ring cleavage catalysed by non-heme iron dioxygenases such as catechol 
3,4-dioxygenases (73) and protocatechuate 4,5-dioxygenase (76). But in contrast to 
heme iron and non-heme iron-containing monooxygenases such as P450 which are 
able to oxygenate completely unactivated alkanes, TDO and IDO require a substrate 
containing a functionalised double bond for catalytic activity. 
Cofactor-less dioxygenases involved in the degradation of N-heteroaromatic 
compounds have been identified (62). Biochemical and spectroscopic studies of the 
purified 2,4-dioxygenases termed Qdo (1H-3-hydroxy-4-oxoquinoline 2,4-
dioxygenase) and Hod (1H-3-hydroxy-4-oxoquinaldine 2,4-dioxygenase) have 
shown that neither enzyme contains any metal or organic cofactors, however, little 
more is known of these proteins to date, and their mode of operation is unknown. 
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1.6 	Catalytic Mechanism 
The catalytic mechanism employed by TDO and IDO are poorly understood, and 
little characterisation of reactive intermediates has been reported. Proposals for the 
catalytic mechanism for tryptophan oxidation by TDO and IDO are illustrated in 
Figures 1.8 and 1.9. 
1.6.1 Reduction of TDO and IDO 
Turnover of L-Trp by TDO or IDO occurs with the enzyme in the ferrous state. Some 
reports of weak catalytic activity by ferric IDO and TDO exist (77, 78), but this is 
likely due to small amounts of the ferrous form being present. Reduction of the heme 
iron is therefore required to facilitate the observation of catalytic activity (4). Under 
physiological conditions it has been proposed that cytocbrome b5 acts as an electron 
transfer protein, donating an electron to ferric IDO (79). It is unknown whether 
cytochrome b5 also reduces TDO, but a similar mechanism would appear likely. 
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Figure 1.8 Proposed catalytic mechanisms for TDO and IDO dioxygenation. 
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1.6.2 Ternary Complex Formation 
In the enzyme active site, 02 and L-Trp must both bind to the active site, forming a 
ternary complex [2], before any reaction can take place (Figures 1.8 and 1.9). 
Trapping of this ternary adduct (substrate-Fe 2+_02)for both TDO and IDO has 
confirmed its formation [reviewed in 4]. 
TDO 
In TDO, the binding of substrate and dioxygen to the reduced enzyme to form the 
ternary complex (Trp-Fe2 -02) is thought to be an ordered process with L-Trp 
binding first, then 02 (1, 4). Reduced TDO does not readily bind 02 in the absence of 
substrate and addition of dioxygen leads directly to the oxidised enzyme, with no 
detectable intermediates (77). The oxidised enzyme does not bind dioxygen while 
substrate binding is disfavoured compared to the reduced enzyme, making it 
impossible for the oxidised enzyme to form the ternary complex. The ternary 
complex activates 02, and allows the otherwise spin-forbidden reaction between L-
Trp and 02 to proceed. TDO is not thought to utilise superoxide, although some 
generation of reactive oxygen species by TDO in vivo has been reported (80). 
IDO 
In the case of IDO it appears that both the ferric and ferrous forms of the enzyme can 
react with specific oxygen species to form products. It is thought that in vivo IDO is 
reduced by an external factor such as cytochrome b5, before reacting with substrate 
and dioxygen to form the ternary species (79). However, ferric IDO is also capable 
of reacting with superoxide and substrate to form the ternary species (81). 
Ferrous IDO is able to bind either the substrate or dioxygen to form stable binary 
complexes. The formation of the ternary complex can occur as it does in TDO, by 
substrate binding followed by dioxygen binding. In addition, reaction of the binary 
23 
Enzyina tic and Aieclianisric Studies ijito Trjptophw 4J-Dioygcxiac 
oxy-Fe2  adduct (which is stable with a lifetime of seconds) with a substrate yields 
the appropriate product (78) and it seems reasonable that ternary complex formation 
probably occurs via both routes. 
Ferric IDO binds superoxide to form the binary Fe 2+_02 adduct, which can then bind 
substrate as described above (81, 82). However, it is not clear if the binary Fe3 -L-
Trp adduct can react with superoxide. It has been shown by equilibrium binding 
studies of L-Trp to both the ferric and ferrous forms of IDO that L-Trp binds more 
readily to the ferrous enzyme (83). Therefore it seems unlikely that the Fe3 -L-Trp 
adduct would form in vivo and react with superoxide. Some studies have suggested 
that even if this reaction is favourable, any product formation via this route would be 
minimal (81, 84). Unlike TDO, IDO undergoes auto-oxidation during catalytic 
turnover, producing ferric enzyme and superoxide (4, 82). IDO needs to be 
continually reduced in vitro and in vivo to retain catalytic activity. 
1.6.3 Dioxygen Activation in the Ternary Complex 
Various mechanisms have been proposed for the initial step in the dioxygenation of 
L-Trp by IDO and TDO. Catalysis can proceed either via an ionic or a radical 
mechanism, and these routes involve the same intermediates in product formation. 
Early work by Wiseman et al. suggested that it would be energetically unfavourable 
to proceed via a radical mechanism (85) (Figure 1.8). However, the proposed radical 
mechanism involved base-catalyzed deprotonation of the indole NH group to 
generate the Trp anion, which is then reversibly oxidized by (Fe 3+_02)  to form a 
tryptophan radical and (Fe 2+-02) (86). Formation of such a tryptophan radical is a 
highly thermodynamically unfavourable reaction and such a radical mechanism 
became discounted as a valid route for product formation (4). Subsequent work has 
generally proposed ionic catalytic mechanisms with electrophilic addition of the 
bound dioxygen to the indole ring, concerted with proton transfer (an oxygen-ene 
type reaction) (87, 88). Until very recently this was the most accepted mechanism for 
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dioxygen activation. However, a recent density functional theory study into the 
catalytic intermediates involved in TDO and IDO catalysis does not support this 
concerted oxygen-ene type pathway (Figure 1.9) (89). On the basis of DFT 
calculations Chung et al propose that dioxygen activation occurs either via direct 
electrophilic addition of the bound dioxygen or direct radical addition to the Fe3 -O2 
species. Each of these possible mechanisms will now be discussed in detail. 
Formation of a Hydroperoxide Intermediate 
This is an ionic mechanism, proposed on the basis of biochemical studies, whereby 
catalysis proceeds via the formation of a hydroperoxide intermediate. Addition of 02 
to the C3 position of the substrate occurs prior to 0-0 bond cleavage (4, 88). It has 
been proposed that formation of this hydroperoxide intermediate could be catalysed 
by three possible mechanisms - base-catalysed deprotonation of the indole nitrogen 
atom, proton abstraction by bound dioxygen or base catalysed deprotonation by 
solvent, these are discussed below. 
It has been proposed that base catalysed deprotonation of the indole nitrogen could 
facilitate nucleophilic attack from the C3 position of the indole ring to the bound 
dioxygen (4, 88). This mechanism is displayed in Figure 1.9 (a). However, although 
this mechanism may be possible for TDO, which has a histidine residue in its active 
site, IDO does not contain a residue capable of acting as a catalytic base. In fact IDO 
contains a serine residue (ser 127) in the analogous position to histidine in TDO. 
Catalysis by the iron-bound dioxygen in an "oxygen-ene" type reaction is generally 
proposed in the absence of a base (Figure 1.9 (b)) where proton abstraction by the 
iron-bound dioxygen is concerted with electrophilic attack. The indole NI-I group 
interacts with the proximal oxygen atom, weakening the 0-0 bond, facilitating 
electrophilic addition at the C3 position (87-89). Until recently this "oxygen-ene" 
type reaction was favoured as a possible catalytic mechanism. However, the recent 
DFT calculations have suggested that the energy barrier for formation of the 
transition state is high, and therefore unfavourable. 
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(a) 







Figure 1.9 	The ternary complex (Fe 2+ is displayed in both (a) and (b). 
(a) Shows base-catalysed attack on the ternary complex, whilst (b) displays a non-
based catalysed mechanism whereby the reaction proceeds by an "oxygen-ene "-type 
rearrangement. 
Another possibility that has been considered is that proton abstraction is catalysed by 
a solvent molecule in the active site. If this was to occur the pKa values of the groups 
involved must be similar. However, whilst the pKa of enzyme bound L-Trp is 
unknown, that of free L-Trp is quite high (16.9), and any solvent must be more basic 
than this (Figure 1.10) (90). Additionally, as the most probable solvent is water, and 
the crystal structure of xcTDO shows that no water is bound in the appropriate 
position in the substrate-bound active-site this mechanism is consequently considered 
unlikely (1, 2). 
Direct Electrophilic Addition of the Iron-Bound Oxygen 
Dioxygen activation in the ternary complex, by direct electrophilic addition of the 
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favourable by DFT calculations (89), and is shown in Figure 1.8. Addition of oxygen 
to either the C2 or C3 position of the indole ring, uncoupled to proton transfer, is 
predicted to be favourable (Figure 1.8 [3] and [4]). The addition is calculated to have 
the lowest energy barrier when the electronic configuration of dioxygen is a closed-










Figure 1.10 pH-dependant properties of tryptophan. Deprotonation of the indole 
nitrogen atom occurs at a pKa of 16.9, whist formation of the doubly protonated 
species occurs at a theoretical pKa of- 4. 
27 
Enzmatc and Mechanistic Studies into 1 13 ptopliaii 4J-Diujgenae 
Direct Radical Addition 
Direct radical addition of Fe3tsuperoxide species to the C2 position without the 
involvement of proton transfer is predicted by DEl' to be favourable in energy, 
displaying a low energy barrier to reaction. The superoxide species must be in a 
triplet or open-shell singlet state for the reaction to be favourable. The diradical 
intermediate is shown in Figure 1.8 [5]. 
1.6.4 Rearrangement of Addition Intermediate 
The rearrangement of the addition intermediate to form the product has been 
proposed until recently to be catalysed by either a Criegee or a dioxetane pathway. 
However, the recent suggestion of different addition pathways has lead to the 
proposal of new rearrangement mechanisms. All of the proposed rearrangements will 
now be discussed. 
Criegee Rearrangement 
The hydroperoxide intermediate [3], can rearrange via the Criegee or dioxetane 
rearrangements to form the product N-formylkynurenine. The Criegee rearrangement 
is shown in Figure 1. 11, and requires an antiperiplanar arrangement of the 0-0 bond 
and the indole C2-C3 bond to form an intermediate [4] that further rearranges [5] to 
form the product N-formylkynurenine [6]. DFT calculations have suggested that the 
Criegee rearrangement is unfavourable since formation of the antiperiplanar 
conformation required for catalysis demands a very high barrier from the neutral 
indoleine intermediate (89). These calculations cast doubt on the feasibility of a 
Criegee rearrangement in the mechanism of L-Trp dioxygenation. 
28 




60 	 00 
	
02 
 V - F! 2- 	 F12+ 	\ 	 R 
His 	 His 
6 	 5 oe 






Fe 2+ 	 Fe 2+ 
His 	 His 
Figure 1.11 The proposed Criegee rearrangement of the hydroperoxide 
intermediate in the dioxygenation of L-Trp by TDO and IDO. 
Dioxetane Mechanism 
All of the catalytic intermediates proposed to form from initial dioxygen activation 
(Figure 1.8 [3], [4] and [5] and Figure 1.11 [3]) can undergo rearrangement to 
products via a dioxetane rearrangement. The dioxetane mechanism requires a sin-
coplanar configuration of intermediate [6] (Figure 1.8) which then undergoes a retro 
[2+2] cycloaddition to form the product. DFT calculations modelling the Michaelis 
complex indicate that formation of the highly strained dioxetane intermediate and its 
decomposition are energetically favourable. However, no chemiluminescence has 
been detected on decomposition of the dioxetane, which could be expected upon 
decomposition of the four-membered ring. 
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Radical Rearrangement 
After initial radical intermediate formation (Figure 1.8 [2] to [5]), catalysis can 
proceed via a nearly barrier-less charge-recombination step to form the dioxetane 
intermediate and rearrange to products, or alternatively undergo a radical 
mechanism. 
The proposed radical mechanism involves homolytic 0-0 bond cleavage from the 
diradical intermediate followed by oxo attack and facile C2-C3 bond cleavage to 
products. However, the formation of strong oxidant ferryl-oxo species may lead to 
undesired by-products (64). 
1.6.5 Conclusions 
Currently there is little biochemical data to support any particular mechanistic route 
of L-Trp dioxygenation. In this study we attempt to determine detailed information 
on the mechanism of L-Trp dioxygenation, via biochemical and structural 
characterisation of xcTDO. Throughout this thesis the impact of key results on the 
mechanism of ternary complex formation, dioxygen activation in the ternary 
complex and the rearrangement of the addition intermediate will be discussed and 
mechanistic conclusions drawn. These results will provide the basis for the proposal 
of a catalytic mechanism in Chapter 6. 
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1.7 	Crystal Structures 
Crystal structures of five members of this family of heme proteins have now been 
published, and crystallographic information is shown in Table 1.1. 
(The structure of xcTDO was solved by our research group in collaboration with 
Liang Tong (Columbia University, NY, USA) in 2007 and is discussed both below, 
and in Chapter 1). 
Table 1.1 	Crystallographic data regarding the heme dioxygenase family of 
proteins. 
Ligand Resolution (A) PDB codes 
None, L-Trp, 6-F- 2NW7, 2NW8, 
xcTDO (1) 2.7, 1.6 and 1.8 
Trp 2NW9 
rmTDO (88) None 2.4 2NOX 
hIDO (87) PT, Cif 2.3 and 3.4 2DOT, 2DOU 
sIDO (1) None 2.4 1ZEE 
None, L and D-Trp, 1.75, 2.0, 1.75, 2.4, 
PrnB (6) 2V71-2V7M 
L and D-7-Cl-Trp 2.0 
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1.7.1 TDO Structure 
Two structures of TDOs have been published, those of X campestris TDO (xcTDO) 
(1) and R. metallidurans TDO (rmTDO) (88). The crystal structures show that the 
proteins are essentially identical (they share 47 % sequence identity), with the 
regions of the highest sequence similarity located near to the active-site. As the 
structure of X campestris TDO is at a higher resolution, and it is the only structure 
available in the ferrous, active form with substrate bound (L- or 6-F-Trp) it is the best 
available model of substrate binding interactions. 
The structure of TDO is an intimately associated homotetramer with approximately 
4500 A2 of the surface area of each monomer being buried within the tetramer 
interface (Figure 1.12(a)). The structure of the monomer contains 12 a-helices and no 
13-strands and belongs to the family of bacterial TDO-like protein folds, represented 
in Figure 1.13(a). The tetramer may best be described as a dimer of dimers as the N-
terminal residues of each monomer form part of the substrate-binding site in the 
adjacent monomer (residues 21-40 of xcTDO). A "dimer" of xcTDO is shown in 
Figure 1.12(b) and (c). The N-terminal loop from the adjacent monomer points down 
directly to the heme binding site with two tyrosine residues (Tyr 24 and Tyr 27) each 
hydrogen bonding with glutamate residues on the aA-helix forming the back wall of 
the active site pocket (Figure 1.13(b)). It is unknown what function this dimerisation 
may play in the function of TDO in vivo, but similar arrangements are seen in a 
number of allosteric proteins (3). 
In the substrate bound structure of xcTDO a flexible loop (encoding residues 250-
260) just outside the heme pocket has been fully resolved crystallographically. This 
loop appears to be involved in binding both the ammonium and carboxylate moieties 
of L-Trp, and may be acting as a "lid" closing the active site upon substrate binding. 
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Figure 1.12 (a) Tetrameric TDO, with the different monomers shown in magenta, 
cyan, grey and blue. Heme is displayed in grey and 8 bound L-Trp molecules are 
shown in red. Displayed in (b) and (c) are two views of the "dimeric" arrangement 
of TDO 
33 




Figure 1.13 (a) A monomer ofxcTDO with all the helixes labelled. Helices are 
displayed in cyan and loop andjoints in pink, (b) active-site and heme environment 
of xcTDO, one monomer is shown in cyan and the N-terminal arm of the adjacent 
monomer is shown in magenta. Key residues involved in the active site have been 
shown as stick models. 
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Active-site Structure 
Figure 1.13(b) shows the active site of TDO in the reduced, L-Trp-bound form, 
displaying the heme environment. The proximal site of the heme porphyrin is 
occupied by a histidine residue (His 240), whilst the distal heme pocket comprises 
residues from both monomeric TDO and the N-terminal arm of its partner subunit. 
The distal site is the substrate binding pocket where the sixth coordination site of the 
iron is empty. 
The active-site has a preponderance of hydrophobic residues, such as Phe 51, Tyr24 
and Tyr 27, creating a "greasy pocket", similar to that found in globins that 
encourage hydrophobic substrate binding (3). Interactions of the substrate with the 
active site can be split into two categories - interactions with the carboxylate and 
ammonium groups of L-Trp, and those with the indole ring system. 
The interactions of the substrate carboxylate and ammonium groups include an 
electrostatic interaction between the side chain of Argi 17 and the substrate 
carboxylate group, which is also hydrogen-bonded to the phenolic group of Tyrll3 
and the main chain amide group of Thr254. This carboxylate-binding motif appears 
to be essential for substrate binding; arginine reorientates in the presence of 
substrate, coordinating the carboxylate group of L-Trp, with "open" and "closed" 
conformations observed (Figures 1.14 (a) and (b)). The closed conformation is only 
observed in TDO crystals grown in the presence of tryptophan (Figure 1.14(b)), 
although no L-Trp is bound to rmTDO (This absence is probably due to a low 
affinity of L-Trp binding to oxidised rmTDO, similar to that observed for xcTDO 
(Kd, Fe3  = 3.8 mM), whilst only 1mM L-Trp was present in the crystallization 
solution (88)). 
The substrate ammonium group is hydrogen-bonded to the side chain hydroxyl group 
of Thr254, the 7-propionate group of the heme, and a water molecule. Thr254 is 
involved in binding both the ammonium and carboxylate moieties of L-Trp and is 
part of a flexible loop (comprising residues 250-260 of xcTDO) located just outside 
the active-site. This loop is only ordered in the structures grown in the presence of L- 
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Trp (xcTDO and rmTDO), because substrate binding appears to induce ordering. In 
the absence of L-Trp this loop region is also disordered in the TDO structure. 
In xcTDO the substrate indole ring binds into a hydrophobic pocket, interacting with 
the side chain of Phe5 1 and several other hydrophobic residues, including Tyr24 and 
27 from the adjacent monomer, anchoring the indole ring of tryptophan in the active-
site. This extensive network of enzyme-substrate interactions serves to stabilise the 
active site and control substrate binding and catalysis. 
Secondary Allosteric Binding Site 
In the crystal structure of L-Trp-bound xcTDO in the ferrous state there is a second 
L-Trp binding site in the tetramer interface, and this is shown in Figures 1.15(a) and 
(b). It would appear that this is a specific interaction with L-Trp, and in light of 
reports of allosteric activation of TDO by L-Trp it is possible that this site represents 
an allosteric effector site. This site is not occupied in the 6-F-Trp complex, possibly 
because of the lower concentration of the substrate in the crystallization solution. 
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Figure 1.14 Active site stick structures of (a) ferric, substrate free xcTDO, (b) 
ferrous, substrate bound xcTDO, (c) ferric, substrate free rmTDO, (d) ferric, P1-
bound hIDO. The heme porphyrin is shown in grey, and tryptophan and P1 are 
shown in red. 
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Figure 1.15 (a) Interfacial binding offour additional L-Trp molecules to xcTDO, 
(b) specific interactions at the interfacial binding site, L-Trp is bound diagonally 
across the tetramer, interacting with two monomers in separate "dimers ". 
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1.7.2 IDO 
The first crystal structure of a member of the heme dioxygenase family to be 
published was that of eukaryotic IDO by Sugimoto et al (87), in complex with 4-
phenylimidazole (P1), a known inhibitor and heme ligand, and with cyanide (CN) 
(Table 1.1). The PT bound enzyme structure of IDO is shown in Figure 1.16 and 
shows that MDO is a monomeric protein, with the structure divided into two distinct 
domains, a large (C-Terminal) domain and a small (N-Terminal) capping domain. 
Inter-domain contact is extensive, with a buried surface area of 3100 A2, and the two 
domains are linked by a long loop, comprising residues 250-267. The larger domain 
is completely helical, with thirteen cc-helices and two 310  helices, and belongs to the 
family of IDO-like protein folds, while the smaller N-terminal domain consists of six 
cc-helices, two short 3-strands, and three 3 10 helices, and displays some similarity to 
the C-terminal domain of glutathione S-transferase. The larger domain is essentially 
topologically identical to a protomer of tetrameric TDO, and the structures readily 
super imposable (Figure 1.16). The heme-binding pocket of hIDO is located mainly 
within the larger domain, close to the domain interface buried within the protein 
architecture. The loop region connecting the two domains lies above the distal face 
of the heme, providing part of the binding cavity. In the IDO structures, residues 
comprising a flexible loop (of a similar length to that resolved in the TDO structure) 
just outside the heme pocket have not been fully resolved crystallographically. It is 
thought that this flexible loop may play a role in substrate binding like that in TDO, 
and substrate binding may aid its resolution crystallographically. 
Active-site 
In contrast to TDO, the structure of IDO is not available with any substrate bound, 
but has been solved with the inhibitor P1 at the active site. This model shows P1 binds 
to the heme iron as expected, but does not yield any information regarding the mode 
of substrate binding in IDO. Figure 1.14 (d) shows the active site of IDO in the P1- 
39 
Enzymatic and iidechanis tic Studies into ii3ptophan 2,3-Dio.ygenasc 
bound form, displaying the heme environment with the proximal site of the heme 
porphyrin occupied by a histidine residue (His 346). The heme pocket is formed by 
residues from the small domain (Tyr126, Cys129) and from the large domain 
(Phe163, Phe164, Phe226, Arg231, Ser263, G1y261 and G1y262) and has a 
preponderance of hydrophobic residues. 
1.7.3 	Comparison of IDO and TDO 
With the exception of the smaller N-terminal domain of IDO, the structures of IDO 
and TDO are very similar. Indeed, in comparing 201 structurally equivalent Ca 
atoms between xcTDO and the large domain of hIDO the root mean square 
difference is only 3.1 A (Figure 1.16). The above-mentioned 'dimeric' arrangement 
in TDO, which involves the N-terminal region of one monomer comprising part of 
the substrate-binding site in the adjacent monomer, is clearly not possible in 
monomeric IDO. However, the two tyrosine residues in TDO that are proposed to be 
important in this arrangement, Tyr24 and Tyr27, are in equivalent positions to 
Tyr126 and Cys129 in IDO. These tyrosine residues all hydrogen-bond to glutamate 
residues, and this tyrosine / glutamate motif is conserved in most TDO and IDO 
species, linking either the N-terminal loop of the adjacent monomer to the active site 
in TDO, or between the capping and larger domains in IDO (Figure 1.16 and 1.17). 
However, in addition to these similarities, it should be noted that the equivalent 
region in IDO of the loop comprising residues 250-260 of TDO is disordered in the 
IDO structure. This region is particularly important in TDO because it includes 
Thr254 that, as mentioned above, is involved in binding the ammonium and 
carboxylate moieties of L-Trp. In the absence of L-Trp this loop region is disordered 
in the TDO structure, and substrate binding is required to induce its ordering. This 
may also be the case for IDO, but the possibility exists that there is no equivalent 
interaction between IDO and L-Trp. 
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Figure 1.16 Homo sapiens IDO in the ferric, P1 bound state. The smaller C-
terminal capping domain is shown in grey, and the larger N-terminal domain in blue. 
The heme porphyrin is shown in grey and Try 126 is shown as sticks, linking the 
capping domain to the active site. 
Figure 1.17 TDO and IDO overlaid. IDO is shown in grey and blue as in whilst 
monomeric TDO is shown in magenta. 
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In contrast to TDO, the structure of IDO is not available with any substrate bound, 
but has been solved with the inhibitor P1 at the active site. Currently, the only 
structures available with substrate bound at the active site are of xcTDO or PrnB (6). 
Since PrnB has no proven dioxygenase ability in its purified form little information 
therefore exists on the mode of substrate binding in the heme dioxygenase family. 
Given the similarity between the active sites of TDO and IDO, it is perhaps 
reasonable to assume a similar substrate-binding mode in the active-site. 
In a comparison of the active-sites of TDO and IDO it can be seen that many 
residues are equivalent to each other - Arg 117 in TDO to Arg23 1 in IDO, Phe5 1 in 
TDO to Phe163 in IDO, and Tyr24 in TDO to Tyr126 in IDO. Similarly, the position 
occupied by Tyrll3 in TDO is taken by the similar amino-acid Phe226 in IDO. 
Perhaps the most obvious difference between the active sites of the two enzymes is 
the presence of His55 in xcTDO and its equivalent Ser167 in hIDO. In TDO, the 
histidine side chain is hydrogen bonded with the indole nitrogen atom of L-Trp, and 
the role of His55 would appear to be for regulating substrate binding. The role of 
Ser167 in IDO is less clear in the absence of a substrate-bound crystal structure, but 
it is unlikely that this residue plays any crucial role in IDO. 
Residues equivalent to xcTDO Argi 17 and Tyrl 13 are found in all TDO and IDO 
enzymes, although tyrosine 113 is replaced by phenylalanine in approximately 50% 
of IDO species. As discussed above, this carboxylate-binding motif appears to be 
essential for substrate binding; arginine reorientates in the presence of substrate, 
interacting with the carboxylate group of L-Trp, with "open" and "closed" 
conformations observed (Figures 1.14 (a), (b), and(c)). 
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Table 1.2 	Active-site bond distances 
Enzyme Atoms Distance (A) 
xcTDO H240 - Fe 2.3 ± 0.2 
Fe — Waterl 3.5±0.2 
Water 1 - G125 amide 
N 
2.8 ± 0.2 
Water 1 - L-Trp a- 
amino N 
3.0 ± 0.2 
Water 1 - L-Trp indole 
N 
3.3 ± 0.2 
H55 - L-Trp indole N 2.6 ± 0.2 
rmTDOa H257-Fe 2.2 ± 0.3 
hIDO H346—Fe 2.1±0.3 
Fe-4-PI 2.1±0.3 
43 
Enzymatic and Mechanistic Studies into Tnptophan 2,3-Dioxvenase 
1.8 	Allostery 
Allosteric regulation is the ability of an effector molecule to influence binding at an 
allosteric site, and relates to enzymes containing one or more binding sites. Effectors 
which enhance the proteins activity or binding capabilities are known as allosteric 
activators, and those which decrease these properties are known as allosteric 
inhibitors. Allosteric regulation is often used in biological systems to regulate 
substrate concentrations in metabolic pathways, or to transport molecules around the 
body (91, 92). 
Cooperativity can be displayed only by enzymes with multiple binding sites. 
Cooperativity refers to the binding of substrate or an effector at one active site 
influencing the binding at another or all other binding sites. Confusingly this can also 
be referred to as allostery, and literature on this subject appears to use the two terms 
almost interchangeably. For example, the most commonly known allosteric protein is 
hemoglobin, and hemoglobin is commonly used in textbooks to describe basic 
concepts of allostery and cooperativity (93, 94). 
Cooperativity in binding of substrate or molecules to a protein is diagnostic of the 
protein's interaction between binding sites- the binding of one molecule at a binding 
site affects the binding of others. A sigmoidal binding curve (dissociation or 
association) for a substrate is seen, which is analysed by the Hill equation (95). The 
Hill equation gives n, the Hill constant, which increases with the degree of 
cooperativity of a reaction. This provides a simplistic characterisation of ligand 
binding: if n=1, the reaction is non-cooperative and equal to Michaelis-Menton 
kinetics, when n >1, positive cooperativity is observed, where effector ligand binding 
increases the affinity of the protein for further reaction or ligand binding. The 
maximal value of n is equal to the number of ligand binding sites accessible. 
Negative cooperativity is displayed when n < 1, where effector ligand binding 
decreases the affinity of the enzyme to further reaction or binding. 
Previous studies of TDO have indicated some degree of cooperativity in its binding 
of substrates (96, 97) and the recent crystal structure of xcTDO showed the specific 
binding of four L-Trp residues in the interface of the tetramer (1). These additional 
binding sites raise the possibility that these may be allosteric effector sites, where 
binding of substrate changes the conformation of the protein, affecting the binding of 
further molecules at the active site (which is the "allosteric site" described above). 
For TDO there is an apparent activation towards binding of diatomic ligands, such as 
oxygen, cyanide, nitric oxide and carbon monoxide at the active site, in the presence 
of L-Trp, tryptamine and 5-hydroxy-L-tryptophan (4, 96, 98, 99), as evidenced by 
dramatically decreased Kd values. In addition there is an increased affinity for 
oxygen in the presence of a-methyl-tryptophan, a substrate analogue that is neither a 
substrate nor an inhibitor of enzyme activity (96). This is strong evidence that 
substrate binding alters the conformation of the protein, although it is unknown if 
this allosteric activation is occurring within one monomer, with binding at the active 
site or the effector site influencing binding in each monomer separately, or if it is a 
more global, cooperative activation between active sites and effector sites in different 
monomers of the protein. 
The reaction velocity of allosteric enzymes can be regulated by small changes in 
substrate concentration and often regulate metabolic pathways where the substrate 
concentration fluctuates over a narrow range. It is possible that TDO may play such a 
"housekeeping" role, regulating the tryptophan concentration and keeping it within 
certain parameters (38). 
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1.9 	Spectroscopy of TDO and IDO 
Electron paramagnetic resonance (EPR), resonance Raman, magnetic circular 
dicroism (MCD), and nuclear magnetic resonance (NMR) spectroscopies have been 
used to characterize this family of proteins, and the results of these studies are 
discussed below. EPR data of the substrate-free and L-Trp-bound forms of IDO and 
TDO, in the ferric state, are shown in Table 1.3. 
1.9.1 Spectroscopic Investigations of TDO 
The heme environment of TDO is well characterised due to the availability of crystal 
structures with and without the presence of L-Trp in the active-site (bond distances 
are shown in Table 1.2). EPR experiments on human, rat liver and Pseudomonas 
TDOs in the ferric state have shown the presence of two distinct species in solution, 
a high-spin form and a low-spin form (77, 96, 100). At acidic pH only the high-spin 
state has been reported and on increasing the pH a transition to a mixed-spin state 
occurs, containing a mixture of the two forms. The spin state of the alkaline form of 
ferric TDO is temperature-dependent, and the proportion of high spin species 
increases with elevating temperature. Histidine occupies the axial coordination 
position to the heme iron, whilst sixth ligand in the high-spin species is postulated to 
be a water molecule whilst that of the low-spin species is postulated to be hydroxide 
(77). This is possible for substrate-free TDO since a histidine residue is present in the 
active site to deprotonate a bound water molecule that is present in the X campestris 
substrate free active site (1). This is in contrast to IDO where no equivalent residue is 
available, but data so far are inconclusive. 
EPR data on rat liver and Pseudomonas enzymes show that addition of L-Trp to the 
ferric enzyme causes an increase in the low-spin component at neutral pH, with a 
decrease in the high-spin component (96, 100). MCD studies have suggested that this 
high spin component may be distinct from that observed in the substrate-free 
enzyme, but little data are available for analysis at present (101). The spectral 
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changes indicate that L-Trp binding to the ferric protein causes increased 
deprotonation of the heme bound water. L-Trp binding to the ferric enzyme also 
significantly modifies the pH of the spin state transition, decreasing the pH at which 
this transition occurs by about 1.6 units. This substrate-induced shift could be caused 
by the bound L-Trp deprotonating the bound water molecule, as in IDO, rather than 
the active site histidine. Deprotonation of the water by the indole nitrogen is possible, 
since the bond distance is 3.3 A (Table 1.2). 
Contrary to the data on the prokaryotic TDO, recent EPR analysis has shown that 
addition of L-Trp to human TDO causes the creation of an additional low-spin 
species (Table 1.3) (77). The high-spin and two low-spin species observed have 
similar g-values to those of human IDO under analogous conditions, and they are 
proposed to have similar ligands in their distal position (78, 102). This result is 
clearly different to that of the prokaryotic TDO species studied, and poses many 
questions as to the differences in the heme environment and substrate binding 
interactions between TDO enzymes from different species and between IDO and 
TDO. 
1.9.2 Spectroscopic Characterization of IDO 
UV/Visible, EPR and MCD spectra of ferric human IDO show the presence of two 
distinct species in solution, high- and low-spin heme, in approximately equal 
population at pH 6 (77, 101-103). The two species are shown to be in equilibrium, 
and on increasing the pH there is an increase in the low spin component, with a 
concomitant decrease in the high spin component. Histidine is the proximal ligand to 
the heme iron in both species, with a nitrogen-iron bond distance of 2.1 A (87). The 
high-spin species is confirmed by MCD and resonance Raman spectroscopy as 
arising from water ligation in the distal position. The identity of the sixth ligand in 
the low-spin species is thought to be an as yet unidentified nitrogenous ligand, as 
there is not an available nitrogen ligand in the active-site (102). The spectra are 
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shown to be pH independent - indicating that no ionisable residue affects binding, 
and there is no formation of hydroxide bound heme whilst substrate is absent. 
In the presence of L-Trp at pH 8 MCD and EPR confirm that there are three distinct 
species in solution, one of which is high-spin and the other two are low-spin (102). 
The sixth heme ligand for the additional low-spin species is hydroxide, and this is the 
predominant species in solution. The bound L-Trp provides a hydrogen-bond 
acceptor to stabilize deprotonation of the bound water molecule. Ferric substrate-free 
human [DO does not form a hydroxide-bound species because IDO lacks a 
hydrogen-bond acceptor to facilitate deprotonation of the bound water molecule. In 
contrast, for the ferric substrate-bound enzyme, the spectra are pH dependent due to 
an ionisable interaction affecting the formation of the hydroxide species in the active 
site. L-Trp is thought to act as a proton acceptor, deprotonating the bound water 
molecule and forming the hydroxide bound species and this is supported by 
resonance Raman studies (104, 105). The relation of these studies and those above to 
the active site structure is currently limited by the lack of a substrate bound crystal 
structure. 
Resonance Raman spectra of CO and NO binding to ferric, L-Trp bound human TDO 
(104) and human IDO (105, 106) enzymes suggests that in TDO the C2-C3 double 
bond of the tryptophan ring faces the distal diatomic ligand of the heme. This is in 
contrast to IDO, where the indole nitrogen appears to hydrogen-bond with the 
diatomic heme ligand. 
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Table 1.3 	EPR identification of all species observed in the absence or presence 
of L-Trp for TDO and IDO 
Enzyme Species g-value 
H. sapiens TDO (77) High spin 5.71 and 2.01 
Low spin 2.89, 2.30 and 1.62 
Low spin a 2.63, 2.20 and 1.84 
P. acidovorans TDO (96) High spin 5.8 
Low spin 3.67, 2.20 and 1.80 
H. sapiens IDO (102) High spin (H20) 5.96 and 1.99 
Low spin (N) 2.94, 2.25 and 1.50 
Low spin (OH)" 2.52 2.19 and 1.86 
('Only observed in the presence of L-Trp, TSimilar  data are observed in the study by 
Brady et a! (107)). 
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1.10 Objectives 
At the beginning of this PhD, a very limited understanding of the molecular details of 
tryptophan oxidation existed, since there was no published structure for TDO. The 
nature of substrate and dioxygen binding to the enzymes were unclear and little 
biochemical data on substrate binding, redox states or reaction intermediates existed. 
Detailed information on the mechanism of L-Trp oxidation by TDO and IDO, and its 
control at the molecular level needs to be determined and the ultimate aim is the 
complete description of the mechanism of TDO. The catalytic mechanisms employed 
by TDO and IDO have not yet been fully elucidated although a number of 
mechanisms for tryptophan dioxygenation have been proposed. In this study we 
attempt to resolve the question of whether an active site base is necessary for 
catalytic activity, utilising a TDO from Xanthomonas campestris (xcTDO). 
Xanthomonas campestris is a pathogenic gram-negative aerobic bacterium that 
infects plants, such as the crucifers Brassica and Arabidopsis (108, 109). 
Xanthomonas campestris TDO shares 34% sequence identity with human TDO, 
making it a good model for investigating TDOs biochemical properties (Figure 1.2). 
To this end, the bacterial xcTDO was isolated and was characterised using a range of 
biochemical, potentiometric and structural techniques. To achieve this, firstly, an 
efficient bacterial expression system was designed and implemented to provide 
useful quantities of pure protein. 
Secondly, structural studies provided information on the enzyme structure, revealing 
the substrate binding interactions of the active site and allowing the construction of 
active-site mutants based on these critical residues. Biochemical and potentiometric 
characterisation of the wild-type enzymes and its variants has provided insight into 
binding characteristics and oxidation state of the enzyme in the catalytically active 
form. From this mechanistic conclusions have been formed and provide insight into 
the mechanism of TDO. 
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Chapter 2 
Materials and Methods 
2.1 	Molecular biology and Mutagenesis 
A full-length Xanthomonas campestris TDO (xcTDO) construct was created at the 
centre for Advanced Biotechnology and Medicine (Northeast Structural Genomics 
Consortium), Rutgers University, Piscataway, NJ 08854. The expression plasmid 
was produced by cloning full-length xcTDO (Q8PDA8 XANCP, NESG ID XcR13) 
into a pET21d (Novagen) derivative, generating the plasmid pXcRl3-21.3, with a C-
terminal hexa-histidine tag. The full length amino-acid sequence for xcTDO is shown 
in Appendix C. The resulting XcR1 3 contains eight non-cleavable, non-native 
residues at its C terminus to allow efficient purification. BL21(DE3) pMGK cells 
were used for initial colony identification, as they allow efficient plasmid 
transformation, and the plasmid was then extracted using a Qiagen QlAprep® Spin 
Miniprep Kit. The extracted plasmid was then transformed and expressed using the 
One Shot® BL21(DE3) (Invitrogen), E. coil expression system, which produces high 
levels of xcTDO protein expression. 
The point mutation of histidine 55 to alanine (1155A) was created by Rong Xiao and 
Li Zhao at the Centre for Advance Biotechnology and Medicine, Rutgers University, 
Piscataway, NJ 08854, whilst the point mutation histidine 55 to serine (1155S) was 
created in our laboratory. In both cases point mutations were created by employing 
the QuikChange II sitedirected mutagenesis kit (Stratagene, La Jolla, CA). DNA 
polymerases require a short sequence of single stranded DNA called a primer, which 
can bind to the wild type-sequence at the location where the mutation is to be 
introduced. The oligonucleotide primers directing the mutation were designed in an 
automated fashion by using the Primer Prim'er program, 
www.mnr.cabm.rutgers.edu/bioinfon-natics/Primer Primer/ and the primers designed 
are displayed in Appendix C. All mutations and their associated open reading frames 
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were verified by DNA sequence analysis the Edinburgh University SSBS sequencing 
lab. Mutated plasmids were extracted and expressed in the same manner as wild-type 
TDO, using the One Shot® BL21(DE3) Invitrogen, E. coli expression system. 
Bacterial strains expressing TDO and its mutant forms were stored long term as 
dimethyl sulfoxide (DMSO) stocks (923 p1 starter culture, 77 p1 DMSO) at —80 °C. 
2.2 	Growth and Expression 
Wild-type TDO and its mutants H55A and H55S were all expressed and purified in 
the same way. Bacterial cultures were grown in Luria Bertani broth (LB), previously 
sterilised at 121 °C for 20 minutes in a Kestral autoclave (Table D. 1, Appendix D). 
All solutions were prepared with Millipore Q Ultrapure water. Agar plates were 
prepared with sterilised LB/agar solution and allowed to cool prior to solidification 
in sterile Petri dishes with ampicillin (Table D. 1, Appendix D). 
Starter cultures for large scale growth were prepared by inoculating 20 ml of sterile 
media with DMSO stock via a sterile pipette tip and incubated for 24 hours at 37 °C, 
225 rpm in a Gallenkamp shaker. Growth flasks (11 flasks containing 400 ml LB 
broth) were inoculated with imi of starter culture and 500 jtl of 25 mM ampicillin 
and grown for 12 hours at 37 °C and 150 rpm. Protein production was then induced 
with isopropyl-3-D-thiogalactopyranoside (IPTG) at a final concentration of 250 mg 
l' and 1 ml of 7 mM hemin solution added to encourage heme incorporation into the 
protein. The temperature was also decreased to 30 °C and left for a further 12 hours 
at 150 rpm until the cells were harvested by centrifugation (10 minutes at 8000 rpm) 
using a Sorvall RC-5B refrigerated centrifuge at 4 °C. The resulting cell pellets were 
either lysed and purified immediately (as described below) or stored at —20 °C until 
required. 
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2.3 	Enzyme Extraction and Purification 
2.3.1 Cell Lysis 
All buffers used in purification of the enzymes are described in Table D.2, Appendix 
D. The harvested cells were re-suspended in buffer A (5 ml of buffer per gram of cell 
culture) and cell lysis was initiated by incubating the cell suspension with egg white 
lysosyme (ling per ml of suspension) for 30 minutes with phenylmethylsulfonyl 
fluoride present (1 mg per ml of suspension) in order to inhibit proteolytic enzymes 
present. Lysis was completed by ultrasonication of the suspension, (20 second bursts 
at 10 microns amplitude, Sanyo soniprep 150). This was performed on ice, resting 
for 1 minute and stirring between bursts in order to minimise overheating and 
protease activity, and was complete when the viscosity of the lysed material 
decreased. Cell debris was then removed via ultracentrifugation, 1 hour at 20,000 
rpm, 4 °C, and the supernatant collected. 
2.3.2 Chromatographic Purification 
Purification of the protein was achieved using column chromatography - the His-
tagged protein can be separated from the cell supernatant by specific, reversible, 
binding of the His tag to a nickel agarose (Ni-NTA) gel column (Qiagen). Selective 
binding of the protein to the resin allows impurities to be washed off and the 
subsequent elution of the protein provides purified material. All purification steps 
were performed in a cold room at 4 °C and purification buffers are described in 
Appendix D. 
A Ni-Agarose column containing 20 ml Ni-Agarose resin solution (Qiagen) was 
suspended in a minimal amount of buffer A and packed to form a column 6x2 cm in 
dimensions. The column was washed with buffer A and the supernatant was loaded 
onto the column where it bound strongly to form a tight red band. The column was 
then washed with a further two column volumes of buffer A to remove supernatant 
and any unbound proteins. It was further washed with four column volumes of buffer 
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B, then four column volumes of buffer C to remove further protein impurities. 
Elution was achieved using a minimal amount of buffer D, with the dark red protein 
fraction collected and subsequently concentrated by centrifugation using a FALCON 
6-300 centrifuge and Amicron Centriprep concentrators with a membrane cut-off of 
30 kDa at 2500 rpm for 1 hour until there was -5 ml of protein solution. 
G-25 sephadex resin was suspended in a minimum amount of buffer E and packed to 
form a column 2 xl 5 cm in dimensions. The column was equilibrated with 5 column 
volumes of buffer E, and the 5 ml of protein loaded onto the column. When all the 
protein was loaded, buffer E was passed down the column and the dark red imida.zole 
free protein was collected and concentrated by centrifugation at 2500 rpm as before, 
until the required concentration was achieved (typical protein concentrations were 
0.5-1.5 mM but the protein can be concentrated to 	mM before precipitation 
occurs). Aliquots of 200 il purified and concentrated protein were flash frozen in 
cryovials using liquid nitrogen and stored at —80 °C until required. 
2.4 	Purity Determination 
2.4.1 SDS-PAGE analysis 
SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) was used 
to verify the purity of the protein, and monitor the degree of purification. SDS-PAGE 
shows the different proteins present in a sample over a fixed range and can therefore 
be used to verify the purity of a protein sample. 
2.4.2 Gel Loading and Electrophoresis 
Samples for gel electrophoresis were loaded onto a gel and a potential difference 
applied causing a migration of proteins through the gel. The distance travelled is 
determined by their effective mass, which is then estimated according to how far 
they migrate compared to a known set of standards. 
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Samples were prepared by placing 75 p.1 distilled water, 25 p.1 SDS sample buffer 
(Invitrogen) and 1 p.1 protein in an eppendorf tube and boiling the sample for 3 
minutes to denature the polypeptide chain. 
Pre-poured 4-12 % Bis-Tris gels (Invitrogen) were used and prepared by washing 
with distilled water before use. Prepared protein samples were loaded into the wells 
at the top of the gel, including one lane of pre-prepared marker samples (typically 5 
p.L molecular marker (Seeblue Plus 2, Invitrogen). The gel was placed in a gel tank 
filled with running buffer. A voltage of 150 V, (120 mA, 60 W for 1 hour) was 
applied, until the dye front reached the foot of the gel. The gel was removed from the 
tank and stained for both heme and total protein content. The gel buffers are outlined 










Lane 1 2 3 4 
Figure 2.1: Coomassie stained SDS-PAGE analysis of TDO. Lane 1 is a molecular 
weight marker lane, with weights indicated to the left hand side. Invitrogen SeeBlue® 
Plus 2 marker system was used. Lane 2 shows purified wild-type TDO (wtTDO), 
Lane 3 shows purified H55A and lane 4 shows purified H55S. 
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2.4.3 Coomassie Staining 
Coomassie stain can be used to detect the presence of any polypeptide in the samples 
run by staining them blue. Coomassie stain was applied to each gel for 15 minutes, 
before removal. The gel was then immersed in a destaining solution for several 
hours. An example is shown in Figure 2.1. Coomassie blue can be used on gels 
previously stained for heme presence, in order to assess polypeptide content. 
2.4.4 Heme Staining 
As c-type cytochromes are covalently bound to the protein backbone, they are not 
lost during denaturation of the protein by boiling. As a result, any c-type 
cytochromes present in the protein sample can be stained by a hydrogen peroxide I, 
3', 5, 5'-Tetramethylbenzidine stain. In addition, some proteins containing b-type 
heme porphyrins can be analysed via this method. An enzyme containing b-type 
heme or hemes may sometimes still retain contact with the porphyrin after 
denaturation by boiling. 
The gel was equilibrated in the heme stain equilibration buffer as shown in Table 
D.3. After 30 minutes, a small quantity of 3, 3', 5, 5'-Tetramethylbenzidine (10 mg) 
was added and incubated for 15 minutes in the dark. Hydrogen peroxide was then 
added, and the colour due to heme presence developed within minutes. 
2.4.5 Purity Determination via Spectrophotometric Observation 
IJVI Visible spectra were recorded over the range 250-800 nm using a Shimadzu 
UV-2 101 PC spectrophotometer and quartz cuvette with a 1 cm path length, and the 
relative absorbance ratio of the Soret band to the peak at 270 rim was recorded. The 
absorption at 270 nm is due to the aromatic residues in the protein, and so is 
indicative of the protein concentration, whilst the peak at 405 nm (the Soret Band) is 
due to absorbance by the heme groups. For wtTDO and its mutants a ratio of 
A405/A270 > 2 is an indication of pure protein. 
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2.5 	Enzyme Concentration Determination 
2.5.1 Bradford Assay 
Initial protein concentration was determined by employing a Bradford assay (110), 
using the Bio-Rad (Bradford) Protein Assay Kit with bovine plasma albumin 
standard. This kit utilises the shift in the absorbance maximum of Coomassie 
Brilliant Blue G-250 from 465 nm to 595 nm upon protein binding. This method is 
particularly useful as the extinction coefficient of the dye-albumin complex is 
constant over a 10-fold concentration range, allowing a large range of proteins to be 
analysed. Firstly a standard graph is plotted utilising bovine plasma albumin, shown 
in Figure 2.2, and then samples of the protein of interest are reacted with Coomassie 
Brilliant Blue G-250, and compared to the standard to calculate the protein 
concentration. Results are obtained in triplicate and repeated at two different protein 














0.2 	 0.4 	 0.6 	 0.8 	 1.0 
Protein (mg/ml) 
Figure 2.2: Standard graph of bovine plasma albumin concentration against 
absorbance displaying straight line characteristics 
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2.5.2 Liquid Chromatography - Mass Spectrometry (LC-MS) 
The molecular mass of wt TDO was determined using LC-MS. LC-MS was carried 
out using a mass spectrometer utilising a AllianceTMHT, WatersTM  2795 separations 
module, Micromass platform and WatersTM  486 Tunable Absorbance Detector. 
Samples consisted of 10 mM protein in a 0.1 % formic acid solution. Analysis and 
recording of data was achieved by using MassLynx V4.0 Global Mass-Informatics. 
2.5.3 Heme Content Determination 
Knowledge of the degree of heme incorporation is crucial to this work. Failure to 
incorporate heme would result in altered activities and heme content is assessed via 
the pyridine hemochrome assay (111). In addition, the initial determination of 
enzyme concentration and the heme extinction coefficient was based on the total 
heme content, and total protein content, determined by the pyridine hemochromagen 
assay and Bradford assays (I 10) respectively. 
A solution of TDO (5 p.M) was thoroughly mixed with an equal volume of reagent A 
(Table D.4, Appendix D), followed by the immediate addition of 10 pA of 5 mg per 
ml Na2 S204  solution. Spectra of the reduced pyridine hemochromagen was recorded 
over the range 250-800 nm using a Shimadzu UV-2101PC spectrophotometer and 
quartz cuvette with a 1 cm path length. Heme concentrations were calculated using 
the difference extinction coefficient A8556540 = 22.1 mM'cm'. The appearance of the 
reduced pyridine hemochromagen was time dependent and so sufficient equilibration 
was allowed following the addition of dithionite. Each determination was performed 
in triplicate to ensure accuracy. Comparison of the calculated Bradford assay protein 
concentration with the heme concentration calculated from the pyridine hemochrome 
assay gives an indication of heme incorporation. In all cases, heme incorporation was 
determined to be greater than 90%. 
Extinction coefficients at 404nm and 431 rim were calculated per protomer for the 
ferric and ferrous enzymes respectively by comparing the Soret maxima of the ferric 
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and ferrous enzymes with the corresponding protein concentration determined via the 
Bradford assay. Calculated extinction coefficients are shown in Table 2.1. 
During experimental procedures protein concentration was determined from the 
absorbance of the ferric (oxidised) Soret band, by applying the Beer-Lambert Law, 
taking into account the dilution of the protein sample, and using the extinction 
coefficients outlined in Table 2.1. 
Table 2.1 Calculated Extinction Coefficients 
Enzyme 
E405  
(M cm- ') 
E431  
(M 1 cm 1) 
wtTDO 180,500 113,000 
H55A 130,400 120,000 
H55S 132,000 116,000 
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2.6 	Binding of Exogenous Ligands 
Substrate binding titrations give a measure of the affinity that the enzyme has for 
substrate. The addition of substrate to ferric or ferrous wtTDO and its mutants causes 
a shift in the Soret peak and this change can be monitored spectrophotometrically as 
a shift in the absorption spectrum. Dissociation constants (Kd) were determined 
spectrophotometrically by monitoring the change in absorbance at the appropriate 
wavelength stimulated by addition of small aliquots of substrate, using Equation 2.1; 
AAbs = (KD Absjnjt jai + [Litot Ab5fi0 ) / (KD + [Litot) 	Equation 2.1 
Where Absjnit jai and AbSfinal are the initial and final absorbance values, respectively, 
and [L]tot is the total concentration of the ligand. Absorbance changes upon substrate 
binding are small ( 5-10 % of initial peak absorbance) but usually easily 
quantifiable due to tight substrate binding. 
The Kid is a measure of the affinity that the substrate has for the enzyme and is 
equivalent to the substrate concentration at half the maximum absorbance change. Kj 
values for binding to ferric and ferrous wtTDO and mutant enzymes were determined 
in a Belle Technology anaerobic glove box with [021 maintained below 5 ppm. 
An enzyme concentration of 5 !tM was used and aliquots of substrate (0.5-15 tl 
maximal volume) were added sequentially to the cuvette using a Hamilton® syringe. 
Where reduced enzyme was required, the stock enzyme solution was reduced by 
titration with sodium dithionite and excess reductant was removed via gel filtration 
(BioRad G-25, 10 cm3 column). Aliquots of concentrated ligand prepared in the 
same buffer as the enzyme solution were added to the cuvette and the spectra 
recorded from 250 to 800 nm using a Shimadzu UV-PC 1501 spectrophotometer. 
Spectra were recorded after each addition of ligand at 25°C, as shown in Figure 2.3. 
Spectral changes were monitored and difference spectra calculated from ((TD0405)-
(TD0405+substrate)). Dissociation constants were determined by plotting the 
maximal absorbance changes calculated from each difference spectrum against the 
concentration of ligand using Microcal Origin 7.5. 
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Figure 2.3: Example of the spectral changes observed upon L-Trp binding to 
ferric wtTDO, on addition of 0. 5-30 MM L-Trp to the enzyme. The deviations from 
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Figure 2.4 	Michaelis-Menten plot of substrate concentration against calculated 
rate of turnover (k0b). 
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2.7 	Steady-State Kinetics 
Substrate-dependent steady-state turnover is a quantitative study of enzyme catalysis 
used to calculate maximal rates of enzymatic turnover. The derivation of the 
Michaelis-Menten equation and other equations used in this thesis are described in 
Appendix B. The formation or depletion of one of the components necessary for 
turnover must be observed over a set time period - observing at a variety of substrate 
concentrations allows for plotting observed rates against substrate concentration, and 
from this the rate constant kcat and the Michaelis constant, Km, calculated. 
The rate of formation of N-formylkynurenine was monitored by measuring the 
change in absorbance at 321 Mn (6321 of N-formylkynurenine = 3750 M 1cm 1) in a 
Shimadzu UV-2 101 PC spectrophotometer and quartz cuvette with a 1 cm path 
length. Kinetic data were fitted to both the Michaelis-Menten and the Hill equation 
using Origin software (MicroCal, Northampton, MA). All assays were performed at 
25 °C by means of a thermostatically controlled water bath. Assay buffer F was used 
throughout, with 20 mM ascorbate, 10 .ig catalase and 10 p.M methylene blue 
present. Substrate concentration was varied dependent on the substrate of interest, 
(Table (e), Appendix D) and a known concentration of enzyme, (50 nM) was added 
to the cuvette to initiate the reaction. Each measurement was carried out in triplicate. 
The rate of L-kynurenine production over a range of substrate concentrations was 
fitted to the Michaelis-Menten equation using Microcal Origin, Figure 2.4. 
Weak catalytic activity by ferric [DO and TDO has been reported, but turnover is 
generally catalyzed by the ferrous protein. Reduction of heme iron is therefore 
required to facilitate the observation of catalytic activity. Upon reduction, some 
turnover can be observed in the absence of any electron transfer mediators, but full 
catalytic activity is not observed without their presence due to uncoupling of the 
reaction leading to oxidised enzyme production (and subsequent reduction in the 
catalytic activity). Ascorbate, catalase, and methylene blue are employed in the assay 
buffer to achieve this. Ascorbate and methylene blue are reducing agents, but also 
react with dioxygen to form superoxide and peroxide by-products, which can bleach 
the heme and destroy catalytic activity. Catalase is therefore present to remove any 
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superoxide or peroxide in solution and hence allows an efficient turnover of 
substrate. 
2.7.2 pH Dependence of Activity 
The variation of turnover rate with pH for both wild-type and mutant forms of TDO 
was determined by measurement of activity at saturating L-Trp concentrations, and 
over the range pH 6.0 - 8.3, utilising assay buffer F. The profiles obtained were fitted 
by least squares regression to a single pKa value using Microcal Origin 7.5. 
2.7.3 Determination of Inhibition Constants 
There are two main causes of the failure of the Michaelis-Menten equation - 
substrate inhibition or substrate activation and equations describing different types of 
inhibition are described in Appendix C. 
The effect on L-Trp turnover by wtTDO upon addition of an inhibitory molecule was 
studied via the steady-state method. The steady-state turnover of L-Trp was observed 
as described in Section 2.7.1, with no inhibitor present in the assay mixture. The 
assay was then repeated 5 times, with differing amounts of the inhibitor present in 
solution each time. For the determination of the inhibitory constant for D-Trp, the 
assay was repeated 6 times with 0, 3300, 6600, 10000, 15000 and 20000 MM D-Trp 
present in the assay mixture. The data was analysed by plotting 1 I v (the observed 
rate), against 1 / [L-Trp] using Microcal Origin 7.5. 
2.7.4 Preparation of Deuterated Samples for Kinetic Experiments 
The effect on turnover rates upon deuteration of the solvent was studied via the 
steady-state assay method. Buffer and substrate solutions were prepared in D20 as 
described before but using either DC1 or NaOD where appropriate. The pD of the 
deuterated buffer was corrected according to Equation 2.2 (112, 113); 
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pD = pH + 0.4 	 Equation 2.2 
The protein solution was prepared in H20 then concentrated such that the addition of 
the protonated enzyme solution was less than 0.05 % of the total volume of the assay. 
2.8 	Stopped-Flow Spectrophotometry 
Stopped flow spectrophotometry involves the rapid mixing of two solutions and the 
immediate monitoring of any spectral changes over the initial reaction period. 
Mixing occurs within a spectrophotometric cell of fixed path length, and on mixing 
the instrument records the absorbance of the reacting solution, either at a fixed 
wavelength or over a specified range. The resolution of the instrument is restricted 
by its dead-time, a value which is the difference between the point at which the 
reaction can be traced back to (t = 0) and the point at which recording actually begins 
(t = dt). Data is also impaired by the mixing time for the sample of interest. Once the 
two solutions are entered into the reaction chamber observation will begin, however 
until mixing is complete the reaction will not proceed at maximum velocity and a lag 
will be observed. Mixing time is hard to quantify and will depend on the sample of 
interest and its temperature. These factors make reactions occuring at a rate faster 
than 1000 s_i hard to quantify using single wavelength analysis. All stopped-flow 
experiments were conducted using an Applied Photophysics SF. 1 7MV stopped flow 
spectrophotometer using either a single wavelength or diode array (multiple 
wavelengths) detector, with a dead time between 0.9-1.1 ms. The stopped-flow 
equipment was contained in an anaerobic glove box (Belle Technology), maintained 
under a nitrogen atmosphere (02 < 5 ppm). Unless otherwise stated, buffer F was 
used throughout at pH 7.5. 
2.8.1 Detection of an Oxyferrous Ternary Species 
For detection of the oxyferrous ternary complex, all procedures were conducted 
within an anaerobic glove box (Belle Technology, 02 <5 ppm) at either 10 °C or 25 
°C. Firstly 200 p.1 of 50 p.M enzyme was reduced by addition of sodium dithionite, 
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and the dithionite was then removed via gel filtration down a G25 pre-packed 
column (Bio-Rad) equilibrated with buffer F. Reduction was confirmed by LTV I 
Visible spectrometry on a Varian Cary 50 Bio spectrophotometer, also contained 
within the glove box. Substrates (L-Trp, 6-F-Trp or 5-F-Trp) were prepared in buffer 
F and concentrations varied according to substrate. 
Sample A - 0.8 ml aliquot of reduced enzyme was mixed with 0.2 ml substrate, to 
yield a sample containing an excess of substrate (at least a 10-fold excess), and this 
sample was mixed with Sample B - a 1 ml sample of approximately 10 MM 02 in the 
spectrophotometer (02 concentration was determined prior to mixing). The 
subsequent reaction was recorded utilising either a diode array detector between 200 
and 700 nm (Figure 2.5(a)), or at a specific wavelength (Figure 2.5(b)). 
2.8.2 Oxygen Dependence of Turnover 
Steady-state kinetic experiments under varying [02] rather than [substrate] were 
performed using the stopped-flow apparatus. The concentration of 02 present in the 
assay could be controlled due the sealed environment of the mixing chamber. This 
experiment allowed the calculation of the oxygen binding affinity (Km), and the 
maximum rate of turnover of the enzyme of interest under saturating levels of 02. 
All experiments were performed at 25° C in buffer F. The enzyme was reduced with 
dithionite, and the dithionite removed as described above in Section 2.8.1. Sample A 
containing 50 nM reduced enzyme and 25 MM L-Trp (a large excess), was then 
mixed with Sample B, solutions containing various concentrations of 02 (10 —2000 
in the stopped—flow apparatus. The rate of product formation (L-kynurenine) 
was measured, and the rate of turnover was calculated as described in Section 2.7. 
Results were obtained in triplicate, averaged and an error calculated. Parameters 
relating to the oxygen dependence (Km of dioxygen, k,,,,,- and K1) could be calculated 
by plotting the 02 concentration against the apparent rate of turnover, and fitting the 
data to the Michaelis-Menten equation or the Michaelis-Menten equation corrected 
for substrate inhibition using Microcal Origin 7.5. 
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Figure 2.5 	(a) Diode array spectra overlaid for formation of an oxyferrous 
species for wtTDO with L-Trp. (b) Single wavelength detection at 419nm for 
formation (fast  increasing) and decay (slow decreasing) of the oxyferrous ternary 
species for the same reaction as in (a). 
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2.8.3 	CO Binding Kinetics 
CO binding kinetics were performed by varying [CO] and measuring the rate of 
formation of the Fe2 -CO complex at 420 rim, allowing the calculation of the CO 
dissociation constant (Kd). CO binding was recorded using the stopped-flow 
apparatus. The concentration of CO present in the assay could be controlled due the 
sealed environment of the mixing chamber. 
All experiments were performed at 10° C in buffer F. The enzyme was reduced with 
dithionite, and the dithionite removed as described above in Section 2.7. Sample A 
containing 50 nM reduced enzyme was then mixed with Sample B, solutions 
containing various concentrations of CO (100 - 500 mM), in the stopped—flow 
apparatus. Results were obtained in triplicate, averaged and an error calculated. 
Parameters relating to the oxygen dependence (Kd of CO, and k fl') can be calculated 
by plotting the CO concentration against the rate of formation and fitting the data to a 
straight line using Microcal Origin 7.5, where the Kd of CO is equal to minus the x-
intercept and k ff is equal to the y-intercept. 
2.9 	Small Molecule Concentration 
2.9.1 CO Concentration 
CO-saturated buffer solutions were prepared by removing sealed aliquots of buffer F 
from the anaerobic environment, bubbling with appropriate gas for 5 minutes and 
returning to the glove box. Aliquots of saturated buffer were removed via a rubber 
septum using a syringe to ensure the gas concentration remained constant. 
CO-saturated buffer CO concentrations were determined spectrophotometrically 
using the characteristic P450 CO binding technique. UV / visible spectra were 
recorded over the range 250-800 nm using a Shimadzu UV-2101PC 
spectrophotometer and quartz cuvette with a 1 cm path length. A protein sample (10 
jil protein in 990 t1 buffer) was reduced using sodium dithionite and a spectrum 
recorded. An aliquot of CO saturated buffer (1-5 tL dependent on saturation) was 
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then added to the cuvette and a second spectrum taken. CO concentrations were 
determined from the difference spectra (Enzyme-CO)-(Enzyme) at 450 nm, using 
the Beer-Lambert law with an extinction coefficient of E = 92,000 M 1cm'. 
2.9.2 NO Solutions 
NO-saturated buffer solutions were prepared in the same manner; however 
determination of NO concentration is difficult and was not necessary during the 
course of the experiments. Since the typical NO concentration of a NO saturated 
solution is above 100 tM, an excess of NO (at least 10 times the enzyme 
concentration) was used in all reactions involving NO in this thesis. 
2.9.3 02 Concentration Determination 
Oxygen concentrations were determined spectrophotometrically by UV/visible 
spectrophotometry, within an anaerobic glove box. Oxygen-saturated buffer 
solutions were prepared as for CO. and a separate buffer sample was used for each 
experiment to ensure 02 concentrations were uniform. The concentration of oxygen 
in a prepared solution was checked on an hourly basis to record any small changes. 
A solution of reduced methyl viologen ('20 [LM) was prepared by electrochemical 
bulk reduction and the spectrum was recorded. (Methyl viologen concentrations were 
determined by UV/ visible spectrophotometry over the range 250-800 Mn using a 
shimadzu UV-2101PC spectrophotometer and quartz cuvette with a 1 cm path 
length, contained within an anaerobic glove box. Absolute concentrations were 
calculated using the extinction coefficient 6600 = 13,000 M'cm'. An aliquot 
(typically 10 p.1) of oxygenated buffer was then added to the cuvette and a second 
spectrum taken. Oxygen concentrations were assessed from the difference of the two 
spectra at 600 rim assuming that four methyl viologen molecules are required to 
provide the 4 electrons necessary to reduce oxygen to water. 
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2.10 Redox Potentiometry 
The mid-point reduction potential of the heme group (Fe 3 /Fe2 ) couple present in the 
enzyme was investigated by potentiometric titrations. The standard redox potential 
(E°) is a thermodynamic property dependent on the Gibbs free energy change (AG) 






Where n is the number of electrons and F is the Faraday constant. In terms of 
electron transfer, electrons travel favourably from more negative E° to positive E° 
due to a negative AG. E° is measured sequentially by reducing and oxidising the 
enzyme using an applied voltage and monitoring the spectroscopic changes to the 
absorbance, at 25°C. Plotting the change in absorbance (AAbs) against the applied 
potential (V), and fitting to the Nernst equation, Equations 2.4 and 2.5, allows E° to 
be obtained. 
E 11 = E° - RL In Q 	 Equation 2.4 
nF 
Which when expressed in terms of base 10 logarithms, 
E 11 = E° - 59.1 mV logo aR 	 Equation 2.5 
aO 
At equilibrium, E = 0 and Q = K, therefore, substituting these values into Equation 





Equation 2.6 relates the standard electrode potential to the equilibrium constant of a 
redox reaction. 
Mol 
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2.10.1 OTTLE Electrochemistry 
Optically Transparent Thin Layer Electrode (OTTLE) potentiometry is used to 
calculate mid-point reduction potentials. Firstly a modified EPR tube with an 
optically transparent flat cell, path length 0.3 mm, is filled with the enzyme solution 
of interest. A platinum/ruthenium gauze working electrode, a platinum counter 
electrode and an Ag IAgC1 reference electrode are fitted to the cell, and it can be 
sealed with rubber septa to exclude oxygen if an anaerobic environment is required. 
A potential is applied to the cell, and at each potential a spectra (250 - 700 mn) is 
recorded to observe the sample as shown in Figure 2.6 (a). The proportion of enzyme 
reduced (measured at 431 nm) against the applied potential is plotted. The potential 
of the working electrode was decreased in 50 mV steps and increased in 50 mV steps 
offset by 25 mV relative to the reductive trace. Heme reduction potentials were 
determined by fitting the data to a Nernst equation for a single-electron process using 
Microcal Origin software, as shown in Figure 2.6 (b). The AgIAgC1 reference 
electrode was calibrated against either indigotrisulfonic acid (-99 mV vs. SHE) or 
phenazine methosulfate (+82 mV vs. SHE). Applied potentials were corrected 
relative to SHE where [(potential Ag!AgC1) + 205 my] = [potential SHE]. 
In all experiments the sample was prepared in an anaerobic environment and sealed 
from the atmosphere before removal from the glove box as described in (1, 114). 
Samples were prepared to a final enzyme concentration of approximately 50jtM. 
Titrations were performed in the presence and absence of substrate for WT TDO (15 
mM L-Trp), the H55A mutant (5 mM L-Trp) and the H55S mutant (10 mlvi L-Trp). 
On preparation of the enzyme sample a range of mediators were added (2-hydroxy-
1,4-naphthoquinone (-145 mV vs. SHE), 5-hydroxyl,4-naphthoquinone (-3 mV vs. 
SHE), phenazine ethosulfate (+55 mV vs. SHE), phenazine methosulfate (+82 mV 
vs. SHE), and 1,2-naphthoquinone (+135 mV vs. SHE)) to ensure efficient reduction 
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Figure 2.6 (a) Absorbance change in wtTDO spectrum (b) Relative proportion of 
reduced wtTDO upon oxidation (0) and reduction (.) by electrochemical potential, 
fitted to the Nernst equation. 
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2.11 Liquid Chromatography- Mass Spectrometry (LC-MS) 
Liquid chromatography-mass spectrometry (LC-MS) combines the physical 
separation capabilities of liquid chromatography with the mass analysis capabilities 
of mass spectrometry. LC-MS is a powerful technique used for many applications 
which has very high sensitivity and specificity. Generally its application is oriented 
towards the specific detection and potential identification of chemicals in a complex 
mixture. 
LC-MS was carried out to determine the mass of wild type TDO using the mass 
spectrometer in the University of Edinburgh, School of Chemistry, as described in 
Section 2.4.2. 
LC-MS upon the reaction products produced by TDO and its mutants was carried out 
at the University of Leicester, Chemistry Department with Dr. Graham Eaton. A 
Micromass Quatro LC spectrometer, was used, and the sample was run with MeCN / 
1120 (0.1% formic acid) as the solvent. A C18 (2.0mm x  250mm x  5PM) column 
was used to separate the reactants and products. 
Samples for LC-MS to analyse turnover products were prepared by allowing enzyme 
turnover to proceed, then running the sample through the LC- MS. Aliquots of 10 tl 
were used as described in Section 2.7. Assay buffer F was used throughout, with 
20mM ascorbate, 10 tg catalase and 10 1iM methylene blue present. Substrate 
concentration was 4 mM for L-Trp turnover experiments and 1.5 mM for 1 -Me-Trp 
turnover experiments. Approximately 300 nM of enzyme was added to the cuvette 
for each enzyme studied. The reaction was allowed to proceed for 30 minutes, and 
was then quenched by the addition of 200 p.L of a 30% solution of trichioroacetic 
acid. The sample was then centrifuged to collect the degraded protein and the 
supernatant was then filtered using a Millipore 0.45 p.M filter unit to ensure no 
protein remained in solution. The samples were then flash frozen and stored at -80° 
until required. 
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2.12 Mass Spectrometry-Mass Spectrometry (MS-MS) 
MS-MS upon the reaction products produced by TDO and its mutants was carried 
out at the University of Leicester, Chemistry Department with Dr. Graham Eaton. A 
Micromass Quatro LC spectrometer, was used, and the sample was run with MeCN I 
H20 (0.1% formic acid) as the solvent. A C18 (2.0mm * 250mm *5M)  column was 
used to separate the reactants and products. Samples were produced as described 
above for LC-MS. 
2.13 Protein Crystallisation and Data Collection 
2.13.1 Wild Type TDO - Oxidised substrate free structure 
Crystallisation of TDO was attempted for the oxidised form of the protein by the 
hanging drop vapour diffusion method. Crystals were grown at 18 °C in a well 
solution comprising 0.1 M MES (2-(N-morpholino)ethanesulfonic acid) buffer pH 
6.1, 8 % polyethylene glycol 1000 (PEG 1000), 60 mM MnC12 and 30 MM L-
tryptophan. Drops were prepared by addition of 2 .il protein (10 mg/ml in buffer E) 
to 2 jtl of well solution. After approximately one week large (0.5 x  0.4 x  0.1 mm) 
plate-like crystals were formed. These crystals were immersed in mother liquor 
supplemented with 23 % glycerol as cryoprotectant prior to mounting in nylon loops. 
A data set was collected at SRS Daresbury (Station 14.2, ) = 0.979 A) to 2.6 A 
resolution. The crystal was found to belong to space group P 21 21 21 with cell 
dimensions a = 89.885 A, b = 109.767 A, and c = 146.616 A. 
2.13.2 Wild Type TDO - Reduced substrate bound structures 
To obtain the structure of TDO in the ferrous state, the protein was reduced by the 
addition of sodium dithionite, and all steps were performed in a Belle Technology 
anaerobic glove box with the 02 concentration maintained below 5 parts per million. 
Excess sodium dithionite was removed by gel filtration (Sephadex G25 column) 
before crystallization. Crystals of TDO were grown by the sitting-drop vapour- 
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diffusion method  with a well solution comprising 100 mM MES (pH 6.3), 10-12% 
(wt / volume) polyethylene glycol 4000, 60 mM MnC12, 10 mM sodium dithionite, 
and 2 mM L-Trp or 8 mM 6-fluoro-D/L-tryptophan. Before mounting in nylon loops 
and flash-freezing in liquid nitrogen, crystals were immersed in a cryoprotectant 
solution composed of mother liquor (with L-Trp concentration increased to 50 mM) 
supplemented with 23% (volume/volume) glycerol. In the case of the L-Trp complex, 
the solution was bubbled with nitric oxide for 15 min before use. Data sets for both 
crystals were collected at the BM14 beam line at the European Synchrotron 
Radiation Facility (Grenoble, France) to 1.60 A resolution for the L-Trp bound 
enzyme, and to 1.80 A resolution for the 6-fluoro-tryptophan bound enzyme. 
Crystals of the binary complex of TDO (with L-Trp or 6-F-Trp) belong to space 
group P3121, with cell dimensions a = b = 114.1 A, and c = 96.2 A. In this case, the 
asymmetric unit contains two TDO monomers. 
2.13.3 H55A and H55S mutant forms 
Crystallisation of H55A and H555 TDO mutant forms was carried out by hanging 
drop vapour diffusion at 18 °C in Linbro plates. Crystals were obtained with well 
solutions comprising 9-10% (w/v) polyethylene glycol 1000, 80 mM MES buffer pH 
6.3, 20 mM bicine buffer pH 9.0, 40 mM MnC12, 400 mM MgCl2, 8-15 mM NaCN 
and 20 mM L-Trp. Hanging drops (4 .tl volume) were prepared by adding 2 p1 of 8 
mg ml-1 protein (in 50 mM TrisHCl buffer pH 8.0, 5 mM in 
ethylenediaminetetraacetic acid (EDTA)) to 2 p1 of well solution. Red tetragonal 
shaped crystals appeared after approximately one week, reaching full size after two 
weeks. Crystals were immersed in mineral oil prior to being mounted in nylon loops 
and flash cooled in liquid nitrogen. For crystals of the H55A and H55S enzymes, 
data sets were collected to a resolution of 2.15 A and 1.90 A respectively at station 
10.1 at SRS Daresbury Q. = 1.381 A for H55A TDO, ? = 1.045 A for 1155S). In both 
cases crystals belonged to space group P21 with unit cell parameters a = 78.2 A, b = 
117.6 A, c = 139.3 A, /1 = 957 (H55A), and a = 77.9 A, b = 117.8 A, c = 139.1 A, 
/3 = 957 (H55S). 
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2.13.4 Data Processing 
For wtTDO data processing was carried out using the HKL package (115). The 
tetrameric TDO structure (PDB ID 1 YWO), stripped of water was used as the initial 
model for molecular replacement. Electron density fitting was carried out using the 
program TURBO-FRODO (116). Structure refinement was carried using Refmac5 
(117). 
For H55A and H55S mutants data processing was carried out using the CCP4 
package (118) and PHENIX(1 19). The wild-type TDO Apo enzyme structure (PDB 
ID 1YWO), stripped of water was used as the initial model. Electron density fitting 
was carried out using PHENIX and TURBO-FRODO. Refinement was carried out 
using PHENIX and Refmac. 
2.14 Molecular Graphics 
Figures of crystal structures were generated using PyMOL, DeLano Scientific LLC, 
(www.pymo1.org) (120), unless otherwise stated. Moiscript and Raster3D (121) 
programmes have also on occasion been employed. 
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Chapter 3 
Characterisation of Xanthomonas campestris TDO 
	
3.1 	Introduction 
In this chapter the purification, biochemical characterisation and structure 
determination of wild-type xcTDO will be described. The aims of these studies were 
to reveal key aspects of the structure of wtTDO, and determine kinetic and 
thermodynamic information relating to its catalytic function. 
3.2 	Expression and Purification 
TDO was expressed and purified as described in Section 2.2, and produced a yield of 
approximately 80 mg of purified enzyme per litre of culture. Denaturing SDS-PAGE 
analysis of the purified enzyme sample is shown in Figure 3.1(a). A wide main band 
is observed at 35 kDa, corresponding to monomeric TDO and two bands at 65 
kDa and 70 kDa, both corresponding to dimeric TDO (as explained by ESI-MS 
below). The purified enzyme sample gave a characteristic Soret absorption maximum 
at 405 nm, corresponding to oxidised TDO (Figure 3.2 and Table 3.1). 
3.2.1 Electrospray Ionization Mass Spectrometry (ESI-MS) 
The purified TDO was shown by electrospray ionisation mass spectrometry to have 
two forms, with either 6 or 17 amino-acid residues removed from the N-terminus of 
the protein by proteases. ESI-MS analysis calculated the molecular masses as 34970 
± 90 Da and 33750 ± 90 Da respectively, with equal amounts observed (Figure 
3.1(b)). As the protein is non-homogeneous, all protein batches were tested for 
catalytic activity after purification. Catalytic activity was observed to remain 
constant (20 s'), indicating that the clipping does not affect catalytic activity, 
allowing the purified TDO to be used for biochemical and structural analyses. 
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Figure 3.1 	(a) Coomassie stained SDS-PAGE analysis of TDO. Lane 1 is a 
molecular weight marker lane, with weights indicated to the left hand side. 
Invitrogen SeeBlue®  Plus 2 marker system was used Lane 2 shows purified WT 
TDO, Lane 3 shows purified H55A and lane 4 shows purified H55S. For all three 
lanes one wide main band is observed at 35 kDa and two bands at -65 kDa and 
70 kDa, (b) ESI-MS analysis ofpurfled TDO gives two proteins of molecular mass 
34970 kDa and 33750 kDa due to clipping off-terminal amino acids 
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3.3 	Concentration and Heme Content Determination 
The concentration of all protein samples were determined using the Bradford assay, 
as described in Section 2.4, with enzyme concentrations ranging from 0.2-2 mg m1 1 . 
Determination of the heme content was carried out using the pyridine hemochrome 
method described in Section 2.5. Heine incorporation was greater than 90 % for all 
samples tested when the results were compared to those calculated by the Bradford 
assay. This gave a value of at least 3.6 heme groups per tetramer of TDO, which can 
reasonably be assumed to indicate one heme group per monomeric unit of TDO. This 
result differs to some previous studies which observed two hemes per tetramer for 
mammalian TDOs (96, 122-124). However, purification methods vary greatly 
between studies, and in this study increased heme incorporation may be due to 
addition of hemin during induction of E. coil protein production to ensure that heme 
incorporation is not limited by the quantity of heme available in the cell 
environment, and the relatively simple method of purification. 
These data allowed the calculation of the extinction coefficients for the main Soret 
peak of ferric and ferrous wtTDO, and extinction coefficients are displayed in 
Chapter 2, Table 2.1. Both the ferric and ferrous extinction coefficients calculated for 
wtTDO are typical of b-type heme proteins. 
3.4 	Spectroscopic Characterisation 
The UV—vis absorbance spectra for this family of proteins are characteristic of b-type 
heme-containing proteins with an axial histidine ligand. Spectrochemical data are 
shown in Table 3.1 for wtTDO and some related proteins. 
The spectrum of the ferric form of wtTDO has maxima at 405, 503 and 633 nm, 
consistent with a high-spin heme species (Figure 3.2). Reduction of ferric wtTDO 
results in a red-shift in the Soret band (from 405 to 431 nm) and the formation of two 
peaks in the visible region (555 and 588 nm) (Figure 3.2). The binding of L-Trp to 
ferrous wtTDO leads to a decrease in the Soret band, and no other visible changes to 
the spectrum, indicating little change of spin state upon substrate binding. 
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Figure 3.2 	Spectra offerric (red) andferrous (black) wtTDO. 
Table 3.1 Spectroscopic data relating to some TDO and IDO proteins. Peak 
wavelengths are given in nm. 
X campestrisz H. sapiens Rat liver TDO H sapiens 
Derivative 
TDO (1) TDO (77) (123) IDO (78, 102) 
404, 500, 535, 3+  Fe 405,503,633 408,533,621 406,500,630 
633 
Fe3 - L-Trp 405,585 410, 536, 565 407, 498, 632 411, 540, 576 
Fe2  431,555,588 428,560 430,557 425,527th,558 
Fe2 -L-Trp 433,555,588 426,533,560 421,557 425,556 
Fe2 -O2  dnf 413 dnf 412,539,576 
Fe2 -CO 419,541,568 421,540,564 420,538,569 419,539,565 
Fe3-CN 418,538,570th 419538566sh - 
= Shoulder, dnf= does not Jbrm. 
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3.5 	Structural Studies 
The structure of TDO has been described in Section 1.7, and PDB codes and 
crystallographic information for the following structures are described in Table I.I. 
All crystallisation procedures, data collection and data analysis on wild-type xcTDO 
were performed by Dr Chiara Bruckmann and Dr Chris Mowat. 
3.5.1 Solved Crystal Structures 
Crystals of TDO in the oxidised state, in the absence of substrate, were grown in 
aerobic conditions as described in Section 2.13.1, producing a data set to a resolution 
of 2.7 A (PDB ID 2NW7). Subsequent data analysis and inspection of the electron 
density revealed no binding of L-Trp in the active site of any monomer, and gave a 
tetrameric structure for TDO, described in Section 1.7.1. The first 22 amino acids 
were unresolved, presumably due to a flexible N-terminal region outside the active 
site pocket, although some clipping of these amino-acid residues may occur during 
purification, as evidenced by mass spectrometry. 
Crystals of TDO in the reduced state, with L-Trp or 6-F-trp bound (PDB ID 2NW8 
and 2NW9), were grown in anaerobic conditions as described in Section 2.13.2, 
using data sets to 1.6 and 1.8 A resolutions respectively. The structure of the 6-F-Trp 
binary complex is essentially identical to that of the L-Trp binary complex (Figure 
3.3). In addition the structure of xcTDO in the reduced state with partial occupancy 
of the substrate L-Trp has been solved to a resolution of 1.95 A. In this structure there 
are two monomers in the asymmetric unit (half of the physiological tetramer), and L-
Trp is bound at the active site of one monomer whilst there is no L-Trp in the other. 
This has allowed us to compare the reduced substrate bound, reduced substrate-free 
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Figue 3.3 	Binary complexes of wtTDO with L-Trp and 6-F-Trp bound, overlaid 
The protein backbone is shown in marine blue and cyan, L-Trp is shown in yellow 
and 6-F-Trp is shown in red. The substrates align identically in the active-site. The 
crj-aK loop is circled. 
Figure 3.4 (a) Monomer B of wtTDO L-Trp bound structure (PDB ID 2NW8), 
displaying the active site and surrounding structure. The flexible aJ—aK loop is 
unresolved (b) Structure of monomer A, showing fully bound L-Trp. The flexible af—
ctK loop is resolved and is shown interacting with L-Trp. 
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3.5.2 TDO is an Induced-Fit Enzyme 
Structural comparisons suggest that TDO is an induced-fit enzyme. Upon recognition 
of the L-Tip a complex and extensive network of interactions is established, thus 
stabilizing the active-site region. The evidence for this behaviour is described below. 
The active-site region is exposed to solvent in the substrate-free enzyme- but it is 
almost completely shielded from solvent upon L-Trp binding, with only the 
carboxylate group of the 6-propionate of heme visible on the surface. Substrate 
binding "closes" the active site-pocket, and in the L-Trp and 6-F-Trp bound 
structures, the aJ—aK loop, which helps to form the walls of the active-site pocket is 
well-defined crystallographically, whilst it is disordered in the substrate-free enzyme 
(Figure 3.4). 
As described in Section 1.7, comparison between the substrate-bound and substrate-
free structures shows reorientation of Arg 117 upon binding of tryptophan, with the 
side-chain undergoing a movement of 6 A to interact with the L-Trp carboxylate 
group. An Arg/Tyr pair is a common binding motif for carboxylates in proteins, also 
displayed in P450 BM3 (126, 127) and mandelate dehydrogenase (128, 129). This 
carboxylate-binding motif appears to be essential for substrate binding; arginine 
reorientates in the presence of substrate, interacting with the carboxylate group of L-
Trp, with "open" and "closed" conformations observed (Figures 3.5 A, B and Q. 
The movement of Arg 117 is accompanied by the movement of a loop spanning the 
active site, leading to a flip of serine 124 into its hydrogen-bonding position in the 
active site of the reduced enzyme. 
Additional evidence for the induced-fit behaviour is observed in the active site of the 
second TDO monomer in the asymmetric unit. The binding mode of the L-Trp 
substrate is very different in this monomer, as shown in Figure 3.5. The L-Trp side 
chain is not positioned as deeply into the pocket, and the hydrogen bond between the 
indole nitrogen atom and His 55 is lost. Both nitrogen atoms are instead hydrogen-
bonded to a water molecule, located 3.5 A from the heme iron in a position distinct 
from that of the water in the active site of the other monomer. This conformation may 
also be stabilized by crystal packing interactions, as the 7-propionate of heme is ion- 
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(a) 
(c) 
Figure 3.5 	Active-site conformations of wt TDO with (a) no substrate bound 
(2NW7), (b) L-Trp bound, monomer B (2NW8), L-Trp bound monomer A (2NW8). 
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paired with an Arg residue from another TDO tetramer in the crystal. The main chain 
atoms of L-Trp appear to be disordered because no clear electron density was 
observed for them. Consistent with this finding, the cd—aK loop is disordered in this 
molecule, similar to that in the substrate free enzyme (Figures 3.4 and 3.5). This 
complex may represent an initial stage in the formation of the Michaelis complex of 
TDO. Proper positioning of the L-Trp substrate for catalysis would lead to the 
recognition of its main chain atoms and the ordering of the aJ—aK loop. 
3.5.3 A Model for the Michaelis Complex. 
To help provide further insight into the catalysis by these enzymes, a model of the 
Michaelis complex was built using the L-Trp bound structure by placing one oxygen 
atom of the dioxygen substrate directly over the heme iron, at a distance of 2.1 A 
(Figure 3.6). The distal oxygen atom was placed such that the 0-0 bond is parallel to 
the C2—C3 bond of indole ring, giving a Fe—O-0 angle of 1350,  in a trans position to 
the indole ring, described in Section 1.7.1 (2). The distal oxygen atom in this 
conformation is within 0.5 A of the water molecule observed in our substrate-bound 
structure, suggesting that this water should be ejected from the active site upon 
dioxygen binding, leaving the active-site completely devoid of solvent molecules. In 
the model of the Michaelis complex, the oxygen atoms are in a trans configuration 
relative to the C2—C3 atoms of L-Trp 
The modelled dioxygen binding mode reveals information on the activation 
mechanism of this ternary complex. TDO has an ordered catalytic cycle in which the 
protein binds L-Trp to the ferrous form, then 02,  forming the ternary complex which 
then undergoes reaction (4). The positioning in our modelled Michaelis complex 
indicates that electrophilic addition or radical addition mechanisms will be favoured 
over an "oxygen-ene" type addition. In the model, the distal oxygen atom interacts 
with the L-Trp ammonium moiety and the backbone amide nitrogen of Gly 125. The 
Lewis acidity of these hydrogen-bonding donors, coupled with the electron-
withdrawing nature of the heme, increases the electrophilicity of the bound dioxygen, 
making it more reactive, and therefore more likely to facilitate electrophilic attack on 
the substrate C3 or C2 atoms. Studies with heme oxygenase suggest that the 
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hydrogen-bonding interactions with the dioxygen substrate may also help to prevent 
its heterolysis, and the exclusion of water probably removes a hydrogen-bond 
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Figure 3.6 	Stereo view model of the Michaelis complex. The water molecule is 
shown as a small sphere in green, ti'yptophan is shown in orange, 02 is shown as two 
red spheres. Produced with Molscript and rendered with Raster3D (121). 
3.5.4 A Potential Allosteric Binding Site 
The crystal structure of wtTDO has revealed four secondary interfacial L-Trp binding 
sites, as described in Section 1.6.1. The residues Asp 228, Tyr 220, Arg 85 and Lys 
92, which are located on the aJ and aC helices, interact with L-Trp, binding it to the 
enzyme (Figures 1.13 and 1.14). In addition the aJ helix encodes histidine 240, 
which coordinates directly the heme group. The aJ helix links the interfacial binding 
site and the active-site, and suggests a mechanism for allosteric regulation in the 
enzyme. 
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3.6 	Substrate Binding Titrations 
Substrate binding titrations give a measure of the affinity that the enzyme has for 
substrate allowing dissociation constants to be calculated as described in Section 2.6. 
L-Trp binds to TDO in the oxidised, non-reactive, state, causing a decrease in the 
Soret band at 405 nm and an increase in absorption at 565 nm. Spectrophotometric 
data for the binding of a number of ligands to the ferric or the ferrous protein are 
displayed in Table 3.2. Binding of substrate and substrate analogues to the reduced 
enzyme produces a decrease in the Soret peak at 431 nm. Changing p1-I between pH 
6 and 8.3 does not affect the change in the spectrum upon binding of substrate in 
both the ferric and ferrous states. 
These binding studies provide direct evidence for the induced-fit behaviour of TDO. 
Indeed, there is a large increase in the affinity of the enzyme for L-Trp when the 
heme iron is reduced (Kd, Fe 3+ = 3840 tiM, whereas Kd, Fe 2+ = 4.1 kiM). Binding of 
L-Trp to the ferric protein is described in Section 2.6 and displayed in Figures 2.3 
and 3.7. L-Trp preferentially binds to ferrous protein rather than ferric, by a factor of 
almost a thousand. The substrates 6-F- D/L- and 5-F- D/L-Trp bind to wtTDO in a 
similar manner to L-Trp, with a large difference in the Kd values for binding to ferric 
and ferrous enzyme (Table 3.2). Slightly smaller Kd values for binding to both the 
ferric and ferrous enzyme indicates that these substrates may bind tighter than L-Trp, 
but this effect is not substantial. 
The substrate analogue indolepropionic acid (IPA) binds to ferrous wtTDO with low 
affinity - Kd = 185 j.tM, displaying a binding curve analogous to that of the TDO 
substrates. 5-Br-Trp and tryptamine are only weakly soluble to non-saturating 
concentrations, causing binding values to go undetermined. 
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Figure 3.7 Plot of binding of L-Trp to ferric wtTDO. The change in absorbance 
(Azlabsorbance) is plotted against substrate concentration. 
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Table 3.2 Substrate binding to wtTDO 
Substrate Fe3 , Kd, (.tM) Fe2 , Kd, (tM) 
L-Trp 3840 + 140 4.1 ± 0.2 
6-F-D/L-Trp 1510 ± 80 <1.00 
6-Me- D/L-Trp >2000* >200 
5-F- D/L-Trp 2450 ± 420 <1.001  
5-Me- D/L-Trp >2500* 51 ± 7 
D-Trp >50,000* nc 
Indole Propionic Acid >10,000* 185 
Tryptamine >4,000* >500 
Binding was too tight to be measured. Values quoted represent the minimum 
Kd that can be measured under standard assay conditions. 
* 	Maximum solubility of the substrate investigated. 
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Figure 3.8 	TDO substrates, L-Trp, 5-F-Trp, 5-Me-Trp, 6-F-Trp and 6-Me-Trp, 
the inhibitor D-Trp, and the substrate analogues tiyptamine and indole propionic 
acid. 
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3.7 .1 Steady-State Turnover Kinetics 
Steady-state kinetic rates of turnover were determined as described in Section 2.7. A 
variety of substances have been tested for enzymatic activity, with wtTDO 
displaying high substrate specificity, only catalysing the dioxygenation of L-Trp, 6-17-
Trp, 6-Me-Trp, 5-F-Trp and 5-Me-Tip. WtTDO is inactive toward D-Trp, tryptamine 
and indole propionic acid (IPA) which are substrates for IDO, confirming its 
designation as a TDO. Reactivity's are shown in Table 3.3 and the structures of some 
of these compounds are shown in Figure 3.8. WtTDO catalyses the dioxygenation of 
L-Trp with a kcat of 19.5 s_ I (Figure 3.9(a)), whilst the kcat for 6-F-D/L-Trp is 37 s, 
twice the rate of that for L-Trp. It is probable that catalysis only occurs with the L-
isomer of 6-F-Tip, indicating a 4-fold increase in kcat compared to L-Trp. As fluorine 
is highly electron withdrawing, it can be postulated that this electron-withdrawing 
effect inductively activates tryptophan oxidation, decreasing the energy of activation 
for electrophilic addition to the indole ring by the bound dioxygen. Molecular 
modelling simulations (not shown), comparing the activation energy for the 
conversion of L-Trp, 5-F-L-Trp and 6-F-L-Trp suggest that the reaction is most 
favourable for 6-F-L-Trp, in agreement with the experimental observations (85). 
The narrower substrate specificity of TDO compared to IDO could be due to the tight 
substrate binding pocket in TDO. Previous studies have shown that IDO catalyses the 
dioxygenation of D-Trp, although at a slower rate than for L-Trp (4, 102). As Table 
3.3 shows, D-Trp is not a substrate for TDO and is in fact a weak competitive 
inhibitor of wtTDO at high concentrations, with a K1 of 16.5 mM as shown in Figure 
3.9 (b) (The K1 was determined as described in Section 2.7.3). This different 
specificity can be explained by considering the binding of D-Trp to wtTDO, and 
comparing the structures of xcTDO and hIDO. Binding data show that D-Trp has 
much lower affinity for the ferrous, catalytically active state of wtTDO than L-Trp. 
This is consistent with our structural information - ionic interactions are important for 
recognizing the L-Trp ammonium ion and carboxylate group, and these make the 
enzyme stereospecific to L-Trp. Some of these electrostatic interactions are 
conserved in IDO (Arg23 1 and the heme 7-propionate), however, some hydrogen- 
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bonding interactions to the substrate are absent. For example Tyrll3 of xcTDO is 
replaced by Phe226 in hIDO (Figure 1.2), removing at least one hydrogen bonding 
interaction. Additionally the xcTDO Thr 254 residue, which interacts with the 
substrate carboxylate, may not have an equivalent in hIDO because the flexible loop 
which orders on substrate binding in xcTDO is disordered and therefore absent from 
the hIDO crystal structure. This loop region has a highly divergent sequence in IDO 
species compared with TDO species and a residue able to play this role may not be 
present. Therefore IDO may have weaker interactions with tryptophan, and this may 
be the reason why it cannot completely distinguish among the indoleamine 
substrates, catalysing the dioxygenation of D-Trp, whilst wtTDO does not. 
The catalytic activity of allosteric enzymes can often be regulated by small changes 
in substrate concentration, allowing regulation of metabolic pathways where the 
substrate concentration fluctuates over a narrow range. It has been proposed that 
TDO may play such a "housekeeping" role, regulating the tryptophan concentration 
and keeping it within certain parameters (38). However, no evidence of allostery was 
observed during L-Trp turnover, indicating that L-Trp is not an allosteric effector of 
wtTDO, and its binding does not appear to influence the activity of the enzyme. 
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Table 3.3 Steady-state kinetic data for xcTDO and some similar proteins. 
Xcampestris TDO (1) Hsapiens TDO'(77) H.sapiens IDOU(78) 
Substrate kcat (sd ) Km (.tM) kcat (s') Km (jiM) kcat (s') Km (jiM) 
1.40± 
L-Trp 19.5± 1.2 114± 1 222± 15 1.4±0.1 7.0±0.8 
0.02 
6-F-D/L- 
37.3±0.6 186± 12 
Trp 
6-Me- 
41.0± 1.2 975±48 
D/L-Trp 
5-F- D/L- 0.18± 0.76± 
2.4±0.1 100±6 360±28 6.0±0.8 
Trp 0.01 0.01 
5-Me- 
3.6±0.1 357±12 a a 3.8±0.2 98±14 
D/L-Trp 
Ki 1570 
D-Trp n/a b b 3.9±0.1 
16.5mM ±100 
Steady-state kinetics performed at pH 8.0 in 50mM Tris buffer. 	- 
a 	Catalytic turnover at [D-Trp] = 50 mM was measured due to low activity, 
and kcat 0.073 S '. 
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Figure 3.9 	(a) L-Trp turnover by wild-type wtTDO atpH 7.5. Data is fitted to the 
Michaelis Menten equation, and plotted in Microcal Origin 7.5, (b) Plot of 1/[L-Trp] 
against I/ Rate of turnover for xcTDO activity with differing concentrations of D-Trp 
(shown in pM) present in the assay. 
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3.7.2 pH Dependence of Turnover 
Experiments were performed as described in Section 2.7.2. Figure 3.10 shows the 
change in kcat and Km for L-Trp dioxygenation by wtTDO with varying pH. Little 
variation of 	occurs between pH 5.5 and 8.3, indicating that a base may not be 
required for catalysis. If a base was involved in the catalytic mechanism of L-Trp 
dioxygenation it could be supposed that varying the pH would have an effect on the 
rate of turnover. However, as kcat remains constant with varying pH, this would 
indicate that a non-base catalysed mechanism may operate. 
The Michaelis constant, Km, is shown to decrease with increasing pH between pH 6.0 
and 7.0, with a pKa value of around 6.5. However, little variation in Km is observed 
above pH 7.0. This indicates that turnover is optimised above pH 7, and pH 7.5 is 
therefore used as the standard p11 throughout this thesis. 
3.7.3 Steady-State Deuterium Kinetic Isotope Effect 
The rate of L-Trp turnover could involve deprotonation of the indole nitrogen, or be 
influenced by hydrogen bonding via water molecules in the active site. To probe 
these effects deuterated water was used during turnover, using the method stated in 
Section 2.7.3. Catalytic turnover of L-Trp by wtTDO in deuterated conditions gave a 
kcat almost identical to that obtained in non-deuterated solvent (21 ± 0.2 s'), 
indicating that proton delivery is not rate limiting to turnover. The Km was 
determined to be 138 ± 5 tM, again close to that observed in non-deuterated solvent, 
supporting the idea that base-catalysed deprotonation of L-Trp does not play a rate 
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pH 
Figure 3.10 Plot of Km and kcat vs. pHfor turnover of L-Trp by TDO. 
3.7.4 	LC-MS Analysis of Products 
LC-MS analysis was used to detect products produced upon catalytic turnover of L-
Trp by wtTDO, as described in Section 2.11. The equipment was calibrated to detect 
L-kynurenine (209 Da), N-formylkynurenine (237 Da) and L-Trp (205 Da). LC-MS 
analysis is shown in Figure 3.11, and it can be seen that both the product N-
formylkynurenine, hydrolysed N-formylkynurenine, (L-kynurenine), and the reactant 
L-Trp are present in the sample. 
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Figure 3.11 LC-MS analysis of wtTDO L-Trp turnover products, (a) LC trace 
calibrated to detect the (M+H) ion of L-Kynurenine (209 Da) vs. time, (b) LC trace 
calibrated to detect the (M+I-t) ion of N-formylkynurenine (237 Da) vs. time, (c) LC 
trace calibrated to detect the (M+)t) ion of L-Trp (205 Da) vs. time, (d) MS of the 
(M+H) ion of L-Trp peak detected in (c), (e) MS of the (M+ft) ion of N-
formylkynurenine peak detected in (b). 
Li2zIiia1ic iind 107 cchanislic. 1iidies 11110 1 rropJ1ai1 4i-1hox'vnase 
3.7. 5 MS-MS Analysis of Products 
MS-MS analysis was conducted on the same sample as that used for LC-MS, as 
described in Section 2.12. The data produced confirms that L-Trp, N-
formylkynurenine and L-kynurenine are found in the sample. L-kynurenine is only 
found to be present in a small quantity. MS-MS analysis is shown in Figure F.1 in 
Appendix F. These data confirm that the product of the reaction of wtTDO with L-
Trp is N-formylkynurenine, and that no other products are observed to be formed. 
3.8 	Steady-state Turnover in Varying Oxygen Concentrations 
Steady-state kinetic experiments investigating the effect of oxygen on L-TIP turnover 
were performed as described in Section 2.8.2. Under experimental conditions TDO 
substrate turnover is limited only by the amount of oxygen available. The rate of 
turnover observed is therefore indicative of the maximal rate at the oxygen 
concentration used. Plotting the rates observed against oxygen concentration gives an 
indication of the binding affinity of oxygen and its effect on the turnover of substrate. 
Shown in Figure 3.12, the observed rate constant for turnover is dependent on 
dioxygen concentration, [021, under saturating L-Trp concentrations (25 mM). The 
data is fitted to the Hill equation, indicating that the effect of varying oxygen 
concentration on turnover is slightly cooperative, with an n value of 1.16. As this is 
only a small variation from Michaelis-Menten kinetics, any cooperative behaviour 
displayed is highly suspect. Turnover may be occurring according to Michaelis 
Menten kinetics, with the variation an artefact of the method of analysis. Further, 
more sensitive analysis of this reaction is needed before any conclusions can be 
drawn as to if there is any cooperativity occurring, and if it is catalytically relevant. 
At room temperature (25°C) the concentration of 02 in assay buffer F is 
approximately 140-160 .tM (determined spectrophotometrically via the methyl 
viologen assay described in Section 2.9.3). Therefore the concentration of 02 used in 
the steady-state turnover experiments (described in Sections 2.7 and 3.7) was 140-
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with the rate displayed in Figure 3.12 at approximately 150 p.M. Turnover is limited 
by the dioxygen concentration at 150 p.M, and maximal turnover is not achieved till 
oxygen saturation of greater than 600 p.M. The maximal rate observed kcat, is 354 
and indicates that turnover is only 60 % of maximal under standard conditions. 
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Figure 3.12 Rate of production of kynurenine (s') against oxygen concentration 
for TDO, data fitted to the Hill equation using Microcal Origin 7.5. 
3.9 	Oxygen binding 
Experiments were performed as described in Section 2.8.1. On addition of oxygen to 
reduced wtTDO at 25 °C, no binding is observed to occur to the active site, with the 
heme porphyrin becoming oxidised to the Fe 3+ state, and a characteristic shift in the 
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Soret peak to 405 nm occurring. This is shown in Figure 3.13(a). When substrate is 
not present it can be hypothesised that the correct groups necessary to bind oxygen in 
the active site are not present and oxidation of the ferrous iron occurs. 
On addition of oxygen to an L-Trp saturated solution of wtTDO at 25 °C a peak is 
observed to form at 417 nm, which quickly decays back to the reduced TDO 
spectrum. It is hypothesised that this is the formation of an oxy-ferrous species, 
which then undergoes a catalytic reaction to form the product. The product is then 
released by the active site, and the enzyme remains in the reduced, ferrous state, 
which is observed as a rapid decay back to the initial reduced species (Figure 3.13 
(a)). The data fits to a second order exponential, indicating more than one 
mechanistic step is required to facilitate production of the stable species, consistent 
with mechanisms of dioxygen activation proposed in Section 1.3. It has been 
observed that IDO forms a similar oxy-ferrous species on dioxygen binding in the 
presence of L-Trp, and is predicted to catalyse substrate dioxygenation in a similar 
(or identical) manner to TDO. 
After this initial evidence suggesting the formation of an oxy-ferrous species, 
experiments were carried out using other substrates and substrate analogues in the 
same manner, in the hope of observing a more stable oxy-ferrous intermediate. 
Unfortunately, as yet no stable oxy-ferrous intermediate has been discovered which 
displays a longer lifetime than that observed with L-Trp as the substrate. 
Addition of dioxygen to a reduced, 6-F-Trp saturated solution of wtTDO produced 
an oxyferrous species displaying the same spectral characteristics as that formed 
when L-Trp was present and rates for the second order decay back to the reduced 
spectrum were similar to those of L-Trp. This indicated that turnover of 6-F-Trp 
proceeds in an analogous fashion to L-Trp turnover and is consistent with the 
identical binding of 6-F-Trp and L-Trp to the enzyme, (Table 3.2), which would 
suggest similar stabilities for any catalytic intermediates. 
Addition of dioxygen to a reduced, 5-F-Trp saturated solution of wtTDO gave partial 
generation of an oxyferrous species, with the spectrum indicating that part of the 
sample remains in the dioxygen—free reduced state (Figure 3.13(b)). The oxyferrous 
species then decays back to the reduced species. 
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Figure 3.13 (a) Production of the wtTDO oxyferrous complex. The peak positions 
of the oxyferrous complex are at 420 nm, 548 nm, and 578 nm. This decays back to 
ferrous enzyme and product (N-formylkynurenine - peak position 321 nm), (b) 
Addition of oxygen to reduced, 5-F-Trp saturated wtTDO shows an oxyferrous 
intermediate partially formed during substrate turnover. 
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This indicates that the reaction is partially uncoupled i.e. inefficient turnover of 5-F-
Trp is occurring, with a percentage of the ternary complex dissociating rather than 
forming products. Efficient, fully-coupled production of product does not occur. This 
uncoupling is reflected in the lower rate of 5-F-Trp turnover (only —10 % of L-Trp), 
and may be caused by greater steric hindrance to the formation of reactive 
intermediates due to the addition of a fluorine atom to the aromatic ring. 
3.10 Binding of Diatomic Molecules 
Binding of diatomic molecules to TDO can mimic the effect of binding oxygen at the 
active site. Binding diatomic molecules in the presence of substrates and substrate 
analogues can aid our understanding of the formation of the ternary complex, and 
give insight into the residues involved in complex formation. 
3.10.1 CO Binding 
CO binding experiments were conducted as described in Section 2.8.3. CO 
coordinates to the ferrous and ferric protein, displaying tighter binding to the ferrous 
form. Since all catalytic activity occurs in the ferrous state, only binding to the 
ferrous enzyme will be considered. CO binding to the ferrous enzyme to produce 
(Fe2tCO), induces a shift in Soret band from 431 nm to 420 nm. In addition, the 
Soret peak diminishes upon binding, and a change in the spectral bands at 560 and 
590 nm occurs (Figure 3.14 (a)). 
In the presence of L-Trp, CO binding to produce (Fe 2 -L-Trp-CO) leads to a shift in 
the Soret peak from 431 to 417 nm, with the height of the peak increasing by around 
25% (Figure 3.14 (b)). The characteristic peaks at 560 and 590 nm change in height 
till they are no longer observed, with peaks, at around 540 and 570 nm forming. 
As there is a large spectral difference between the binding of CO to wtTDO in the 
presence or absence of L-Trp, this change can be used to probe the possible side 
chain interactions between the L-Trp molecule and the bound CO. Tryptarnine and 
indole propionic acid are L-Trp analogues which can be used to probe the effect of 
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the amine and carboxylate groups of tryptophan upon CO binding to the active-site, 
and their use is discussed below. 
3.10.2 Probing the Side-Chain Interactions of L-Trp 
The structures of tryptamine and IPA are shown in Figure 3.8. IPA lacks the amine 
group of L-Trp, whilst tryptamine lacks the carboxylate group. These two derivatives 
of tryptophan can be used to probe the effect of the amine and carboxylate groups of 
tryptophan upon binding of small molecules to the active-site. Comparison of the 
binding of CO to substrate-free, L-Trp-bound, IPA-bound and tryptamine-bound 
wtTDO will allow evaluation of the roles of the amine and carboxylate groups of L-
Trp in small molecules binding. 
The binding of CO to wtTDO with IPA or tryptamine bound to the active-site to 
produce (Fe'-IPA-CO) and (Fe2tTryptamineCO) are shown in Figures 3.14 (c) and 
(d) respectively. The binding of CO to ferrous wtTDO with IPA bound at the active-
site produces a spectrum analogous to that of (Fe2 -CO) in the substrate-free state. A 
peak is observed at 420 nm, with no decrease in the peaks at 560 and 590 nm. The 
binding of CO to wtTDO with tryptamine bound, gives a spectrum analogous to that 
of (Fe2 -L-Trp-CO). The Soret band is shifted to 417 nm, and peak height is 
increased although not to the extent of that seen for L-Trp. Also the bands at 560 and 
590 nm are replaced by ones at 540 and 570 nm. 
These results suggest that the amine group of tryptophan must be important in the 
binding of small molecule, such as CO. Both L-Trp and tryptamine can coordinate to 
CO through the amine in the ternary complex, whilst in the substrate free-enzyme 
and IPA-bound wtTDO this is not possible due to the absence of the amine group. 
The amine nitrogen therefore appears to play a role in the binding of CO, and it can 
be hypothesised that it will also play a role in the binding of 02 in the ternary 
complex. This correlates with the observed active-site structure displayed in the L-
Trp bound crystal structure. The amine group coordinates to a water molecule, which 
is predicted to lie in the position where the distal atom of dioxygen will reside in the 
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Figure 3.14 CO binding to wtTDO with (a) no substrate present, (b) L-Trp present, 
(c) indolepropionic acid present and (d) tryptamine present. 
3.10.3 Calculating the Dissociation Constant for CO 
To calculate the Kd for CO binding to both substrate-free and L-Trp bound wtTDO, 
experiments were performed as described in Section 2.8.3. The rate of formation of 
the CO adduct was measured by observing the absorbance spectrum at 420 Mn 
(Figure 3.15(a)) (Note; a nanomolar concentration of wtTDO was used to ensure that 
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Figure 3.15 (a) Trace showing the production of the CO binding complex at 
420nm over time, (b) plot of CO concentration against observed rate offormation of 
CO adducts fitted linearly. 
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These results show that CO binds to wtTDO, proportionally with increasing CO 
concentration (Figue 3.15 (b)). Binding is directly proportional to the CO 
concentration present in solution, and does not display any sigmoidal or parabolic 
effects which could be associated with cooperative or allosteric binding. The Kd, for 
CO binding is 90 p.M, indicating that CO binds tightly to wtTDO. The rate of loss of 
CO from the complex, k0ff, is 1.5 s 1, showing that binding is reversible and decay of 
the CO adduct occurs over a measurable timescale. As a consequence of these 
properties, at standard room temperature and pressure, and in vitro where the 
concentration of CO is low, CO binding to wtTDO does not affect catalytic turnover. 
3.10.4 NO Binding 
Binding of NO to wtTDO was too fast to be measured by stopped-flow. The spectral 
characteristics of the species formed are displayed in Table 3.1. No dissociation or 
association constants of NO to the enzyme have been measured due to the difficulty 
in obtaining accurate data on the concentration of NO in solution. 
3.10.5 Cyanide Binding to TDO 
Cyanide was used to probe the active-site of wtTDO. Cyanide binds strongly to the 
oxidised heme iron producing a characteristic change in the Soret peak from position 
405 nm to 424 nm, with a Kd of approximately 15 p.M and no indication of 
cooperativity in the binding. The binding of cyanide to substrate-free TDO is 
stronger than the binding of L-Trp to the enzyme, which is most probably due to the 
direct coordination of cyanide to the heme iron. 
The binding of cyanide is observed to be pH dependent, with Kd varying between 
around 500 p.M to around 10 p.M on increasing the pH from 6.0 and 8.3 (Figure 3.16 
(a)). This trend can be fitted to a pH curve which gives a pKa for the binding of 
6.5, consistent with a histidine residue being present at the active site. 
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3.10.6 Cyanide binding to TDO with Substrate Present 
The binding of cyanide to ferric wtTDO with L-Trp present gives a decrease in the 
Soret peak at 405nm, and an increase at 419 nm, with a Kd of 1.5 jiM at pH 7.5. 
Hence the enzyme displays greater affinity for cyanide in the presence of L-Trp. This 
trend is displayed across the pH range from pH 6.0 to 8.3, with Kd varying from 3 to 
1.5 p.M, with a pKa of 6.5. 
Contrary to substrate free enzyme, binding of cyanide in the presence of L-Trp 
displays cooperative binding. This is shown in Figure 3.16 (b), where the Hill 
coefficient is shown to vary with pH within the range n = 1.5-2.2. The Hill 
coefficient is seen to peak at pH 7.5, with a maximum value of 2.2. Binding of CN 
when other substrates are present can give an indication of which parts of the active 
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Figure 3.16 (a) Kd against pH for binding of CN to wtTDO with no substrate 
present, (b) Binding of CI'T to TDO with L-Trp present, displaying Kd against pH, 
and the variation of the hill coefficient (n) with pH 
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3.11 OTTLE Potentiometry 
Substrate-free and substrate-saturated heme reduction potentials were determined as 
described in Section 2.10. The heme reduction potential is a measure of the tendency 
of TDO to receive or accept electrons. Typically the addition of substrate leads to a 
positive increase in the heme reduction potential generating a more positive driving 
force for the electron transfer and hence acting as a thermodynamic switch. 
The substrate-free and substrate-bound heme reduction potentials for wtTDO and 
some related proteins are shown in Table 3.4. The mid-point reduction potential of 
substrate free wtTDO is 8 mV and substrate-bound wtTDO is 144 mV, a shift of 136 
mV on substrate binding (Figure 3.17). In fact, the shift in reduction potential almost 
perfectly correlates with the increase in affinity for L-Trp on reduction, both giving 
an estimated AAG of 15 kJ / mol. A thousand fold increase in the L-Trp binding 
affinity is observed upon enzyme reduction (Kd Fe(III) = 3800 jiM, Kd Fe(II) = 
4tM), disfavouring the mechanistically unproductive binding of L-Trp to the 
oxidized enzyme. 
Few reduction potentials for either IDO or TDO have so far been reported, but those 
available show clear trends (Table 3.4). Upon binding of the substrate, there is an 
increase in reduction potential for both IDO and TDO, reflecting additional 
stabilization of the ferrous derivative. The increase is larger for TDO proteins (with 
the exception of human TDO), compared to IDO proteins. For both IDO and TDO, it 
is not clear whether heme reduction precedes substrate binding or vice versa, but a 
thermodynamic stabilization of the reduced form would clearly favour reduction 
prior to substrate binding. The large positive change in the reduction potential for 
both enzymes suggests that there is a significant stabilization of the ferrous form 
when substrate is bound. This stabilization could also play a physiological role in 
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Figure 3.17 (a) Change in WTTDO spectrum on oxidation and reduction by 
electrochemical potential. The 405 nm peak is the oxidised protein, which gradually 
shifts to 430 nm on reduction and vice versa, (b) oxidative (A and.) and reductive 
(A and o) potential sweeps on WTTDO, with and without L-Trp present. Curves are 
fitted to the Nernst equation, giving one electron equilibrium reduction potentials for 
the heme group with and without L-Trp. 
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Table 3.4 Electrochemical midpoint reduction potentials (m V vs. SHE) 
Substrate-free Substrate 
Enzyme Substrate L\Emid 
Emid Bound Emid 
X campestris 
L-Trp 8±5 144±6 +136 
TDO (1) 
Rat liver TDO 
L-Trp +100 +160 +60 
(100) 
H sapiens 
L-Trp -92 ± 3 -76 ± 6 +16 
TDO (77) 
H. sapiens 
L-Trp -30±4(-63) 16±3 +46(+79) 
IDO' (78, 102) 
S. oneidensis 
IDO 
L-Trp -105 -74±2 +31 
PrnB (6) L-Trp -109 -243 -134 
PrnB (6) 7-C1-L-trp -109 -195 -86 
a Two potentials are quoted for H sapiens IDO in separate studies 
fl Unpublished data 
(Note potentials for H. sapiens  IDO, H sapiens TDO and rat liver TDO obtained at 
pH 7. 0, and those for X campestris TDO, S. oneidensis IDO and PrnB were obtained 
at pH 7.5). 
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3.12 Conclusions 
The structure of catalytically active, ferrous xcTDO in complex with L-Trp has been 
determined to 1.6 A. In addition, the structure of the catalytically inactive, substrate-
free oxidised xcTDO has been determined to 2.7 A. These structures show the 
substrate binding interactions at the active-site and reveal that TDO is an induced-fit 
enzyme, with significant reorganisation of the active-site upon substrate binding. 
The crystal structure of wtTDO has revealed a histidine residue is present at position 
55, near to the active site, hydrogen bonding to the nitrogen of the indole ring, in an 
analogous position to a serine residue in human IDO (serine 167) (87). As a base is 
not present for proton abstraction in IDO, suggesting that substitution of histidine 55 
in xcTDO to alanine or serine could reveal whether a base is necessary for catalysis. 
TDO displays robust L-Trp activity with little variation of kcat values occurring with 
p1-I, indicating that a catalytic base may not be required for catalysis. In addition 
catalytic turnover of L-Trp by wtTDO in deuterated conditions gave a kcat value 
identical to that obtained in non-deuterated solvent, supporting this theory. 
The binding characteristics of small molecules to TDO suggest that the amine group 
of tryptophan is important in the binding of small molecules, such as CO or 02.  The 
amine group of L-Trp plays a role in the binding of CO, and it can be hypothesised 
that it will also play a role in the binding of 02 in the ternary complex. This 
correlates with the active-site arrangement in the L-Trp bound crystal structure. The 
amine group coordinates to a water molecule, which is predicted to lie in the position 
where the distal atom of dioxygen will reside in the Michaelis complex 
A thousand fold increase in the L-Trp binding affinity is observed upon enzyme 
reduction (Kd Fe(III) = 3800 jtM, Kd Fe(II) = 4p.M), disfavouring the unproductive 
binding of L-Trp to the oxidized enzyme. This is confirmed by electrochemical data 
which shows a large, positive shift in reduction potential (AEmid = 136 mV) in the 
presence of L-Trp, which correlates with the increase in affinity for L-Trp on 
reduction. These data show that there is a significant stabilization of the ferrous form 
when substrate is bound. This stabilization could also play a physiological role to 
keep the protein reduced, and therefore active, when L-Trp is present. 
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Chapter 4 
The Role of Histidine 55 
4.1 Introduction 
It has been proposed that the catalytic mechanism for TDO and IDO involves the 
base-catalyzed deprotonation of the indole nitrogen of the substrate (131). The 
results discussed in the previous chapter show that in xcTDO histidine 55 hydrogen 
bonds to L-Trp and could possibly act as an active site base (1). This chapter reports 
the crystallographic and biochemical study of two TDO mutants, where the active-
site residue histidine 55 has been substituted by alanine (H55A) and serine (H55S). 
These structural data, in conjunction with potentiometric and kinetic studies on the 
mutants, is used to resolve the question of whether an active site base is necessary for 
catalytic activity in TDO and to provide information on the molecular mechanism 
used by TDO to control substrate binding. 
4.2 Results 
4.2.1 SDS-PAGE 
The H55A and H55S mutants of TDO were expressed and purified as described in 
Chapter 2, and produced a yield of approximately 70-100 mg of purified enzyme per 
litre of culture. Denaturing SDS-PAGE analysis of the purified enzyme sample is 
shown in Figure 3.1 (Chapter 3). Wide main bands are observed at 35 kDa, 
corresponding to monomeric H55A and H55S and two bands at -65 kDa and -70 
kDa, both corresponding to dimeric H55A and S mutants (as explained for wild-type 
TDO by mass spectrometry in Section 3.2.1). The purified enzyme samples produced 
absorption spectra with characteristic Soret absorption maxima at 405 run, 
corresponding to oxidised H55A and H55S. No peak was observed at 430 rim, 
indicating that the enzymes purified in the oxidised form only. 
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4.3 	Concentration and Heme Content Determination 
The concentration of all protein samples was determined using the Bradford assay 
(110), as described in Section 2.5.1. Heme incorporation was greater than 95% for all 
H55A samples tested when the results were compared to those calculated by the 
Bradford assay and greater than 90% for all H55S samples. These results correlate 
with those obtained for wtTDO, and both mutants can be assumed to contain one 
heme per monomer. These data allowed the calculation of the extinction coefficients 
for the main Soret peaks of ferric and ferrous H55A and H55S, and these are 
displayed in Table 2.1. 
4.4 	Spectroscopic Characterisation 
The UV—vis absorbance spectra for this family of proteins are characteristic of b-type 
heme-containing proteins with an axial histidine ligand. Spectrochemical data are 
shown in Table 4.1 for wtTDO, H55A and H55S proteins. Both H55A and H55S 
enzymes display similar spectra to wtTDO in both the ferric and the ferrous state, 
with and without substrate bound. 
The spectra of the ferric forms of H55A and H55S are consistent with high-spin 
heme species, exactly the same as for wtTDO (Figure 3.2). Reduction of ferric H55A 
and H55S results in a red-shift in the Soret band (from 405 to —431 urn) and the 
formation of two peaks in the visible region (555 and 588 mn) analogous to wtTDO 
(Figure 3.2). 
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Table 4.1 Spectroscopic data relating to wtTDO, H55A and H55S proteins. Peak 
positions are given in nm 
X campestris X campestris 
Derivative X campestris H55S 
wtTDO(1) H55A 
Fe3  405, 503, 633 405, 503, 633 404, 500, 633 
Fe 3+ - L-Trp 405,585 405, 595sh 404, 498, 600 
Fe 2+ 431,555,588 431,555,588 431,555,586 
Fe2 -L-Trp 433,555,588 432,555,588 432,555,586 
Fe2 -CO 419,541,568 419,539,568 418,521,549 
Fe2 -NO 418,545,574 418,545,573 418,544,573 
Fe3 - CN 418, 538, 570s'419, 538, 570sh 419, 539, 567sh 
sh = shoulder 
114 
1LZ JJ1/iiC i1U i1LLüd1ii'iJL )U!UiC 111W 1 11]W)11d11 ,J-iJ1L)X11WL' 
4.5 	Crystallography 
All crystallisation procedures, data collection and data analysis on the H55A and 
H55S mutants of xcTDO were performed by Dr Chiara Bruckmann, Laura Campbell 
and Dr Chris Mowat (2). 
Crystals of the H55A and H55S mutants in the oxidised state, in the presence of 
substrate, were grown in aerobic conditions as described in Section 2.13.3. It was 
possible to obtain crystals of oxidised H55A and H55S mutant enzymes in complex 
with L-Trp due to the much greater affinity of L-Trp for the oxidised mutant enzymes 
compared to wtTDO (see Section 4.6). For the H55A mutant a data set was solved to 
a resolution of 2.15 A, whilst for H55S the resolution was to 1.90 A. The atomic 
coordinates have been deposited in the Protein Data Bank, accession codes 3BK9 
(H55A) and 3E08 (H55S) (2). 
4.5.1 Comparison of the overall structures to wtTDO 
The structure of wtTDO has been previously described (Sections 1.7 and 3.5). The 
average root mean square fit of all backbone atoms between all monomers of the 
H55A and H55S models, and wtTDO (PDB code 2NW8) is 0.6-0.8 A, indicating no 
major differences between the three protein structures. 
For both the H55A and H55S enzymes the N-terminal region is better defined than in 
the wtTDO structure. In the wtTDO structures, the N-terminus is only resolved from 
the 17th amino acid upwards as the enzyme is lacking these residues due to protelytic 
cleavage, as shown in the mass spectrometry. In both of the histidine substituted 
enzymes the N-terminus is resolved from the 7th amino acid upwards. The increased 
definition of the N-terminal region shows that these residues (7-21) interact with the 




Enzniatic and Mechanistic 5tudies into Inptophan 2,.$-Dioxgcnase 
Figure 4.1 	Stereoview of electron density around the heme, bound L-Trp, 
arginine 117, and residue 55 at the active site of (a) H55A and (b) H55S. 
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4.5.2 Active-Site Structure 
The binding orientation of L-Trp at active site of the H55A mutant enzyme is slightly 
different from that observed in the wtTDO structure and stereoviews of electron 
density at the active-sites of H55A and H55S are shown in Figure 4.1(a) and (b). 
The bound L-Trp molecules in the H55A and H55S mutant enzymes are shifted 
towards the side chain of residue 55 relative to the position of L-Trp in the wild-type 
enzyme. An overlay of the active sites of WT TDO, H55A and H55S is shown in 
Figure 4.2. Due to the substitution of histidine 55 by alanine or serine the hydrogen 
bonding interaction between residue 55 and the substrate indole nitrogen atom is lost. 
The positions of the side chains of other active-site residues are unperturbed by either 
substitution or the resultant change in substrate orientation. In particular, substrate 
carboxylate interactions with tyrosine 113, arginine 117 and the heme 7-propionate 
moiety are maintained in both mutant enzymes. Furthermore, the van der Waals 
interactions between the substrate indole ring and residues Phe 51, Tyr 24 and 27 and 
Leu 28 (the latter three belonging to the N-terminal arm of the adjacent monomer) 
are conserved in both mutant enzymes. 
The active sites of wtTDO and both the H55A and H55S mutant enzymes contain a 
water molecule above the distal face of the heme, shown in Figure 4.3. In all three 
enzymes this water is H-bonded to the ammonium group of L-Trp and Gly 125, but is 
too far (~! 2.7 A) from the heme iron to be a ligand. Further to this, an additional 
water molecule is found in the active site of the H55A and H55S mutant enzymes 
(water B in Figure 4.3) in a position which would be sterically inhibited by histidine 
55 in wtTDO. In the H55A mutant enzyme water B is H-bonded to the substrate 
indole nitrogen, but in the H55S model water B is instead H-bonded to the side chain 
hydroxyl group of serine 55, which is too far away (3.4 A) from L-Trp to maintain a 
hydrogen-bonding interaction. 
In wtTDO the histidine 55 imidazole moiety hydrogen bonds to a water molecule in 
the substrate-free ferrous state, which is displaced upon binding of substrate. The 
removal of the histidine side chain in either mutant enzyme would almost certainly 
result in the absence of a water molecule in such a position. 
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Figure 4.2 An overlay of the active site region of WT TDO (yellow), H55A 
(green), and H55S (orange) TDO viewed from the side (a) and from above (b). The 
L-Trp from the H55A enzyme (in green) is rotated toward alanine/serine 55 and the 
heme, relative to the position of the substrate in WT TDO (yellow). The H-bond 
between histidine 55 and the substrate is lost as a result of the substitution by 
alanine. 
Figure 4.3 	The active site of (a) H55A and (b) H55S. Hydrogen bonding 
interactions are indicated by dashed lines. The subtly different  positions of water B 
in the mutant enzymes can be seen. 
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4.5.3 A Potential Allosteric Binding Site 
An interesting finding in the structure of the substrate-bound ferrous wtTDO was the 
existence of a second L-Trp binding site in the tetrameric interface, and it is possible 
that this represents an allosteric site (Section 1.8) (1). In the structures of the H55A 
and H55S mutant enzyme these interfacial sites bind four L-Trp molecules per 
tetramer interacting with arginine 85, lysine 92 and aspartate 228 from one monomer 
and lysine 86 from another. (It should be noted that the H55A unit cell contains two 
tetramers, only one of which has four L-Trp molecules bound at the interfacial sites) 
4.6 	Substrate Binding 
Substrate binding titrations were performed as described in Section 2.6, and the 
results are shown in Table 4.2. In wtTDO there is a large increase in the affinity of 
the enzyme for L-Trp for ferrous vs. ferric 	 2+ enzyme (Kd Fe = 3.8 mM, Kd Fe = 4.1 
jiM) (1). This is in contrast to recent findings for human TDO, where there was 
found to be little discrimination of binding between the ferric and the ferrous enzyme 
(77). For both mutant proteins this effect is essentially destroyed, with only a small 
increase shown in the affinity of the ferrous enzyme for L-Trp relative to ferric. This 
trend in Kd is repeated for other substrates. These findings suggest that one role of 
histidine 55 is to disfavour substrate binding to the oxidised protein, and its removal 
increases binding affinity by a factor >300. It can therefore be hypothesised that 
histidine 55 is responsible for controlling the binding affinity of the active site for L-
Trp, effectively gating the binding of substrate to wtTDO. In this way histidine 55 
greatly disfavours the mechanistically unproductive binding of L-Trp to the oxidized 
enzyme, promoting the productive binding of L-Trp to the reduced enzyme. 
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Table 4.2 Binding Constants 
wtTDO (Kd) H55A (Kd) H55S (Kd) 
Substrate Fe 3+  Q.tM) Fe 2+  Q.tM) Fe 3+  (tM) Fe 2+  QM) Fe 3+  (tM) Fe 2+  (tM) 
3840 ± 
L-Trp 4.1±0.2 11.8±0.2 3.7± 1.3 18.4±3.0 5.3± 1.0 
140 
6-F-D/L- 
1510±80 <1.001  165±44 73.0±3.0 86± 12 6.2±0.9 
Trp 
6-Me- 
>1650 >200 75± 11 40±6 >200 73± 15 
D/L-Trp 
5-F- D/L- 2450± 
<1.00T 67± 20 9.0± 1.7 73.4± 5.0 <5.0 
Trp 420 
5-Me- 
>2500 51±7 103± 10 83±7 >300 197± 18 
D/L-Trp 
Binding too tight to be measured 
120 
LAL 	J1U1L 	 IL& JJt1 	Ji1iUi 	1111(1 1 1IJJL /iLLiL 	 - 
4.7.1 Steady State Turnover Kinetics 
H55A and H55S mutant enzymes show catalytic activity toward L-Trp, 6-F- D/L-Trp, 
5-F-D/L-Trp, 5-methyl-D/L-tryptophan and 6-methyl-D/L-tryptophan only. Kinetic 
parameters are shown in Table 4.3, and there is about a 7-fold decrease in kcat values, 
compared to wtTDO, for both mutant enzymes. Catalytic activity is observed only 
for the ferrous enzyme in wtTDO and its mutant forms. 
The substitution of histidine 55 might have been expected to render the enzyme 
inactive if a base is required in the catalytic cycle, but the possibility that a water 
molecule could be bound in the vacant space made by the substitution of histidine 55 
must be considered. This water molecule could possibly act as an active site base 
dependent on its pKa in the active site. A water molecule is found near this position 
in both the mutant enzymes, but it is not optimally aligned for the deprotonation of L-
Trp. It is also located 3.3 A away from the indole nitrogen atom, outside the range of 
a normal hydrogen bonding interactions, and we propose that it plays no role in the 
catalytic cycle. These data and the relative insensitivity of the wtTDO kcat to pH 
support the idea that histidine 55 or a solvent molecule is not required to deprotonate 
the indole nitrogen atom. In IDO where the active site is devoid of solvent, the 
equivalent residue to histidine 55 is serine 167, which is unlikely to act as a catalytic 
base. Turnover still occurs, and like TDO kcat is observed to be insensitive to pH. 
The decrease in kcat for L-Trp oxidation in both the H55A and H55S mutants may be 
explained by the movement of L-Trp in the active site. It can be seen from the crystal 
structures that for both mutants L-Trp has rotated towards the substituted amino acid 
(and away from the iron atom) relative to the position of L-Trp in wtTDO. The L-Trp 
indole ring has also shifted towards the heme. These movements are accompanied by 
a slight increase in the substrate Km values, implying a small decrease in the stability 
of the Michaelis complex. The rotation has resulted in the displacement of 
tryptophan indole ring from the dioxygen binding site, thus decreasing overlap of the 
molecular orbitals involved in catalysis. The transition state for the reaction will be 
less stable, thus increasing the activation energy for catalysis. This will decrease the 
turnover rates for both mutants compared to wtTDO. 
121 
L11Z112iiJL iJ1U Al L( ijil ill,-, i1c , 0id1L' 111(t) . AjJ iIjJULl1 ,ji )1t hd(: 
Table 4.3 Steady-State Kinetic Data 
wtTDO H55A H55S 
Substrate kcat (s') Km (p.M) kcat (s') Km (tiM) kcat (s') Km (tiM) 
2.86± 2.60± 
L-Trp 19.5±1.2 114±1 133±7 197±2 
0.10 0.01 
6-F- D/L- 3.78± 3.80± 
37±1 186± 12 195± 1 546±36 
Trp 0.10 0.04 
6-Me- 1.65 ± 4.66 ± 1980 ± 
41±1 980±50 386±4 
D/L-Trp 0.03 0.18 170 
5-17- D/L- 0.68 ± 0.80 ± 
2.4±0.1 100±6 194±25 183±12 
Trp 0.14 0.01 
5-Me- 0.40 ± 1.45 ± 
3.6±0.1 357±12 395±20 1300±20 
D/L-Trp 0.01 0.01 
4.7.2 LC-MS Analysis of Products 
LC-MS analysis was used to detect products produced upon catalytic turnover of L-
Trp by H55A and H55S, as described in Section 2.11. The equipment was calibrated 
to detect L-kynurenine (209 Da), N-formylkynurenine (237 Da) and L-Trp (205 Da). 
LC-MS analysis of the products of turnover for H55A and H55S respectively are 
shown in Figures 4.4 and 4.5. It can be seen that both the product N-
formylkynurenine, and the reactant L-Trp are present in solution for both enzymes, 
showing that dioxygenation of L-Trp is occurring. Additionally a small quantity of 
the hydrolysed product, L-kynurenine is also detected in solution. 
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Figure 4.4 LC-MS analysis of H55A L-Trp turnover products, (a) LC trace 
calibrated to detect the (M+It) ion of L-Kynurenine (209 Da) vs. time, (b) LC trace 
calibrated to detect the (M+It) ion of N-formylkynurenine (237 Da) vs. time, (c) LC 
trace calibrated to detect the (M+H) ion of L-Trp (205 Da) vs. time, (d) MS of the 
(M+ft) ion of L-Trp peak detected in (c), (e) MS of the (M+Ft) ion of N-
formylkynurenine peak detected in (b). 
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Figure 4.5 LC-MS analysis of H55S L-Trp turnover products, (a) LC trace 
calibrated to detect the (M+Ht) ion ofL-Kynurenine (209 Da) vs. time, (b) LC trace 
calibrated to detect the (M+Ft) ion of N-formylkynurenine (237 Da) vs. time, (c) LC 
trace calibrated to detect the (M+I-t) ion of L-Trp (205 Da) vs. time, (d) MS of the 
(M+H) ion of L-Trp peak detected in (c). 
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4.7.3 MS-MS Analysis of Products 
MS-MS analysis was conducted on the same samples as those used for LC-MS. The 
data produced reconfirms that L-Trp, N-formylkynurenine and L-kynurenine are 
found in the samples. MS-MS analysis for H55A and H55S turnover is shown in 
Figures F.2 and F.3 in Appendix F. These data confirm that the product of the 
reaction of H55A or H555 mutant enzyme with L-Trp is N-formylkynurenine, and 
that no other products are observed to be formed. 
4.8 	Oxy-Ferrous Complex Formation 
WtTDO has an ordered catalytic cycle in which the reduced enzyme-substrate 
complex must be formed prior to 02 binding for turnover to occur (4). No (Fe 2+ 
complex is observed in the absence of substrate (77). Addition of oxygen to ferrous 
wtTDO or the mutant forms in the absence of substrate leads to direct decay to the 
ferric state. This is also the case for human TDO, suggesting that instability of the 
ferrous-oxy species may be common in TDO species (77, 104). The similar L-Trp 
binding affinity of the reduced mutant enzymes compared to wtTDO (3.7 and 5.2 
.tM versus 4.1 tM) and similar Km values for substrates shows that all enzymes can 
bind substrate then dioxygen in productive ternary complex formation 
Formation and decay of the oxyferrous ternary species for the H55A and H55S 
mutants proceeds in an analogous manner to wtTDO (Section 3.9, Figure 3.10 (a) 
and (b)). The (Fe 2+_  L-Trp) binary complex binds 02,  producing the oxyferrous 
ternary complex (Fe 2+_  L-Trp -02), with a corresponding shift in the Soret peak to 
419 nm. This then decays to N-formylkynurenine (shown by an increase in 
absorbance at 321 nm) and ferrous enzyme (displaying a Soret peak at 432 urn). 
These species are also observed with 6-F-D/L-Trp as the substrate, but when 5-F- D/L-
Trp is employed, some uncoupling is seen. This leads to production of the inactive 
ferric enzyme and the superoxide anion (02), and release of the substrate in the same 
manner as wtTDO. 
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The initial rates of formation of the ternary complexes are slower for H55A and 
H55S compared to wtTDO, with rate constants of approximately 50 s_ I compared to 
100 s4 for wtTDO. Oxyferrous decay parallels this with rate constants of 0.4 s-1 and 
2 s for the mutant enzymes and wtTDO respectively. This indicates that neither 
substitution destabilises the ternary complex significantly, but because the rate of 
decay is decreased compared to wtTDO, this correlates with higher activation energy 
for catalysis due to the movement of the indole ring destabilising the transition state. 
4.9 	Steady-State turnover at Varying Oxygen Concentrations 
Figure 4.6 shows how the observed rate constant for turnover is dependent on 
dioxygen concentration, [021, under saturating L-Trp concentrations (25 MM). In 
phosphate buffer (pH 7.5) at 25 °C, Km (02) is approximately 120 .tM whilst the rate 
of L-Trp turnover by WT TDO is only 60% of maximum. However, in the case of 
the H55A and H55S mutant enzymes, the turnover rate is nearly maximal (Table 
4.4). These data seem contrary to the Michaelis model that predicts a lower 02 
binding affinity for the mutant forms. 
Substrate inhibition is observed at high oxygen concentrations for both mutant forms, 
whilst none is observed for wtTDO. This unexpected result may be plausibly 
explained by the lower rate of decay and subsequent slower expulsion of product 
from the active site by the mutant enzymes. As the active site cavity is larger due to 
the removal of histidine and its replacement by alanine or serine in the mutant forms, 
the product, N-formylkynurenine, may be less readily expelled at high oxygen 
concentrations and dioxygen may be able to bind before the product has left. This 
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Figure 4.6 	Plot of the observed steady-state turnover rate (kapparen) versus 02 
concentration for wild type TDO (top), H55A (middle) and H55S (bottom) mutant 
forms. 
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Table 4.4 Oxygen dependence of steady-state turnover of L-tryptophan by wtTDO 
and its mutants. 
tTDO H55A H55S 
kmax (5 ') 35.4 ± 0.9 3.86 ± 0.26 7.88 ± 0.60 
Km (1M) 119±2 45.7±5.6 99±16 
K(M) 1380:L 140 480 ± 50 
Table 4.5 Electrochemical midpoint reduction potentials (m V vs. SHE) 
Substrate-free Substrate 
Enzyme Substrate AEmid 
Emid Bound Emid 
X campestris 
L-Trp 8±5 144±6 +136 
TDO(1) 
H55A (2) L-Trp 64± 3 87± 2 +23 
H555(2) L-Trp 44±2 101±2 +57 
H sapiens 
L-Trp -30 ± 4 (-63) 16 ± 3 +46(+79) 
IDO(78, 102) 
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4. 10 Electrochemical Studies 
Electrochemical data for wtTDO and the H55A and H55S mutant enzymes are 
shown in Figure 4.7 and the measured midpoint potentials are displayed in Table 4.5. 
There is a much smaller shift in the reduction potential upon binding of substrate 
(LEmid H55A= +23 mV) (AEmid H55S= +57 mV) for the mutant enzymes compared to 
wtTDO (AEmid WT = +136 mV). The shift in reduction potential of 23 mV for the 
H55A mutant enzyme almost perfectly correlates with the increase in affinity for L-
Trp for ferrous vs. the ferric form (Kd (Fe (II)) = 3.7 jiM vs. Kd (Fe (III)) = 11.8 jiM), 
both giving an estimated AAG of 3.5 kJ mor'. In fact, the difference in these AAG 
values calculated for wtTDO and the H55A mutant enzyme is approximately 11.5 kJ 
moi', within the range of energies for a single hydrogen bond. The data are less clear 
for H55S, with a 57 mV shift in the reduction potential on L-Trp binding. The 
increase in affinity for L-Trp to the ferrous H55S vs. the ferric give an estimated 
AAG of 5.5 kJ mor1. It is possible that the lower affinity of oxidised wtTDO for 
substrate may be attributed to subtle changes in the structure of the active site (in 
terms of the hydrogen-bonding pattern) between the oxidised and reduced enzymes. 
Binding of L-Trp ejects solvent from the active site and results in the formation of a 
hydrogen-bond between His55 and the Ni atom of the indole L-Trp moiety. 
In the H55A mutant the alanine side chain is unable to form the same hydrogen-
bonds that HisS 5 can in wtTDO. Consequently there may be less rearrangement of 
the active site hydrogen-bonding interactions to allow L-Trp binding, and the Kd for 
substrate binding to ferric enzyme is correspondingly low. All other amino-acid 
interactions binding L-Trp to the active site are analogous to wtTDO. Consequently, 
the absence of significant oxidation-state-dependent changes in the active site of 
H55A results in decreased specificity of binding to the oxidised or reduced enzyme. 
The case is similar for the H55S mutant enzyme since the senile side chain is unable 
to form the same hydrogen-bonds that HisS 5 can in wtTDO. It is possible that the 
serine could form a hydrogen-bonding interaction with a nearby solvent molecule 
(water 250), but the data suggest that less rearrangement of active site hydrogen-
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Potential (mV vs SHE) 
Figure 4.7 	01TLE potentiometric curves for wild type TDO (black line, open 
circles), H55A mutant (red line, closed circles) and H55S (green line, open triangles) 
with (right hand plots) and without (left hand plots) L-Trp substrate present (± L-
Trp). Each curve is produced from both reduction and oxidation of the layer of 
interest. 
4.11 Conclusions 
In this chapter it has been investigated whether a putative active site base, histidine 
55, is necessary for catalytic activity in TDO. The data presented show that in the 
mutant enzymes H55A and H55S, turnover still occurs. This indicates clearly that 
histidine 55 is not an essential base. Instead, a different role for histidine 55 in 
controlling substrate binding at the active site has been revealed. Based on structural, 
kinetic and electrochemical data we have proposed that the role of histidine 55 is to 
prevent the formation of the non-productive ferric enzyme-substrate complex. This is 
most likely achieved by histidine 55 controlling the water content of the substrate-
free active site. 
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IDO plays an important role in the body's immune response, and has been implicated 
as a potential drug target for cancer treatments (43, 49). The most-studied inhibitor of 
IDO is 1 -Me-Trp, a competitive inhibitor that exists as two stereoisomers, 1 -Me-D-
Trp and 1 -Me-L-Trp (51). It is unclear as to which isomer effects the greatest 
inhibitory response in vitro, as discussed in Section 1.3.3, and this is currently a 
pertinent question since IDO is a therapeutic target for the development of new 
anticancer, transplant and HIV drugs (47, 132, 133). However, previous studies have 
shown 1 -Me-D/L-Trp to be ineffective against TDO activity, raising the question as 
to the biochemical differences between the enzymes. 
5.2 	1-Methyl-tryptophan Binding 
Attempts were made to bind both 1 -Me-L-Trp and 1 -Me-D-Trp to wtTDO and the 
H55A and H55S mutant forms, in both the ferric and the ferrous states. 1-Me-D-Trp 
does not appear to bind to any of the enzymes in either the ferric or the ferrous states, 
and no Kd values could be obtained. The Kd of 1-Me-L-Trp binding to wtTDO, H5 5A 
and H55S in both the ferric and the ferrous states was measured as described in 
Section 2.6, and results are displayed in Table 5.1. 
It can be seen that 1-Me-L-Trp binds weakly to wtTDO in both the ferric and the 
ferrous forms, with a Kd of more than 200 p.M in the ferrous form. In comparison, L-
Trp binds with a Kd of only 4.1 p.M. This can be explained by considering the active-
site L-Trp binding interactions in wtTDO. In wtTDO the indole nitrogen of L-Trp is 
directly hydrogen-bonded to the His55 side chain with a distance of 2.7 A between 
the nitrogen of His55 and the indole Ni atom. The addition of a methyl group to L- 
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Trp to produce I -Me-L-Trp would clearly cause a steric clash with this residue, with 
a distance of only 1.5 A between the methyl carbon and the nitrogen atom of His 55 
(Figure 5.1). Therefore, 1-Me-L-Trp does not bind tightly to TDO, and does not 
inhibit its action. A comparison of the active-sites of TDO and IDO explains the 
differences in the inhibition of activity by I -Me-Trp. His55 is replaced by Serl 67 in 
lilDO (87), which creates a small pocket that can accommodate the 1-methyl group. 
This enables 1 -Me-Trp to bind to IDO and inhibit activity. However, as IDO binds 
and dioxygenates both D- and L-Trp (102), we cannot rule out that both 1-Me —D-Trp 
and 1 -Me-L-Trp could inhibit its action. 
For the H55A and H55S mutants of TDO, it can be seen that the binding constants of 
1 -Me-L-Trp to the ferric and ferrous enzymes are approximately equal to those of L-
Trp (2). Since the His55 residue has been substituted for the smaller alanine and 
serine residues in these mutant enzymes, a larger binding cavity has been created at 
the indole nitrogen. An additional methyl group on the indole nitrogen atom of L-
Trp is easily accommodated in the larger binding cavity, and subsequently the Kd for 
1 -Me-L-Trp is similar to that of L-Trp. 
Figure 5.1 	Active site of xcTDO (a) L-Trp binding (b) 1-Me-L-Trp binding 
model. The Ni-methyl group clearly sterically clashes with the His55 residue. 
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5.3 	Steady-State Kinetics 
Steady-state turnover assays (at pH 7.5) for oxidation of 1-Me-D-Trp and l-Me-L-
Trp were performed as described in Section 2.7, but, no activity was detected in wt 
or mutant TDOs when utilizing 1 -Me-D-Trp (purchased from sigma) as a substrate. 
No consistent dioxygenation of 1-Me-L-Trp could be observed for wtTDO by 
spectrophotometric methods, however a small amount of product (N-Me-
formylkynurenine) was detected by LC-MS (Figure 5.2). ). It was concluded that the 
rate of 1-Me-L-Trp turnover by wtTDO must be less than 0.001 s_I, similar to the 
background level of activity from the assay components, and no accurate 
measurements could be obtained. In comparison, both H55A and H55S displayed 
robust activity toward 1-Me-L-Trp. The recorded kcat was 1.7 % of that of L-Trp by 
H55A, and 2.0 % of that for L-Trp by H55S (Table 5.2). 
On addition of 1 -Me-D-Trp or I -Me-L-Trp to wtTDO there is no inhibition of 
wtTDO catalytic activity upon L-Trp, as previously reported [4]. Similarly, on 
addition of 1-Me-D-Trp to H55A or H55S no inhibition is observed. However, 
addition of 1-Me-L-Trp to H55A or H55S leads to competitive inhibition of L-Trp 
activity. 
These differences in catalytic activity between the wild-type protein and its mutant 
forms can be explained by the binding affinity of 1 -Me-L-Trp. WtTDO is unable to 
bind 1-Me-L-Trp tightly in its active site, due to a steric clash between the methyl 
group and His 55 (Figure 5.1). Histidine 55 would need to be reoriented, or l-Me-L-
Trp adopt a different conformation to allow binding and dioxygenation. In 
comparison, H55A and H55S can bind 1-Me-L-Trp tightly, forming stable Michaelis 
complexes that undergo catalytic activity. The calculated Km for the H55A and 
H55S, 1-Me-L-Trp Michaelis complexes are lower than those for L-Trp, indicating 
their stability. 
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5.4 LC-MS 
LC-MS analysis was used to detect products produced upon catalytic turnover of 1-
Me-L-Trp by wtTDO, H55A and H55S as described in Section 2.11. The equipment 
was calibrated to detect 1 -Me-kynurenine (223 Da), I -Me-formylkynurenine (251 
Da) and 1 -Me-Trp (219 Da). It should be noted that no stereochemical distinction of 
the products can be made by this method of analysis. LC-MS analysis is shown in 
Figures 5.2, 5.3 and 5.4 
From the assay of I -Me-L-Trp and wtTDO a very small amount of the product 1-Me-
formylkynurenine is detected in the solution. However the quantity detected is 
insufficient to perform mass-spectrometry upon. The reactant 1 -Me-(L)-Trp is the 
main component detected in the sample, and additionally a tiny quantity of 
hydrolysed 1-Me-formylkynurenine, (1-Me-kynurenine) is detected in solution. 
These data show that wtTDO does in fact catalyse the dioxygenation of 1 -Me-Trp, 
but at a very slow rate. 
For both the H55A and H55S mutant enzymes, the product 1-Me-formylkynurenine 
and the hydrolysed product 1 -Me-kynurenine were detected in large quantities in 
solution. 
5.5 	MS-MS Analysis of Products 
MS-MS analysis was conducted on the same sample as that used for LC-MS. The 
data produced reconfirms that 1 -Me-Trp, 1 -Me-formylkynurenine and 1-Me-
kynurenine are found in the H55A and H55S catalysed samples. However, the 
quantities of 1 -Me-formylkynurenine and 1 -Me-kynurenine in the wtTDO sample 
were too small to be measured. MS-MS analysis is shown in Figure F.4, F.5 and F.6, 
Appendix F. 
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Table 5.1 	1-Me-L-trp Binding to wtTDO and its mutants 
wtTDO (Kd) (1) H55A (Kd) (2) H55S (Kd) (2) 




4.1±0.2 11.8±0.2 3.7± 1.3 18.4±3.0 5.25±1.0 
1-Me-L- 
Trp 
>2000 (>200) 15.3 ± 2.2 3.6 ± 0.7 16.2 ± 3.3 2.5 ± 0.38 
Table 5.2 	Steady-state kinetics for 1-Me-L-Trp turnover by xcTDO, H55A and 
H555. 
wtTDO (1) H55A (2) H55S (2) 
Substrate kcat (s') Km (jiM) kcat (s') Km (jiM) kcat (s') Km (jiM) 
19.5 ± 2.86 ± 2.60 ± 
L-Trp 114±1 133±7 197±2 
1.2 0.10 0.01 
1-Me-L- 0.048 ± 0.052 ± a - 59±16 70±11 
Trp 0.011 0.009 
a  Some turnover was on occasion recorded, up to a value of 0.002 s, but results 
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Figure 5.2 LC-MS analysis of wtTDO turnover products, (a) LC trace calibrated 
to detect 1-Me-Kynurenine (223 Da) against time, (b) LC trace calibrated to detect 
1-Me-formylkynurenine (251 Da) against time, (c) LC trace calibrated to detect 1-
Me-Trp (219 Da) against time, (d) MS of L-Trp peak detected in (c). 
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Figure 5.3 	LC-MS analysis of H55A turnover products, (a) LC trace calibrated 
to detect 1-Me-Kynurenine (223 Da) against time, (b) LC trace calibrated to detect 
1-Me-formylkynurenine (251 Da) against time, (c) LC trace calibrated to detect 1-
Me-Trp (219 Da) against time, (d) MS of L-Trp peak detected in (c), (e) MS of 1-Me-
formylkynurenine peak detected in (d). 
137 
.L. 	1,JIIj 	!i1LJ 	JiiiJL,1iL ..1LL1 JC iiih) 	Iij)itiJ)lILi1 _,J-L1JU\4,L iL1.'L 
	
ioa 	 542 
55 
- 	 &57 	
847 
ioo 	 3,,61 
./J  
o p 	. 	. 	p , p' , p , 1 	' 'V 	, Tp'r' i' .• F' •-.  
ioo 	 585 
I / 
'/01 	 II  
/ 
o /--- 	- - - 	 •,pI..,-m;---r 	 Time 










113 	140 	175 	 251 
181 241 	 289 	311 
103  	mlz 
0 	 ..............r. 	 ................. 
1001101 20  130140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 
Figure 5.4 	LC-MS analysis of H55S turnover products,, (a) LC trace calibrated 
to detect 1-Me-Kynurenine (223 Da) against time, (b) LC trace calibrated to detect 
1-Me-formylkynurenine (251 Da) against time, (c) LC trace calibrated to detect 1-
Me-Trp (219 Da) against time, (d) MS of 1-Me-Trp peak detected in (c), (e) MS of 1-
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5.6 	Conclusions 
Analysis of wtTDO and the H55A and H55S mutant forms has shown that they all 
catalyse the dioxygenation of 1 -Me-L-Trp, a substrate which is unable to undergo 
deprotonation during dioxygen activation. The catalytic differences are explained by 
comparison of the active sites of the enzymes, and support the proposal that a 
catalytic base is not necessary for enzymatic activity. 
The possible catalytic mechanisms employed by TDO were discussed in Section 1.6. 
Dioxygen activation is proposed to occur via either base-catalysed attack, an 
"oxygen-ene" type rearrangement to a hydroperoxy intermediate, or by direct 
electrophilic or radical addition (89). In the previous chapter it has become clear that 
a catalytic base is not essential to catalytic activity, leaving two possible mechanisms 
(2). As 1 -Me-L-Trp (or 1 -Me-D-Trp) is unable to undergo an "oxygen-ene" type 
rearrangement, the dioxygenation of 1 -Me-L-Trp must proceed via a direct 
electrophilic or radical addition pathway. 
The ability of TDO and its mutants to catalyse the dioxygenation of 1 -Me-L-Trp has 
currently been submitted for publication. Based on these results it can be theorised 
that IDO may display catalytic activity toward 1 -Me-L-Trp. IDO contains a serine 
residue (serine 167 in hIDO) in an analogous place to histidine in TDO (histidine 55 
in xcTDO), a much smaller residue that does not hydrogen bond to the indole 
nitrogen atom of L-Trp. Methylation of the indole nitrogen atom should be easily 
accommodated in the active-site pocket, as modelled in Figure 5.1. Therefore 
catalytic activity should be able to proceed unhindered, analogous to the histidine 55 
substituted forms of TDO. In addition, as IDO displays wider substrate specificity 
than TDO, catalysing the dioxygenation of L-Trp and D-Trp it can be theorised that 
in addition to utilising 1 -Me-L-Trp as a substrate, IDO may also be able to utilise 1-
Me-D-Trp. As it is currently unknown as to which stereoisomer of I -Me-Trp effects 
the greatest inhibition of activity in vivo, and this study raises questions as to the 
usefulness of 1 -Me-D/L-Trp as an inhibitor in cancer treatments. 
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Chapter 6 
Conclusions 
6.1 	TDO and IDO 
Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase constitute an 
important, yet relatively poorly understood, family of heme-containing enzymes and 
in this thesis the first crystal structure of a tryptophan 2,3-dioxygenase enzyme in 
complex with substrate is reported (1). The structure of catalytically active, ferrous 
X campesiris TDO in complex with L-Trp has been determined to 1.6 A. The crystal 
structure of xcTDO displays a high level of overall structural similarity with R. 
metallidurans TDO (88), H sapiens IDO (77, 102), and S. oneidensis sIDO (1), 
revealing striking evolutionary conservation between enzymes and contributing to 
the understanding of the structure-activity relationships in this important family of 
heme dioxygenases. 
Our structural studies have defined the binding mode of the substrate L-Trp to TDO, 
identifying key interactions that are responsible for its substrate specificity. 
Hydrophobic interactions and hydrogen bonding interactions between the bound 
substrate and active-site residues are fundamental to the substrate specificity of TDO, 
and reveal the structural basis for the stereospecificity of this important enzyme (1). 
Structural investigation of TDO has also revealed induced-fit behaviour upon 
substrate binding to the active site. This induced-fit behaviour is confirmed by 
biophysical studies and appears crucial for the exclusion of water from the active site 
and for stabilizing the enzyme in the presence of the substrates. 
Active-site mutants where histidine 55 was replaced by alanine or serine (H55A and 
H55S) were created and crystal structures of the H55A and H55S mutant forms in 
complex with L-Trp were determined to 2.15 A and 1.90 A resolutions respectively 
(2). Kinetic, electrochemical and structural data indicate that His55 is not an active 
site base, but instead reveal a role for His55 in controlling substrate binding at the 
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active site. A thousand fold increase in the L-Trp binding affinity is observed upon 
enzyme reduction for xcTDO (Kd Fe(III) = 3800 jAM, Kd Fe(II) = 4 NM), 
disfavouring the mechanistically unproductive binding of L-Trp to the oxidized 
enzyme. Substitution of histidine 55 greatly increases the affinity of the oxidised 
enzyme for substrate. Only a small change in the L-Trp binding affmity is observed 
upon enzyme reduction for H55A (Kd, Fe(III) = 12 jAM, Kd Fe(II) = 4 pM) and H55S 
(Kd, Fe(III) = 18 riM, Kd Fe(II) = 5 jiM)), allowing unproductive binding of L-Trp to 
the oxidized enzyme. Histidine 55 regulates the binding of L-Trp to the enzyme, 
allowing precise control of the mechanism of turnover. 
Further analysis of wtTDO and the H55A and H55S mutant forms has shown that 
they all catalyse the dioxygenation of 1 -Me-L-Trp, a substrate which is unable to 
undergo proton transfer during dioxygen activation. These catalytic differences are 
explained by comparison of the active sites of the enzymes, and support the proposal 
that a catalytic base is not necessary for enzymatic activity. In addition, these data 
provide new insight into the use of 1 -Me-Trp as an inhibitor of IDO activity in 
cancer treatments (43). The ability of TDO and its mutants to catalyse the 
dioxygenation of 1 -Me-L-Trp is currently unpublished. It is theorised that IDO may 
be expected to display a similar catalytic activity toward 1 -Me-L-Trp and 1 -Me-D-
Trp due to its wider substrate specificity. It is currently unknown as to which 
stereoisomer of 1 -Me-Trp effects the greatest inhibition of activity in vivo (51), and 
this study raises questions as to the usefulness of 1 -Me-D/L-Trp as an inhibitor. 
6.2 	Catalytic Mechanism 
The catalytic mechanisms employed by TDO and IDO have not yet been fully 
elucidated and a number of mechanisms for tryptophan dioxygenation have been 
proposed (89). The structural and biochemical characterisation of xcTDO presented 
in this thesis has shown a number of these proposals to be inaccurate. Therefore a 
general reaction mechanism for dioxygenation of L-Trp by TDO and IDO, based on 
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Formation of the Ternary Complex 
In the active site of wtTDO histidine 55 greatly decreases the affinity of the oxidised 
enzyme for substrate and regulates the binding of dioxygen (1, 2). This prevents 
unproductive coupling of dioxygen to the ferrous enzyme that would lead to the 
production of superoxide and the dead-end ferric complex. This result confirms that 
substrate must bind to the enzyme first before dioxygen binding can take place, to 
form the ternary complex. 
Dioxygen Activation 
Before a crystal structure of TDO was published, previous work on rat liver TDO 
implicated that a histidine residue played a critical role in the dioxygenation of L-Trp 
at the active-site (122). These results implied that a base may be necessary for 
catalytic activity to occur via deprotonation of the indole proton, facilitating 
nucleophilic attack from the C3 position of the indole ring to the bound dioxygen (4, 
88). The crystal structure of wtTDO has revealed that a histidine residue is present at 
position 55, near to the active site, coordinating to the nitrogen of the indole ring, in 
an analogous position to a serine residue in H sapiens DO (87). As a base is not 
present for proton abstraction in IDO, substitution of histidine 55 to alanine and 
serine was conducted to probe the function of histidine 55. Substitution of histidine 
55 has shown that the histidine residue is not critical to TDO activity, because the 
mutant proteins still catalyse L-Trp dioxygenation. These data and the relative 
insensitivity of kcat to pH indicate that a base is not necessary for catalytic function, 
disfavouring this route of dioxygen activation. 
Modelling of the Michaelis complex for xcTDO, based on the structure of the 
catalytically active ferrous protein in complex with L-Trp, has shown that the highly 
hydrophobic active-site is devoid of solvent molecules during catalysis, suggesting 
that water plays no role in dioxygen activation. This proposal seems logical as the 
absence of solvent or a hydrogen-bonding network from the active-site may protect 
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transient oxygenated species, allowing them to transfer both oxygen atoms to the 
substrate, rather than undergo reaction with water. 
Further analysis of wtTDO, H55A and H55S mutant forms has shown that they all 
catalyse the dioxygenation of 1 -Me-Trp, a substrate which is unable to undergo 
proton transfer in dioxygen activation. This result shows that dioxygen activation 
cannot occur by electrophilic addition concerted with proton transfer, in an "oxygen-
ene" type reaction. These results are supported by DFT calculations that have 
predicted a very high energy barrier to the "oxygen-ene" type transition state (89). 
The results presented in this thesis support initial dioxygen activation occurring via 
direct electrophilic or radical addition of the bound distal oxygen to the electron-rich 
indole carbon. It is proposed that in TDO and IDO, a mild oxidant Fe 2+_02 species or 
a Fe 3+_02*- species reacts with a very electron-rich indole. Electrophilic addition at 
the C2 or C3 position of the indole, or radical recombination at the C2 position are 
all computed to be energetically favourable by DFT (90). The proposed mechanism 
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Figure 6.2 Proposed dioxygen activation intermediates, (a) direct electrophillic 
addition at the C3 position and at (b) the C2 position. 
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Rearrangement Pathway 
DFT calculations have suggested that the Criegee-type rearrangement pathway 
requires a very high barrier from the neutral indole intermediate (90). Instead, the 
zwitterionic and diradical products generated from the direct addition pathways are 
predicted to undergo charge or radical recombination to afford the comparatively 
stable dioxetane intermediate. Since the results in this thesis support the direct 
electrophulic and diradical pathways as catalytically favourable, and do not support 
the formation of a hydroperoxide intermediate, a Criegee-type rearrangement must 
therefore be regarded as an unlikely mechanistic route. Formation of a dioxetane 
intermediate which can then undergo metal-catalyzed ring-opening to give the 
product is therefore favoured as a mechanistic pathway. 
An alternative to the dioxetane formation pathway does exist - homolytic 0-0 bond 
cleavage of the radical intermediate (5) followed by oxo attack and facile C2-C3 
bond cleavage could occur. However, this pathway involves the formation of a 
highly reactive ferryl-oxo species (64) which may lead to the formation of undesired 
products, and requires a number of intermediate steps in product formation, unlike 
the more elegant dioxetane rearrangement. Consequently this pathway appears less 
convincing as a possible mechanistic route, but there is no known evidence against 
its validity. 
This study has advanced the knowledge of the biochemical and structural factors 
influencing the mechanism of TDO and IDO catalysis and advances our 
understanding of heme chemistry. However the precise catalytic mechanism 
employed by these important enzymes has not yet been fully elucidated and further 
study is necessary to fully understand their function. 
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6.3 	Future Work 
Although this study has elucidated the role of histidine 55 in substrate binding, the 
role of many active-site resides are currently unknown. The substitution of a number 
of residues, discussed below, could reveal insight into the regulation and mechanism 
of TDO. 
Of particular interest are the amino-acid residues which coordinate to L-Trp, 
facilitating its precise alignment in the active-site for catalysis. The substrate binding 
residues arginine 113 and tyrosine 117 which interact with the amino and 
carboxylate moieties of L-Trp, and serine 124, which hydrogen-bonds to a water 
molecule in the substrate-bound crystal structure of xcTDO could be substituted to 
probe their function. The structure of xcTDO is composed of a "dimer of dimers" in 
which the N-terminus of one monomer interacts with the active-site of its partner. It 
is currently unknown as to what function this may play. Tyrosine 24 and tyrosine 27 
of this N-terminal arm form part of the active-site pocket in the partner monomer, 
and their deletion or substitution should be investigated. The interfacial L-Trp 
binding sites discovered in the crystal structure of xcTDO suggest that this enzyme 
may be allosterically regulated. Site-directed mutation of key binding residues, such 
as lysine 92, and aspartic acid 228 in combination with identification of allosteric 
effectors may reveal more about this intriguing binding site. 
TDO is implicated in a number of pathophysiological and physiological diseases and 
some studies have suggested that TDO inhibitors may be used to a treat a wide range 
of illnesses, including depression and ischemic brain injury (134, 135). Identification 
of specific inhibitors of TDO function could be beneficial in designing treatments for 
these conditions. 
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Appendix B 
Derivation of Kinetic Equations 
(a) 	The Michaelis-Menten equation 
The Michaelis-Menten equation applies for an enzyme catalysed reaction in a 
"steady state". The concept of the steady-state is an approximation, which generally 
refers to the situation in which the value of a particular quantity is constant, often as 
its rate of formation is balanced by its destruction. In enzyme kinetics the concept is 
applied to enzyme-bound intermediates, when an enzyme is mixed with a large 
excess of substrate. 
In deriving the Michaelis—Menten equation, we assume that the concentration of 
enzyme is negligible compared to that of substrate (as is generally true in practice 
due to the high catalytic efficiency of enzymes), and that substrate binding is rapid 
and reversible, with no chemical changes taking place. It is also assumed that what is 
measured is the initial rate, v, of formation of products, since under these conditions 
changes in substrate concentrations are generally small. 
The catalytic reaction is divided into two processes, formation of the enzyme-
substrate complex, ES, from the enzyme, E, and the substrate, 5, and product 
formation, P, which is rate determining, e.g. 
K1 	K2  
E + S - ES -* E + P 	 Equation 1 
K1 
The rate of change of concentration of the intermediate species, ES (enzyme-
substrate complex), is given by: 
d[ES] = k1 [E][S] - k_1  [ES] - k2[ES] 	 Equation 2 
dt 
Under steady-state conditions the concentration of the intermediate ES is assumed 
constant as the concentration of substrate is depleted, hence the rate of formation of 
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the ES complex equals the rate of decay into the product and free enzyme, therefore 
equation 2 is equal to zero. During the reaction the instantaneous concentration of 
free enzyme is not directly measurable, hence it must be expressed in terms of the 
initial concentration at time t = 0, and is defined as [E0]. 
[E] = [Eo] - [ES] 	 Equation 3 
Substitution of Equation 3 into Equation 2, 
0= ([Eo]-[ES]) kj[S] - k..1[ES] - k2[ES] 	 Equation 4 
Which rearranges to Equation 5: 
[ES] = [E0][S] 	 Equation 5 
(k1 +k2)+[S] 
ki 
The rate of the reaction, V, is given by: 
V = djJ= k2[ES] 	 Equation 6 
dt 
Substitution of Equation 6 into Equation 5 gives the Michaelis-Menten equation: 
V = [E]o[S]k2 	 Equation 7 
(k 1 +k2)+[S] 
k1  




	 Equation 8 
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(b) 	Significance of the Michaelis-Menten Parameters 
kcat 
In the case of the Michaelis-Menten kinetics, kcat is the first order rate constant for 
the conversion of the enzyme-substrate complex, ES, to the enzyme-product 
complex, EP. It is often called the turnover number of the enzyme as it represents the 
maximum number of substrate molecules converted to products per unit time. 
Km 
For simple Michaelis-Menten kinetics Km is the apparent dissociation constant, 
which may be treated as the overall dissociation of all enzyme-bound species. 
kcat / Km 
kcat / Km is an apparent second-order rate constant that refers to the properties and the 
reactions of the free enzyme and free substrate. 
(c) 	Analysis of the Michaelis-Menten Equation 
Graphical analysis of the Michaelis-Menten equation is usually completed by its 
transformation into a linear form (Equation 8), by inverting both sides of Equation 7 
and substituting vma,, for kcat[E]o,  where Vm  is the limiting velocity. Graphical 
analysis of this equation yields the Lineweaver-Burke plot. 
1 	K -= m 
V k[S]0 k t 
Equation 8 
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The main disadvantage of the Lineweaver-Burke plot is that at low substrate 













Figure B. 1: Lineweaver-Burk Plot. The double reciprocal plot gives a linear 
relationship, with the y-intercept being inversely proportional to the maximum 
turnover rate kcat, and the x-intercept inversely proportional to the Michaelis 
constant, Km. 
(d) 	Breakdown of the Michaelis Menten Equation 
There are two main causes of the failure of the Michaelis-Menten equation - 
substrate inhibition, or substrate activation. 
Substrate inhibition is generally caused by a second molecule of substrate binding to 
give an enzyme-disubstrate complex, ES2, which is catalytically inactive. If this 
second binding event is modelled into the Michaelis-Menten equation, representing 
the second dissociation constant as Km* then the observed velocity is represented by 
Equation 15. 
V = 	{E1o[Slkcat 	 Equation 15 
Km* + [S] + [S]2/Km* 
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At low substrate concentrations, the rate is similar to that observed under normal 
Michaelis-Menten conditions, but as the substrate concentration increases a 
maximum value of v is observed, followed by a decrease. 
Competitive Inhibition 
Enzymes may be reversibly inhibited by the non-covalent binding of inhibitors. 
Competitive inhibitors often closely resemble the substrates whose reactions they 
inhibit, allowing them to compete for the same substrate binding site in an enzyme. 
In the case of the Michaelis-Menten equation, an additional equilibrium must be 
considered (Equation 9). 
	
ki 	k2  




Here I is the inhibitor, El is the enzyme-inhibitor complex and K1 is the inhibitor 
dissociation constant. 




The total enzyme concentration must now take into account the quantity of the 
enzyme-inhibitor complex, El, therefore 




In this case the total concentration of enzyme must take into account El, hence 
equation 12: 
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[E]o = [E] + [ES] + [Efl 
	
Equation 12 
Expressing Equation 12 in terms of [El] and substituting into Equation 4 gives: 
[E]0 = [E] +[ES] + [E] [1] 	 Equation 13 
K1  
[E] = [E]o - [ES] 	 Equation 14 
(1 + [I]/K1) 
Expressing Equation 11 in terms of [E] and substituting into Equation 14 gives: 
K,(1 + [I]) = ([E]o— [ES])[S] 	 Equation 15 
K1 	[ES] 
Finally substituting [ES] = V/kcat into Equation 15 gives: 
V = 	[E10[S]kcat 	 Equation 16 
[5] + Km(1 + [I]/K1) 
Equation 16 is expressed in the same form as the Michaelis-Menten equation and 
shows that for competitive inhibition v is unchanged but Km is apparently increased 
by (1 + [I]/K1). 
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Appendix C 
C. 1 Protein Sequences of TOO and 100 
Amino acid sequence of Xanthamonas campestris TDO. 
I 
MPVDK NLRDL EPGIH TDLEG RLTYG GYLRL DQLLS AQQPL SEPAH 
46 
HDEML FIIQH QTSEL WLKLL AHELR AAIVH LQRDE VWQCR KVLAR 
91 
SKQVL RQLTE QWSVL ETLTP SEYNG FRDVL GPSSG FQSLQ YRYIE 
136 
FLLGN KNPQN LQVFA YDPAG QARLR EVLEA PSLYE EFLRY LARFG 
181 
HAIPQ QYQAR DWTAA HVADD TLRPV FERIY ENTDR YWREY SLCED 
226 
LVDVE TQFQL WRFRH MRTVM RVIGF KRGTG GSSGV GFLQQ ALALT 
271 
FFPEL FDVRT SVGVD NRPPQ GSADA GKR 
Amino acid sequence of Home sapiens IDO 
MAHAM ENSWT ISKEY HIDEE VGFAL PNPQE NLPDF YNDWM FIAKH 
46 
LPDLI ESGQL RERVE KLNML SIDHL TDHKS QRLAR LVLGC ITMAY 
91 
VWGKG HGDVR KVLPR NIAVP YCQLS KKLEL PPILV YADCV LANWK 
136 
KKDPN KPLTY ENNDV LFSFR DGDCS KGFFL VSLLV EIAAA SAIKV 
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181 
IPTVF KAI4QM QERDT LLKAL LEIAS CLEKA LQVFH QIHDH VNPKA 
226 
FFSVL RIYLS GWKGN PQLSD GLVYE GFWED PKEFA GGSAG QSSVF 
271 
QCFDV LLGIQ QTAGG GHAAQ FLQDM RRYMP PAHRN FLCSL ESNPS 
316 
VREFV LSKGD AGLRE AYDAC VKALV SLRSY HLQIV TKYIL IPASQ 
361 
QPKEN KTSED PSKLE AKGTG GTDLN NFLKT VRSTT EKSLL KEG 
C. 2 Primer Sequences and Site-Directed Mutants of TDO 
H55A - Primer 1 
50 51 52 53 54 55 56 57 58 59 
G TTC ATC ATC CAG AGC GCG ACC TCC GAG CTG 
H55A - Primer 2 
59 58 57 56 55 54 53 52 51 50 
CAG CTC GGA GGT CAC GCT CTG GAT GAT GAA C 
H55S - Primer 1 
50 51 52 53 54 55 56 57 58 59 
G TTC ATC ATC CAG AGC CAG ACC TCC GAG CTG 
H55S - Primer 2 
59 58 57 56 55 54 53 52 51 50 
CAG CTC GGA GGT CTG GCT CTG GAT GAT GAA C 
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Appendix D 
(a) 	Growth Media and Solutions 
Table D. 1 	Growth Media and Solutions 
Per litre: 




15 gIl Agar dissolved in LB Broth 
62.5 tg / 1 Ampicillin 
Agar 
(Stored @ 4°C, used within 1 week of 
manufacture) 
Ampicillin 25 mg/ml 
7 mM Hemin 
Hemin 
1 mM NaOH 
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(b) Purification Buffers 
Table D.2 	Purification Buffers 
50 mM NaH2PO4 
Buffer A 300 mM NaCI pH 8.0 
10 mM Imidazole 
50 mM NaH2PO4 
Buffer B 300 mM NaC1 pH 8.0 
20 mM Imidazole 
50 mM NaH2PO4  
Buffer C 300 mM NaC1 pH 8.0 
40 mM Imidazole 
50 mM NaH2PO4 
Buffer D 300 mM NaC1 pH 8.0 
250 mM Imidazole 
50 mM Tris/HC1 
Buffer pH 8.0 
1 mM EDTA 
100 mM NaH2PO4, 
Buffer F pH 5.5-8.3 pH 5.5-8.3 
100 mM Na2HPO4 
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(c) SDS-PAGE solutions 
Table D.3 SDS-PAGE Solutions 
500 ml water 
4.9gMES 
Running Buffer 3.0 g Tris 
5.0 g SDS 
0.15 g EDTA 
60 ml H20 
10 ml 2.5 M Sodium Acetate (pH 5.2) 
Herne Stain 30 ml Methanol 
10 mg 3, 3', 5, 5 '-Tetramethylbenzidine 
150 ml Hydrogen Peroxide (100 vols) 
50 ml, water 
40 ml Methanol 
Coomassie Stain 
10 ml Acetic Acid 
1 ml Coomassie Brilliant Blue 
50 ml water 
Destain 40 ml Methanol 
10 ml Acetic acid 
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(d) Pyridine Hemochromagen Assay 
Table D.4 	Reagents for pyridine hemochromagen assay 
200 t1 of 5 M NaOH 
Reagent A 2.5 ml pyridine 
2.3 ml H20 
Reductant 10 d of 0.05 M Na2S204 in H20 
AE556540 = 22.1 mM'cm' 
Pyridine Hemochromagen cc-band = 556 nm 
Characteristics n-band = 524 rim 
7-band = 420 nm 
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(e) Substrate Concentrations for Steady-State Kinetics 
Table D. 5 Substrate concentrations employed in steady-state kinetic experiments 
Substrate concentrations employed in 
Substrate (Solubility in water jiM) 
steady-state kinetic assays (jiM) 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
L-Trp (50,000) 
2000, 5000 
0, 10, 20, 50, 100, 200, 500, 1000, 5000, 
D-Trp (50,000) 
10000, 25000 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
5-F-Trp (8,000) 
2000, 5000 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
6F-Trp (20,000) 
2000, 5000, 16000 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
5-Me-Trp (5000) 
2000, 4750 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
6-Me-Trp (8500) 
2000, 4250 
Indole propionic acid (1000) 0, 10, 20, 40, 80, 160, 320, 500 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
Tryptamine (4000) 
2000 
0, 10, 20, 40, 80, 160, 320, 500, 1000, 
1 -  Me-L-Trp (10,000) 
2000, 5000 
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Appendix E 
Mass Spectrometry - Mass Spectrometry 
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Figure F. 1 MS-MS analysis of wtTDO L-Trp turnover products (a) MS trace 
calibrated to detect 1-Me-Trp (219 Da), (b) MS trace calibrated to detect the 
(M+H) ion of L-Kynurenine (209 Da) vs. time, (c) MS trace calibrated to detect the 
(M+Ft) ion of N-formylkynurenine (237 Da) vs. time, (d) MS trace calibrated to 
detect the (M+ft) ion of L-Trp (204 Da) vs. time, (e) MS of L-Trp peak detected in 
(d), (f) MS of N-formylkynurenine peak detected in (c). 
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Figure F.2 MS-MS analysis of H55A L-Trp turnover products (a) MS trace 
calibrated to detect 1-Me-Trp (219 Da), (b) MS trace calibrated to detect the 
(M+ft) ion of L-Kynurenine (209 Da) vs. time, (c) MS trace calibrated to detect the 
(M+ft) ion of N-formylkynurenine (237 Da) vs. time, (d) MS trace calibrated to 
detect the (M+ft) ion of L-Trp (204 Da) vs. time, (e) MS of L-Trp peak detected in 
(d), (J) MS of N-formylkynurenine peak detected in (c). 
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Figure F. 3 MS-MS analysis of H55S L-Trp turnover products, (a) MS trace 
calibrated to detect 1-Me-Trp (219 Da), (b) MS trace calibrated to detect the 
(M+Jf) ion of L-Kynurenine (209 Da) vs. time, (c) MS trace calibrated to detect the 
(M+Jt) ion of N-formylkynurenine (237 Da) vs. time, (d) MS trace calibrated to 
detect the (M+ft) ion of L-Trp (204 Da) vs. time, (e) MS of L-Trp peak detected in 
(d), (1) MS of N-formylkynurenine peak detected in (c). 
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Figure F. 4 MS-MS analysis of wtTDO 1 -Me-Trp turnover products, (a) MS trace 
calibrated to detect 1-Me-Kynurenine (223 Da) vs. time, (b) MS trace calibrated to 
detect 1-Me-formylkynurenine (251 Da) vs. time, (c) MS trace calibrated to detect 1-
Me-Trp (219 Da) vs. time, (d) MS of 1-Me-Trp peak detected in (c). 
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Figure F. 5 MS-MS analysis of H55A 1-Me-Trp turnover products, (a) MS trace 
calibrated to detect 1-Me-Kynurenine (223 Da) vs. time, (b) MS trace calibrated to 
detect 1-Me-formylkynurenine (251 Da) vs. time, (c) MS trace calibrated to detect 1-
Me-Trp (219 Da) vs. time, (d) MS of 1 -Me -Trp peak detected in (c), (e) MS of 1-Me-
formylkynurenine peak detected in (b). 
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Figure F. 6 MS-MS analysis of H55S 1-Me-Trp turnover products, (a) MS trace 
calibrated to detect 1-Me-Kynurenine (223 Da) vs. time, (b) MS trace calibrated to 
detect 1-Me-formylkynurenine (251 Da) vs. time, (c) MS trace calibrated to detect 1-
Me-Trp (219 Da) vs. time, (d) MS of 1 -Me -Trp peak detected in (c), (e) MS of 1 -Me -
formylkynurenine peak detected in (b). 
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Appendix F 
Publications and Meetings Attended 
(a) 	Publications 
Copies of the publications listed below are bound at the back of the thesis. 
Molecular insights into substrate recognition and catalysis by tryptophan 2,3-
dioxygenase. Forouhar, F., Anderson, J. L. R., Mowat C. G., Vorobiev S. M., 
Hussain, A., Abashidze, M., Bruckmann, C., Thackray S. J., Seetharaman, J., Tucker, 
T., Xiao, R., Ma, L.-C., Zhao, L., Acton T. B., Montelione G. T., Chapman S. K. & 
Tong, L. (2007) Proc NatlAcadSci USA, 104(2): p. 473-8. 
Indoleamine 2,3-dioxygenase and Tryptophan 2,3-dioxygenase. Thackray, S. J., 
Bruckmann, C., Mowat, C. G, Forouhar, F., Chapman, S. K., and Tong, L. (2008) 
Handbook of Metalloproteins, (in press). 
Histidine 55 of tryptophan 2,3-dioxygenase is not an active site base but 
regulates catalysis by controlling substrate binding. Thackray, S. J., Bruckmann, 
C., Anderson, J. L. R., Campbell, L. P., Xiao, R., Zhao, L., Mowat, C. G., Forouhar, 
F., Tong, L., and Chapman, S. K. (2008) Biochemistry 47, 10677-10684. 
Exploring the Mechanism of Tryptophan 2,3-Dioxygenase. Thackray, S. J., 
Mowat, C. G., and Chapman, S. K. (2008) Biochem. Trans 36(6), 1120-1123. 
Reassessment of the Reaction Mechanism in the Heme Dioxygenases. Chauhan, 
N., Thackray, S. J., Rafice, S. A., Mowat, C. G., Eaton, G., Lee, M., Jenkins, P. R., 
Chapman, S. K., and Raven, E. L. (2008) Submitted to J Amer. Chem. Soc. 
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Molecular insights into substrate recognition and 
catalysis by tryptophan 2,3-dioxygenase 
Farhad Forouhar*, J. L. Ross Anderson, Christopher G. Mowatt, Sergey M. Vorobiev*, Arif Hussain*, 
Mariam Abashidze*, Chiara Bruckmannt, Sarah J. Thackrayt, Jayaraman Seetharaman*, Todd Tucker*, Rong Xiaot, 
Li-Chung Mat,  Li Zhaot, Thomas B. Acton*, Gaetano T. Montelionet, Stephen K. Chapmant, and hang Tong*S 
*Department of Biological Sciences, Northeast Structural Genomics Consortium, Columbia University, New York, NY 10027; tSchool of Chemistry, 
University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, United Kingdom; and 'Center for Advanced Biotechnology and Medicine 
and Northeast Structural Genomics Consortium, Rutgers University, Piscataway, NJ 08854 
Communicated by Wayne A. Hendrickson, Columbia University, New York, NY, November 13, 2006 (received for review September 25, 2006) 
Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxyge-
nase (IDO) constitute an important, yet relatively poorly under-
stood, family of heme-containing enzymes. Here, we report ex-
tensive structural and biochemical studies of the Xanthomonas 
campestris TDO and a related protein S04414 from Shewanella 
oneidensis, including the structure at 1.6-A resolution of the 
catalytically active, ferrous form of TDO in a binary complex with 
the substrate L-Trp. The carboxylate and ammonium moieties of 
tryptophan are recognized by electrostatic and hydrogen-bonding 
interactions with the enzyme and a propionate group of the heme, 
thus defining the i-stereospecificity. A second, possibly allosteric. 
L-Trp-binding site is present at the tetramer interface. The sixth 
coordination site of the heme-iron is vacant, providing a dioxygen-
binding site that would also involve interactions with the ammo-
nium moiety of L-Trp and the amide nitrogen of a glycine residue. 
The indole ring is positioned correctly for oxygenation at the C2 
and C3 atoms. The active site is fully formed only in the binary 
complex, and biochemical experiments confirm this induced-fit 
behavior of the enzyme. The active site is completely devoid of 
water during catalysis, which is supported by our electrochemical 
studies showing significant stabilization of the enzyme upon 
substrate binding. 
cancer I heme enzymes I immunomodulation I indoleamine 
2,3-dioxygenase 
Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3- dioxygenase (IDO) catalyze the oxidative cleavage of the 
L-tryptophan (L-Trp) pyrrole ring, the first and rate-limiting step 
in L-Trp catabolism through the kynurenine pathway (1-3). In 
addition, IDO has been implicated in a diverse range of physi-
ological and pathological conditions, including suppression of T 
cell proliferation, maternal tolerance to allogenic fetus, and 
immune escape of cancers (4-8), and is an attractive target for 
drug discovery against cancer and autoimmune and other dis-
eases (2, 9-12). 
Despite catalyzing identical biochemical reactions (Fig. la), 
the sequence similarity between TDO and IDO is extremely low. 
An alignment of their sequences is only possible based on their 
structures, which suggests a sequence identity of 10% between 
them (Fig. lb). In comparison, Xanthornonas campestris TDO 
shares 34% sequence identity with human TDO (Fig. lb), 
demonstrating the remarkable evolutionary conservation of this 
enzyme. TDO is a homotetrameric enzyme and is highly specific 
for L-Trp and related derivatives such as 6-fluoro-Trp as the 
substrate. In comparison, IDO is monomeric, and shows activity 
toward a larger collection of substrates, including L-Trp, D-
tryptophan (D-Trp), serotonin, and tryptamine (3), although the 
Km  for D-Trp is 100-fold higher than that for L-Trp (13). The 
structure of human IDO in the catalytically inactive, ferric 
[Fe(III)]-heme state in complex with the 4-phenylimidazole 
inhibitor has recently been reported (14). Although this struc-
ture gave information about important active site residues, the  
inhibitor is coordinated to the heme iron and does not provide 
any information regarding Trp or oxygen binding. 
To provide direct insight into substrate recognition and ca-
talysis by these enzymes, we report here the crystal structures at 
up to 1.6-A resolution of the active, reduced (Fe(II))TDO from 
X. campestris in a binary complex with the substrate L-Trp or 
6-fluoro-Trp. Our structures reveal for the first time the struc-
tural basis for the stereospecificity of this important enzyme. Our 
structural information is confirmed by biochemical studies and 
offers significant molecular insight into tryptophan dioxygen-
ation by TDO and IDO. 
Results 
Structure Determination. Crystals of the reduced (Fe(ll)) TDO 
from X. campestris in a binary complex with the substrate L-Trp 
or 6-f luoro-Trp were obtained after extensive efforts and by 
using anaerobic conditions, because the oxidized (Fe(II1)) en-
zyme has much lower affinity for L-Trp (see below). The 
structures at up to 1.6-A resolution of these binary complexes 
[Table 1; and see supporting information (SI) Table 3] as well as 
that of the free enzyme were determined by molecular replace-
ment based on the structure of the apo enzyme, in the absence 
of heme, which we had determined by the selenomethionyl 
single-wavelength anomalous diffraction method (PDB entry 
IYWO) (15). 
The structure of the S04414 protein from Shewanella onei-
densis (16) was determined at 2.4-A resolution by molecular 
replacement based on our structure of the apo enzyme (PDB 
entry 1ZEE). 
Structure of TDO. The structure of X. campestris TDO monomer 
contains 12 helices (named aA through aL) and no f3-strands 
(Figs. lb and 2a). TDO is an intimately associated tetramer (Fig. 
2b), and '4,500 A2 of the surface area of each monomer is 
buried in the tetramer. Helices czB and aC are located in the 
extensive, mostly hydrophobic interface between two of the 
monomers. The N-terminal segments (residues 21-40, including 
helix aA) of the two monomers are swapped in this dimer (Fig. 
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Fig. 1. Primary structures of TOO and 100. (a) The biochemical reaction 
catalyzed by TDO and 1130. (b) Amino acid sequence alignment of X. campes-
tris TOO (XcTDO), human TOO (HsTDO), S. oneidensis 504414 (504414), and 
human 100 (HsIDO). The filled circles indicate residues involved in binding 
L-Trp, and the diamonds indicate residues involved in binding heme. The 
symbols for residues before helix aA are given different colors, to indicate that 
they are from another monomer of the tetramer. 
2b), which is important for the catalysis by TDO because several 
residues in this segment are part of the binding site for the Trp 
residue in the active site (see below). 
Binding Mode of the L-Trp Substrate to TDO. Our structure of the 
binary complex defines the molecular mechanism for the recogni-
tion of the L-Trp substrate by TDO. Clear electron density was 
observed for heme and L-Trp in the active site based on the 
crystallographic analysis at 1.6-A resolution (Fig. 3a). The L-Trp 
substrate is located in a pocket over the distal face of the heme, 
having interactions with residues in helices aB and al), and the 
oD-aE and cd-aK loops (Figs. lb and 3b). The carboxylate group 
of Trp is recognized by bidentate ion-pair interactions with the side 
chain of Arg 117 (in helix (xD). The carboxylate group is also 
hydrogen-bonded to the side chain hydroxyl of Tyrll3 (helix aD) 
and the main chain amide of Thr 254 (0-aK loop). The ammonium 
ion of L-Trp is recognized by the 7-propionate side chain of the 
heme group (Fig. 3b), and it is also hydrogen-bonded to the side 
chain hydroxyl of Thr 254. The indole ring is located 3.5 A above 
and perpendicular to the heme and is held in place by van der Waals 
interactions with the side chains of Phe 51 (helix aB) and several 
other hydrophobic residues, including Tyr 24, Tyr 27, and Leu 28 
from the N-terminal segment of another monomer of the tetramer 
Fig. 2. The structure of TOO. (a) Schematic representation of the structure 
of the monomer of X. campestris TOO. The a-helices are shown in yellow and 
labeled. Heme is shown in gray, and L-Trp is shown in orange (labeled W). The 
water molecule is shown as a red sphere (labeled wat). (b) Schematic repre-
sentation of the tetramer of X. campestris TOO. The four monomers are 
colored in yellow, cyan, violet, and green. Helices in the tetramer interface are 
labeled. The Trp molecules in the tetramer interface are also shown. Produced 
with Molscript (35) and rendered with Raster3D (36). 
(Fig. 3b). in addition, the Ni nitrogen of the indole ring is 
hydrogen-bonded to the side chain of His 55 (helix aB) (Fig. 3b). 
A water molecule is present in the active site of this binary 
complex (Fig. 3a), hydrogen-bonded to the ammonium ion of 
L-Trp and the main-chain amide of residue Gly 125 (Fig. 3b). The 
water is 3.5 A from the ferrous atom in the heme, too far for 
ligating interactions. The iron atom is still 0.3 A out of the plane 
of the heme, on the side of the proximal His 240 ligand (SI 
Fig. 5). 
The crystal was exposed to a solution saturated with nitric 
oxide (NO) before being flash-frozen, but we did not observe the 
binding of this dioxygen analog in the structure. This is con-
firmed by our structure of the binary complex with 6-fluoro-Trp, 
which was not exposed to NO but contained the same density for 
the water molecule (SI Fig. 6). The structure of the 6-f luoro-Trp 
binary complex is essentially identical to that of the L-Trp binary 
complex (SI Fig. 6). NO probably dissociated from the heme 
during the cryofreezing manipulations in the anaerobic box. 
Induced-Fit Behavior of TDO. Our structural information suggests 
that TDO is an induced-fit enzyme. Although the active site 
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Ligand L-Trp 6-fluoro-Trp None None None None 
Maximum resolution, A 1.6 1.8 2.7 2.7 2.4 2.3 
Rn,ergo, %* 6.9 (52.7) 8.6 (60.9) 13.0 (32.3) 16.6 (74.0) 10.4 (63.0) 6.6 (30.6) 
Beam line ESRF BM14 ESRF BM14 NSLS X4A APS 21 BM NSLS X4A NSLS X4A 
Completeness, % 87 (65) 87 (61) 72 (54) 82 (68) 83 (60) 87 (71) 
R factor, %t 17.1 (18.9) 16.6 (17.9) 25.7 (25.7) 25.0 (32.1) 21.7 (23.5) 23.4 (26.7) 
Free /? factor, % 18.9 (22.0) 18.4 (21.1) 26.3 (26.2) 29.4 (35.1) 22.5 (24.1) 27.5 (31.5) 
rms deviation in bond 0.005 0.005 0.008 0.011 0.007 0.006 
lengths, A 
rms deviation in bond 1.0 1.0 1.2 1.6 1.1 1.0 
angles, 
Most-favored region. % 92 91 89 86 92 91 
*R,,,erge = 	j!t,j-(!h)I/>!,Tj!,,j. The numbers in parentheses are for the highest-resolution shell. 
tR = zhjFh° - Ff/hFh°. 
pocket is well defined in the binary complex (Fig. 3b), the nJ-aK 
loop, which helps to form the walls of this pocket, is disordered 
in the free enzyme, and the aD-aE loop has a somewhat 
different conformation (Fig. 3c; and see SI Fig. 7). Moreover, the 
Arg 117 side chain assumes a different conformation in the free 
enzyme (Fig. 3c). Upon recognition of the L-Trp substrate, a 
complex and extensive network of interactions is established 
(Fig. 3b), thus stabilizing the active site region. Although this 
region is exposed to the solvent in the free enzyme, it is 
completely shielded from the solvent in the binary complex, and 
only the carboxylate group of the 6-propionate of heme is visible 
on the surface. 
Additional evidence for the induced-fit behavior is observed 
in the active site of the second TDO monomer in the asymmetric 
unit. The binding mode of the L-Trp substrate is very different 
in this monomer (Fig. 3d; and see Si Fig. 7). The Tip side chain 
is not positioned as deeply into the pocket, and the hydrogen 
bond between the ring nitrogen and the side chain of His 55 is 
lost (distance of 3.8 A). Both nitrogen atoms are instead 
hydrogen-bonded to a water molecule, located 3.5 A from the 
heme iron but at a position distinct from that of the water in the 
active site of the other monomer (Fig. 3d). This conformation 
may also be stabilized by crystal packing interactions, as the 
7-propionate of heme is ion-paired with an Arg residue from 
another TDO tetramer in the crystal. The main chain atoms of 
the Tip substrate appear to be disordered, because no clear 
electron density was observed for them (Fig. 3e). Consistent with 
this finding, the aJ-aK loop is disordered in this molecule, 
similar to that in the free enzyme (Fig. 3d). This complex may 
represent an initial stage in the formation of the Michaelis 
complex of TDO. Proper positioning of the L-Trp substrate for 
catalysis would lead to the recognition of its main chain atoms 
and the ordering of the nJ-aK loop. 
Implications for Substrate Binding by IDO. Our structure of the 
binary complex of TDO also has significant implications for 
substrate recognition by the IDOs. The ms distance for 201 
structurally equivalent Ca atoms between TDO and the large 
domain of human IDO (PDB entry 2DOT) (14) is 3.1 A (SI Fig. 
8), calculated with the program Dali (17). Despite sharing only 
10% overall sequence identity, key active-site residues are 
similar in TDO and IDO (Fig. lb; and see SI Table 4), and L-Trp 
may have the same binding mode to the active site of IDO (SI 
Fig. 9). Ionic interactions that are important for recognizing the 
L-Trp ammonium ion and carboxylate group are conserved in 
IDO (Arg 231 and 7-propionate), explaining why L-Trp is a much 
better substrate than D-Trp for IDO. At the same time, hydro- 
gen-bonding interactions to these atoms may be absent in IDO, 
because Tyr 113 of TDO is replaced by Phe 226 in IDO (SI Fig. 
9), and the Thr 254 residue may not have an equivalent in IDO 
because the nJ-aK loop, disordered in the IDO structure (SI Fig. 
9) (14), has highly divergent sequences in IDO compared with 
TDO (Fig. lb). Therefore, IDO may have weaker interactions 
with tryptophan, which may be the reason why it cannot com-
pletely distinguish among the indoleamine substrates. 
The structure comparison explains why 1-methyltryptophan is 
a micromolar inhibitor of IDO (18) but is essentially inactive 
against TDO (10). The Ni atom is directly hydrogen-bonded to 
the His 55 side chain in TDO (Fig. 3b), and its methylation will 
cause steric clash with this residue. In comparison, His 55 is 
replaced by Ser 167 in IDO (SI Table 4), which creates a small 
pocket that can accommodate the 1-methyl group (SI Fig. 9). 
Structural similarity is also observed with the S04414 protein 
from S. oneidensis (SI Fig. 8) (16), with an rms distance of 4.4 A 
for 206 equivalent Ca atoms, suggesting that S04414 may also 
be a dioxygenase. Moreover, the structure contains an extra 
domain that is formed by residues at the N terminus, similar to 
the small domain in human IDO (SI Fig. 8). In contrast to human 
IDO, S04414 is a tetramer but with a different organization 
compared with that of TDO (SI Fig. 10). Our biochemical efforts 
so far have not been able to demonstrate IDO (or TDO) activity 
for this protein, suggesting that S04414 may prefer a different 
substrate for oxygenation. 
A Model for the Michaelis Complex. To help provide further insight 
into the catalysis by these enzymes, we built a model for the 
Michaelis complex, by placing one oxygen atom (01) of the 
dioxygen substrate directly over the heme iron, at a distance 
of 2.1 A (Fig. 4a). The distal oxygen atom (02) was placed such 
that the 01-02 bond is parallel to the C2-C3 bond of indole ring, 
giving a Fe-01-02 angle of 135°. This conformation places the 
02 atom within 0.5 A of the water molecule observed in our 
structure (Fig. 4a), suggesting that this water should be ejected 
from the active site upon dioxygen binding. The active site is 
therefore completely devoid of solvent molecules in this Michae-
lis complex. 
The modeled dioxygen-binding mode reveals the activation 
mechanism of this substrate for the reaction. It has been 
established that TDO has an ordered catalytic cycle in which the 
protein first binds L-Trp to the ferrous form, and then binding 
of dioxygen is facilitated, and nucleophiic attack from the 
substrate C3 is initiated (3, 13, 19). In the model, the distal 
oxygen atom interacts with the L-Trp ammonium moiety and the 






Forouhar etal. 	 PNAS I January 9, 2007 1 vol. 104 1 no. 2 1 475 
Y2 
a 	 e 
f 
L28 	aB 	xE\ 	L28, 'ctB 
eme 
120 
6 	 Fi16 
S2 	 117 
ri 
Fig. 3. Molecular basis for substrate recognition by TDO. (a) Final 2F0—& 
electron density at 1.6-A resolution for heme, L-Trp, and a water in the active 
site. Contoured at 1r. (b) Stereo drawing showing the active site of X. 
campestris TOO in the binary complex with L-Trp. The segment in cyan is from 
another monomer of the tetramer. Hydrogen-bonding interactions are indi-
cated with dashed lines in magenta. (c) Overlay of the structures of the free 
enzyme (in orchid) and the binary complex (yellow and cyan) in the active-site 
region. Regions of conformational differences are indicated with the red 
arrows. (d) Overlay of the active-site region of the second monomer (in green) 
andthat of the first monomer (in yellow). Only the side-chain atoms of Trp are 
shown in the second monomer (in magenta). (e) Final 2F.—F, electron density 
at 1.6-A resolution for heme, L-Trp, and a water in the active site of the second 
TOO molecule in the crystal. Contoured at 1 a-Two conformations for the main 
chain atoms are shown, but neither fit the density well. For the stereo version 
of c and d, please see SI Fig. 7. Produced with Molscript (35) and rendered with 
Raster3D (36). 
of the hydrogen-bonding donors, coupled with the electron-
withdrawing nature of the heme, would increase the electrophi-
licity of the bound dioxygen and render it more susceptible to 
nucleophilic attack by the substrate C3 atom. The increased 
hydrophobicity of the active site upon the exclusion of water 
would also aid the stabilization of an oxyferrous species. Studies 
with heme oxygenase suggest that the hydrogen-bonding inter-
actions to the dioxygen substrate may also help to prevent its 
heterolysis (20), and the exclusion of water probably removes a 
hydrogen-bond competitor to the dioxygen. After the initial 
attack by the C3 atom, the reaction may proceed via a Criegee 
rearrangement or a dioxetane intermediate (SI Fig. 11). In the 
model, the 01-02 atoms are in a trans configuration relative to 
the C2—C3 atoms of L-Trp (Fig. 4a), which may favor the Criegee 
rearrangement pathway (SI Fig. 11) (19). The Criegee pathway 
is also favored based on chemical, thermodynamic, and quantum 
mechanical considerations (3). 
Our model for the Michaelis complex shows that the 01 atom 
is 2.6 A from the Ni atom of L-Trp and therefore can act as the 
general base to extract the proton from the Ni atom (SI Fig. 11) 
(19). The Ni atom is hydrogen-bonded to His 55 in TDO. 
However, our biochemical studies show that the kca t of TDO is 
relatively insensitive to pH over the range examined (pH 6 to pH 
8) (Fig. 4b), and the H55A mutant had only a 10-fold decrease 
in the 	(Table 2), suggesting that this residue is not essential 
for catalysis, consistent with its replacement with a Ser residue 
in IDO. On the other hand, the Km shows a marked increase at 
lower pH (Fig. 4b), probably because of the protonation of this 
residue. 
An Allosteric Binding Site in the Tetramer Interface. We also ob-
served the binding of four L-Trp residues to an allosteric site in 
the interface of the tetramer (Fig. 2b), with well defined electron 
density (SI Fig. 12). The L-Trp residue appears to be recognized 
specifically by the enzyme in this pocket (SI Fig. 12). There have 
been reports of allosteric activation by the substrate L-Trp (21, 
22), and our observations offer a possibility for this effector site. 
Unfortunately, our kinetic studies so far have not shown any 
allosteric effects with X. campestris TDO. This site is not 
occupied in the 6-fluoro-Trp complex, possibly because of the 
lower concentration of this compound in the crystallization 
solution. 
Biochemical Studies Confirm the Structural Observations. X. campes- 
tris TDO has robust catalytic activity toward L-Trp and 6-fluoro-
Trp but is inactive toward D-Trp, tryptamine or indolepropionic 
acid (Table 2), confirming its designation as a TDO. In fact, 
D-Trp is a weak, competitive inhibitor of the enzyme at high 
concentrations (Table 2). Our binding data show that D-Trp has 
much lower affinity for the enzyme than L-Trp (Table 2), 
consistent with our structural information and explaining why 
D-Trp cannot be oxygenated by TDO. 
The biochemical studies also provide direct evidence for the 
induced-fit behavior of TDO. There is a large increase in the 
affinity of the enzyme for L-Trp when the heme iron is reduced 
(Kd [ferric Fe(III) heme] = 3.8 mM, whereas Kd [ferrous Fe(II) 
hemej = 4.1 AM) (Table 2). The electrochemistry data show a 
large, positive shift in reduction potential (+136 mV) in the 
presence of 15 mM L-Trp (Fig. 4c). In fact, the shift in reduction 
potential almost perfectly correlates with the increase in affinity 
for L-Trp on reduction, both giving an estimated zG of 15 
kJ/mol. These data show that there is a significant stabilization 
of the ferrous form when substrate is bound. This stabilization 
could also play a physiological role to keep the protein reduced, 
and therefore active, when L-Trp is present. 
Our structural studies have defined the binding mode of the 
substrate L-Trp to TDO, revealing the structural basis for the 
stereospecificity of this important enzyme. The induced-fit 
behavior of TDO, confirmed by our biophysical studies, appears 
crucial for the exclusion of water from the active site and for 
stabilizing the enzyme in the presence of the substrates. Finally, 
structural comparisons among these enzymes reveal the striking 
evolutionary conservation of the heme-dependent dioxygenases. 
Materials and Methods 
The experimental protocols are summarized here. More de-
tailed information can be found in SI Materials and Methods. 
Protein Expression and Purification. Full-length X campestris TDO 
(NESG ID XcR13) and S. oneidensis S04414 (NESG ID SoR52) 
were cloned into a pET-21d (Novagen, San Diego, CA) deriv-
ative, with a C-terminal hexahistidine tag, and overexpressed at 
17°C in Escherichia coli BL21(DE3) pMGK cells. Hemin (7 AM 
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Fig. 4. Molecular insights into the catalysis by TOO. (a) Model of the Michaelis complex. The water molecule is shown as a small sphere in green. Produced with 
Molscript (35) and rendered with Raster3D (36). (b) The pH dependence of the k 5 and K. values of X. campestris TDO. (c) The presence of L-Trp causes a large, 
positive shift in the reduction potential of TOO. SHE, standard hydrogen electrode. 
final concentration) was included in the media for preparation 
of the holoenzyme samples (23). The protein was purified by 
using nickel-affinity and gel-filtration chromatography. 
Point mutations were created with the QuikChange II site-
directed mutagenesis kit (Stratagene, La Jolla, CA). The mu-
tations and their associated ORFs were verified by DNA se-
quence analysis. 
Protein Crystallization. To obtain the structure of TDO in the 
ferrous state, the protein was reduced by the addition of sodium 
dithionite, and all steps were performed in an anaerobic glove box 
(Belle Technology, Dorset, U.K.), with the 02 concentration main-
tained <2 ppm. Excess sodium dithionite was removed by gel 
filtration (Sephadex G25 column) before crystallization. Crystals of 
TDO were grown by the sitting-drop vapor diffusion method with 
a well solution comprising 100 mM Mes (pH 6.3), 10-12% (wt/vol) 
PEG 4000,60 mM MnCl2, 10 mM sodium dithionite, and 2 mM 
L-Trp. Before mounting in nylon loops and flash-freezing in liquid 
nitrogen, crystals were immersed in a cryoprotectant solution 
composed of mother liquor (with L-Trp concentration increased to 
50 mM) supplemented with 23% (vol/vol) glycerol and bubbled 
with nitric oxide for 15 min before use. 
Data Collection and Processing. X-ray diffraction data were col-
lected at the X4A beam line of National Synchrotron Light 
Source (Brookhaven National Laboratory, Upton, NY), the 
21BM beam line at Advanced Photon Source (Argonne National 
Laboratory, Argonne, IL), and the BM14 beam line at the 
Table 2. Summary of kinetic data on X campestris TDO 







L-Trp 19.5 	1.2 114 -- 1 3.84 - 0.14 4.12 -- 0.24 
o-Trp 0 16.5 mM ± 33* >50t NC 
6-F-D/L-Trp 37.3 --0.6 186 ± 12 2.45 -- 0.42 <1 
5-F-D/L-Trp 2.40 -- 0.10 100±6 1.51 	0.08 <1 
Indolepropionic acid 0 0 >lot 126 - 11 
35.4 -0.9 119 ± 2 0 NA 
H55A mutant L-Trp 2.86 ± 0.10 133 -_ 7 ND 3.7 ± 1.3 
NA, Kd for 02 cannot be measured in the absence of substrate because of oxidation or in the presence of 
substrate because of turnover; NC, No spectral change detected; ND, not done. 
*Inhibitory constant, K. 
tAlthough a spectral change was evident, substrate sol ubility prevented accurate measurement of Kd. Valueswere 
estimated based on the maximum substrate concentration attainable. 
'Binding was too tight to be measured. Values quoted represent the minimum lCd that can be measured under 
standard assay conditions. 
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European Synchrotron Radiation Facility (Grenoble. France). 
The diffraction images were processed and scaled with the HKL 
package (24). The data-processing statistics are summarized in 
Table 1, and more complete information can he found in 
SI Table 3. 
Structure Determination and Refinement. The structures of the apo 
enzymes of TDO and S04414 were determined by the selenome-
thionyl single-wavelength anomalous diffraction method (15). 
The selenium sites were located with SnB (25), and the reflection 
phases were calculated with Solve/Resolve (26). The structures 
of the holoenzymes and the ternary complex were determined by 
the molecular-replacement method, with the programs COMO 
(27) and AMoRe (28). The atomic models were built with the 
program XtalView (29) and TURBO-FRODO (30), and the 
structure refinement was carried out with CNS (31). 
Electronic Spectroscopy, Steady-State Assays, and Dissociation Con-
stant Measurements. Electronic absorption spectra were recorded 
by using a Cary 50-Probe UV-Visible spectrophotometer at 
25°C. Assays for the steady-state turnover (at pH 7.5) of L-Trp 
and derivatives were performed as described (32, 33), except that 
substrate concentrations of 0-15 mM were used. The kinetic 
data were fitted to the Michaelis-Menten equation. The pH 
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dependence of the steady-state kinetics was determined in the 
same manner, by using phosphate (pH 6.0-8.0) and Tris (pH 
8.0-9.0) buffers. The electronic absorption spectra of the steady 
state were recorded by using a stopped-flow spectrophotometer 
(SX.17MV; Applied-Photophysics, Surrey, U.K.) in conjunction 
with a diode array detector, housed in an anaerobic glove box 
([021, <5 ppm; Belle Technology). 
O1TLE Electrochemistry. Anaerobic potentiometric titrations were 
carried out as described (34) at 25°C by using a modified quartz 
EPR OTTLE cell. Titrations were performed in both the 
absence and presence of L-Trp (15 mM), and the heme reduction 
potentials were determined by fitting the data to the Nernst 
equation for a single-electron process by using Origin software 
(MicroCal, Northampton, MA). Reduction potentials are 
quoted versus the standard hydrogen electrode. 
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Histidine 55 of Tryptophan 2,3-Dioxygenase Is Not an Active Site Base but 
Regulates Catalysis by Controlling Substrate Bindings  
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ABSTRACT: Tryptophan 2,3-dioxygenase (TDO) from Xanthomonas campestris 
is a highly specific heme-
containing enzyme from a small family of homologous enzymes, which includes indoleamine 2,3-
dioxygenase (IDO). The structure of wild type (WT TDO) in the catalytically active, ferrous (Fe2 ) form 
and in complex with its substrate L-tryptophan (L-Trp) was recently reported [Forouhar et a]. (2007) Proc. 
Nat!. Acad. Sci. U.S.A. 104, 473-478] and revealed that histidine 55 hydrogen bonds to L-Trp, precisely 
positioning it in the active site and implicating it as a possible active site base. In this study the substitution 
of the active site residue histidine 55 by alanine and serine (1155A and H55S) provides insight into the 
molecular mechanism used by the enzyme to control substrate binding. We report the crystal structure of 
the H55A and H55S mutant forms at 2.15 and 1.90 A resolution, respectively, in binary complexes with 
L-Trp. These structural data, in conjunction with potentiometric and kinetic studies on both mutants, reveal 
that histidine 55 is not essential for turnover but greatly disfavors the mechanistically unproductive binding 
Of L-Trp to the oxidized enzyme allowing control of catalysis. This is demonstrated by the difference in 
the Kd values for L-Trp binding to the two oxidation states of wild-type TDO (3.8 mM oxidized, 4.1 tM 
reduced), H55A TDO (11.8 tM oxidized, 3.7 1tM reduced), and H55S TDO (18.4 tM oxidized, 5.3 ,UM 
reduced). 
Oxidative cleavage of the L-tryptophan (L-Trp)1  pyrrole 
ring and the insertion of molecular oxygen to produce 
N-formylkynurcflifle is the first and rate-limiting step in the 
kynurenine pathway and is catalyzed by tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygenase 
(IDO) (2, 3). The kynurenine pathway processes 95% of 
L-Trp utilized by humans, leading ultimately to the formation 
of nicotinamide adenine dinucleotide (NAD), an essential 
coenzyme (4). Kynurenine pathway metabolites have been 
implicated in a number of diseases ranging from neurological 
disorders, such as cerebral malaria and multiple sclerosis, 
to cataract formation (5, 6). Recent findings have implicated 
tryptophan catabolism via the kynurenine pathway in im-
mune tolerance, including immune suppression in maternal 
fetal tolerance and the immune escape of cancers (7-10). 
The atomic coordinates for H55A and H55S mutant enzymes of 
TDO have been deposited in the Protein Data Bank, entries 3BK9 and 
3E08, respectively. 
* To whom correspondence should be addressed. E-mail: 
S.K.Chapman@ed.ac.Uk.  Tel: +44 131 650 4760. Fax: +44 131 650 
6453. 
University of Edinburgh. 
Rutgers University. 
Columbia University. 
Abbreviations: TDO, tryptophan 2,3-dioxygenase: IDO, indoleam-
ine 2,3-dioxygenase: L-Trp, L-tryptophan; 5-F-Trp, 5-fluoro-DL-tryp-
tophan; 6-F-Trp, 6-tluoro-DL-tryptophan; WT, wild type: H55A. 
histidine 55 - alanine: H55S. histidine 55 	serine: SHE, standard 
hydrogen electrode; OTFLE, optically transparent thin-layer electro-
chemistry. 
These properties make elucidation of the precise catalytic 
mechanism of these enzymes extremely important. 
TDO and IDO belong to a little-characterized family of 
dioxygenases that occurs in both prokaryotes and eukaryotes 
(11). These enzymes have homologous 3-D structures but 
dissimilar primary structures, with sequence identity often 
less than 10% between family members (12). First identified 
in 1936 (13), TDO is mainly found in the liver of mammals 
but has also been recently identified in mammalian mucous 
membranes, epididymis, and brain (14, 15). The enzyme 
discussed here is a prokaryotic TDO from Xanthomonas 
campestris (the causative agent of black rot in cabbages), 
which shares 34% sequence identity with human TDO. The 
enzyme is a homotetramer that displays high substrate 
specificity, catalyzing the oxidation of L-Trp, 5-F-Trp, and 
6-F-Trp (1). In contrast, IDO is found throughout the body 
in mammals, except for in the liver, and no prokaryotic IDO 
protein has yet been identified. IDO is monomeric and 
catalyzes the dioxygenation of L-Trp, D-Trp, serotonin, 
tryptaminc, and 5-OH-Trp, displaying less substrate specific-
ity than TDO (11, 16). The crystal structures of WT X. 
campestris TDO (1, 17) and human IDO (12) have been 
published recently, revealing similarities between the two 
enzymes and allowing the identification of potentially 
important active site residues. 
The catalytic mechanisms employed by TDO and IDO 
have, as yet, not been elucidated, but two proposed mech-
anisms for tryptophan dioxygenation are shown in Figure 1. 
10.1021/bi801202a CCC: $40.75 © 2008 American Chemical Society 
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FIGURE 1: Catalytic mechanism proposed for L-tryptophan dioxy-
genation by TDO. The figure displays an ionic, base-catalyzed 
mechanism of L-Trp dioxygenation. The first substrate binds to the 
protein (1), followed by dioxygen binding to form the ternary 
complex (2). The mechanism proceeds by the formation of a 
hydroperoxide intermediate (3 and 6), which can undergo two 
different rearrangements to form the product, N-formylkynurenine 
(8), a Criegee rearrangement (4 and 5), or a dioxetane rearrangement 
(7). The product is then released leaving the protein in the active 
ferrous state. 
It is proposed that the catalytic mechanism involves the base-
catalyzed deprotonation of the indole nitrogen of the 
substrate. However, the structures of TDO and IDO show 
that while TDO contains a histidine residue in its active site, 
IDO does not contain any residues in its active site capable 
of performing base-catalyzed deprotonation. Instead, it has 
been proposed that proton abstraction is facilitated by a 
bound dioxygen molecule (Figure 2). 
In the TDO active site histidine 55 hydrogen bonds to 
L-Trp and is implicated as the active site base. In this study 
we attempt to resolve the question of whether an active site 
base is necessary for catalytic activity in TDO. To ac-
complish this, histidine is replaced by alanine or serine 
(H55A and H55S mutants of TDO). These substitutions 
were chosen due to the inability of alanine to act as an active 
site base and the presence in IDO of a serine residue in the 
analogous position to histidine 55. We report the crystal 
Thackray et al. 
9N~R 	 H N
-R 
®o o 
Fe 	 Fe2 
His 	 His 
FIGURE 2: Proposed catalytic intermediates involved in proton 
abstraction of the indole nitrogen of L-tryptophan. The ternary 
enzyme—substrate—dioxygen complex can either undergo (a) a 
base-catalyzed proton abstraction or (b) proton abstraction by the 
bound dioxygen. 
structure of the H55A mutant to 2.15 A resolution and the 
crystal structure of the H55S mutant to 1.90 A resolution 
and relate these to electrochemical and kinetic data for the 
mutant enzymes. 
EXPERIMENTAL PROCEDURES 
Genetic Manipulation, Protein Expression, and Purifica-
tion. Full-length X. campestris TDO (NESG (Northeast Struc-
tural Genomics Consortium) ID XcR13) was cloned into a pET-
21d (Novagen, San Diego, CA) derivative with a C-terminal 
hexahistidine tag and overexpressed at 17 °C in Escherichia 
coli BL21(DE3) pMGK cells. Point mutations H55A and H55S 
were created by employing the QuikChange H site-directed 
mutagenesis kit (Stratagene, La Jolla, CA). Oligonucleotide 
primers directing mutations were designed in an automated 
fashion by using the Primer Prim'er program, accessible at 
www-nmr.cabm.rutgers.edu/bioinformatics/Primer_Ptimer/. The 
mutations and their associated ORF were verified by DNA 
sequence analysis (1). 
WT TDO and its mutant forms were purified using nickel-
affinity and gel-filtration chromatography. Protein and heme 
concentrations were determined by the Bradford and pyridine 
hemochrome methods, respectively (18, 19). For WT TDO 
extinction coefficients Enm and r431,, of 180.5 (±0.1) mM' 
cm 	and 113.0 (±0.1) mM cm-' per protomer were 
calculated for the ferric and ferrous enzymes, respectively 
(1). For the H55A mutant enzyme extinction coefficients 
E405nm and E431nm were 130.4 (±0.3) mM cm' and 120.0 
(±0.1) mM' cm-1 per protomer. For the H55S mutant 
extinction coefficients E5nm and E431nm were 132.0 (±0.3) 
mM 	cm' and 116.0 (±0.2) mM cm-1 per protomer. 
Protein Crystallization and Data Collection. Crystalliza-
tion of H55A and H55S TDO was carried out by hanging 
drop vapor diffusion at 18 °C in Linbro plates. Crystals were 
obtained with well solutions comprising 9-10% (wlv) PEG 
1000, 80 mM MES buffer, pH 6.3, 20 mM bicine buffer, 
pH 9.0,40 mM MnC12, 400 mM MgCl,,, 8-15 mM NaCN, 
and 20 mM L-Trp. Hanging drops (4 1uL volume) were 
prepared by adding 2 1uL of 8 mg mL protein (in 50 mM 
Tris-HCl buffer, pH 8.0, 5 mM in EDTA) to 2 uL of well 
solution. Red tetragonal shaped crystals appeared after 
approximately I week, reaching full size after 2 weeks. 
Crystals were immersed in mineral oil prior to being mounted 
in nylon loops and flash cooled in liquid nitrogen. For crystals 
of both H55A and H55S enzymes, data sets were collected 
to a resolution of 2.15 and 1.90 A, respectively, at station 
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10.1 at SRS Daresbury = 1.381 A for H55A TDO, A = 
1.045 A for H55S). In both cases crystals belonged to space 
group P21  with unit cell parameters a = 78.2 A, b = 117.6 
A, c = 139.3 A, and j3 = 95,70 (H55A) and a = 77.9 A, b 
= 117.8 A, c = 139.1 A, and /3 = 95.7 ° (H55S). 
Data processing was carried out using the CCP4 package 
(20) and PHENIX (21). The wild-type TDO apoenzyme 
structure (PDB ID 1 YWO), stripped of water, was used as 
the initial model. Electron density fitting was carried out 
using PHENIX and Turbofrodo (22), and structure refinement 
was carried out using PHENIX and Refmac (23). 
Steady-State Kinetic Analysis and Binding Constant As-
says. UV -visible spectra were recorded at 25 °C using a 
Cary 50-Probe UV-visible spectrophotometer. Steady-state 
turnover assays (at pH 7.5) for oxidation of i-Trp and 
fluorinated derivatives were performed as described by 
Ishimura (24), except that substrate concentrations of up to 
15 mM L-Trp were used. The rate of formation of N-
formylkynurenine was monitored by measuring the change 
in absorbance at 321 nm (632,(N-formylkynurenine) = 3750 
M 1 cm). Kinetic data were fitted to the Hill equation using 
Origin software (MicroCal, Northampton, MA). Dissociation 
constants (Kd) for binding to ferric and ferrous WT TDO 
and mutant enzymes were determined by established pro-
cedures in a Belle Technology anaerobic glovebox with [021 
maintained below 5 ppm. The electronic absorption spectra 
at the steady state were recorded by using a stopped-flow 
spectrophotometer (SX. 17MV; Applied-Photophysics, Sur-
rey, U.K.) in conjunction with a diode array detector, housed 
in an anaerobic glovebox. The oxygen binding affinity (Km) 
was measured by standard methods by adding varying 
concentrations of 02 ( 1 mM) to the L-Trp saturated (25 
mM) assay and by calculating the steady-state parameters 
as described above. Oxygen concentration was determined 
spectrophotometrical ly by titrating aliquots of oxygenated 
buffer into a solution of electrochemically reduced methyl 
viologen. The subsequent change in absorbance at 540 nm 
(e540(methyl viologen) = 13000 M' cm') due to reduction 
of molecular oxygen was used to calculate [02] ( 1). 
077'LE Electrochemistry. Anaerobic potentiometric titra-
tions on WT TDO and mutant enzymes were carried out as 
previously described (1, 25) at 25 °C using a modified quartz 
EPR OTTLE cell, with the exception that 100 mM Tris-
HCI buffer, pH 7.5, and 300 mIvI KCI (with or without 10% 
glycerol) buffer was used. A range of mediators were added 
(2-hydroxy-1,4-naphthoquinone (-145 mV vs SHE), 5-hy-
droxy- 1 ,4-naphthoquinone (-3 mV), phenazine ethosulfate 
(+55 mV), phenazine methosulfate (+82 mV). and 1,2-
naphthoquinone (+135 mV)) to ensure efficient reduction 
and reoxidation of the protein. Titrations were performed in 
both the absence and presence of substrate for WT TDO 
(15 mM L-Trp), the H55A mutant (5 mM L-Trp), and the 
H55S mutant (10 mM L-Trp). Heme reduction potentials 
were determined by fitting the data to a Nernst equation for 
a single-electron process using Origin software. Reduction 
potentials are quoted versus the standard hydrogen electrode. 
RESULTS AND DISCUSSION 
Crystal Structures of H55A and H55S TDO. It was 
possible to obtain crystals of the ferric H55A and H55S 
mutant enzymes in binary complex with the substrate due 
Table I: H55A and H55S Data Collection and Refinement Statistics 
H55A H55S 
resolution (A) 59.66-2.15 17.56-1.90 
total no. of reflections 312593 362159 
no. of unique reflections 131764 189203 
completeness (%) 96.9 93.6 
I/foWl 9.5 7.3 
Rm,rge (%)" 10.0 7.8 
Rrnrngc in outer shell (2.27-2.15 A) (%) 47.4 48.0 
Rryst (%)5 20.5 17.8 
R5 	(%)h 28.5 21.6 
rmsd from ideal values 
bond lengths (A) 0.022 0.007 
bond angles (deg) 2.004 0.952 
Ramachandran analysis 
most favored (%) 91.9 92.2 
additionally allowed (%) 8.1 7.8 
average B-factor (overall) (A2) 23.2 23,2 
average B-factor (substrate) (A2) 25.7 24.1 
Rmcr gc = 	1t1(h) - 1,(h)1/>.511(h), where J,(h) and 1(h) are the ith 
and mean measurement of reflection h, respectively. b  R, = L,lF, - 
FVYF0, where F, and F are the observed and calculated structure factor 
amplitudes of reflection h, respectively. Rfr is the test reflection data set. 
5% selected randomly for cross-validation during crystallographic 
refinement. 
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FIGURE 3: Stereoview of electron density around the heme, bound 
L-Trp, arginine 117, and residue 55 at the active site of (a) H55A 
TDO and (b) H55S TDO. The electron density map was calculated 
using Fourier coefficients 2F0 - F, where F(, and Fc are the 
observed and calculated structure factors, respectively, the latter 
based on the final model. The contour level is I a, where a is the 
rms electron density. This figure was generated using PYMOL (30). 
to the much greater affinity of L-Trp for the oxidized mutant 
enzymes compared to WT TDO (see below and Table 3). 
For H55A TDO a data set to 2.15 A resolution was used to 
refine the structure to a final R-factor of 20.5% (R 
28.5%), while for H55S TDO data to a resolution of 1.90 A 
were used to refine the structure to a final R-factor of 17.8% 
(R11 = 21.6%). Data collection and refinement statistics are 
summarized in Table I. 
For each of the H55A and H55S mutant enzymes the final 
model consists of two TDO tetramers (1 and 2), one of which 
(tetramer 1) is better defined than the other in the electron 
density map. The quality of the final electron density map 
around the active site of chain A of tetramer 1 of both mutant 
enzymes is shown in Figure 3. 
In both mutant enzymes each monomer also binds one 
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FIGURE 4: An overlay of the active site region of 'NT TDO (yellow), 
H55A TDO (green), and H55S TDO (orange) viewed from the side 
(a) and from above (b). The L-Trp from the H55A and H55S 
enzymes (in green and orange, respectively) are rotated toward 
alanine/scrine 55 and the heme, relative to the position of the 
substrate in WT TDO (yellow). The H-bond between histidine 55 
and the substrate is lost as a result of the substitution by alanine/ 
serine. The position of the water molecule (water A; see Figure 5) 
above the heme group in H55A and H55S TDOs is slightly different 
than in WT enzyme due to the altered substrate binding. This figure 
was generated using PYMOL (30). 
b 	WaterB 
Ser55 	 I ru 
Arg117 	 4,1Ar911 
WaterA 
FIGURE 5: The active site of (a) H55A TDO and (b) H55S TDO. 
Hydrogen-bonding interactions are indicated by dashed lines. The 
subtly different positions of water B in the mutant enzymes can be 
seen. This figure was generated using PYMOL (30). 
second L-Trp molecule is observed at the intersubunit 
interface close to each of chains A, B, C, D, and E in the 
H55A TDO structure, and in the H55S model there is one 
interfacial L-Trp per monomer. In addition, the H55A and 
H55S models contain 1026 and 1955 water molecules, 
respectively. The atomic coordinates have been deposited 
in the Protein Data Bank, accession codes 313K9 (H55A) 
and 3E08 (1455S). 
Binding Mode of L-Trp to H55A and H55S Mutants. The 
binding orientation of L-Trp at the active site of the H55A 
mutant enzyme is slightly different from that observed in 
the WT TDO structure. An overlay of the active sites of 
WT TDO and the H55A and H55S enzymes (based on a-C 
overlay) is shown in Figure 4. The bound L-Trp substrates 
belonging to the H55A and H55S mutant enzymes (in green 
and orange, respectively) are shifted toward the side chain 
of residue 55 relative to the position of L-Trp in the wild-
type enzyme (in yellow). Due to the substitution of histidine 
55 by alanine or serine the hydrogen-bonding interaction 
between residue 55 and the substrate indole nitrogen atom 
is lost. The remaining interactions between the substrate and 
active site residues that are observed in the wild-type enzyme 
are maintained in both mutant enzymes (Figure 5). 
The active sites of WT TDO and both of the H55A and 
H55S mutant enzymes contain a water molecule above the 
distal face of the heme (water A in Figure 5). In all three 
enzymes this water is H-bonded to the ammonium group of 
L-Trp and the main-chain amide nitrogen of glycine 125 but  
is too far (a2.7 A) from the heme iron to be a ligand. Further 
to this, an additional water molecule is found in the active 
site of the H55A and H55S mutant enzymes (water B in 
Figure 5) in a position which would be sterically inhibited 
by the histidine 55 side chain in WT TDO. In the H55A 
mutant enzyme water B is H-bonded to the substrate indole 
nitrogen (Figure 5a), but in the H55S model water B is 
instead H-bonded to the side-chain hydroxyl group of serine 
55 (Figure Sb), too far away (—.3.4 A) from L-Trp to maintain 
a hydrogen-bonding interaction. 
In WT TDO the histidine 55 imidazole moiety H-bonds 
to a water molecule in the substrate-free ferrous state, which 
is displaced upon binding of substrate. The removal of the 
histidine side chain in either mutant enzyme would almost 
certainly result in the absence of a water molecule in such a 
position. 
Steady-State Kinetics and Substrate/Substrate Analogue 
Binding. It has been previously reported that WT TDO shows 
catalytic activity toward L-Trp, 6-F-Trp, and 5-F-Trp. We 
have also observed activity toward 5-methyl-DL-tryptophan 
and 6-methyl-DL-tryptophan. H55A and H55S mutant en-
zymes show catalytic activity toward L-Trp, 6-F-Trp, 5-F-
Trp, 5-methyl-DL-tryptophan, and 6-methyl-DL-tryptophan but 
no activity with any other compounds investigated. Kinetic 
parameters are shown in Table 2, and there is about a 7-fold 
decrease in 	values, compared to WT TDO, for both 
mutant enzymes. As previously reported, there is no inhibi-
tion of WT TDO catalytic activity on addition of I -Me-DL-
tryptophan, and the same result is obtained for the mutant 
enzymes (1). This contrasts with findings on IDO, where 
1-Me-DL-tryptophan is a known inhibitor of L-Trp dioxy-
genation activity (11). Catalytic activity is observed only by 
the ferrous enzyme for both WT TDO and its mutant forms, 
in contrast to recent findings that show catalytic activity by 
ferric human TDO. 
The substitution of histidine 55 may have been expected 
to render the enzyme inactive if a base is required in the 
catalytic cycle, but the possibility that a water molecule could 
be bound, in the vacant space made by the substitution of 
histidine 55, must be considered. This water molecule could, 
possibly, act as an active site base dependent on its pKa in 
the active site. A water molecule is found near this position 
in both of the mutant enzymes, but it is not optimally aligned 
for the deprotonation of L-Trp. It is also located 3.3 A away 
from the indole nitrogen atom, outside the range of a normal 
H-bonding interactions, and we propose that it plays no role 
in the catalytic cycle (Figure 1). These data, and the relative 
insensitivity of the WT TDO k to pH (Supporting Informa-
tion Table I), support the idea that histidine 55 or a solvent 
molecule is not required to deprotonate the indole nitrogen 
atom. In IDO where the active site is devoid of solvent, the 
equivalent residue to histidine 55 is serine 167, which is 
incapable of acting as a catalytic base. Turnover still occurs, 
and like TDO kcai is observed to be insensitive to pH (26). 
The decrease in kc at for L-Trp oxidation in both the H55A 
and H55S mutants may be explained by the movement of 
L-Trp in the active site. It can be seen from the crystal 
structures that for both mutants i.-Trp has rotated toward the 
substituted amino acid (and away from the iron atom) relative 
to the position of L-Trp in WT TDO. The L-Trp indole ring 
has also shifted toward the heme (shown in Figure 4). These 
movements are accompanied by a slight increase in the 
AI 
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Table 2: Kinetic Parameters for X. campestris TDO Wild Type and Mutants 
WT TDO 	 H55A 	 H55S 
(s') 	Km (tiM) kt/Km 	kcac (s') 	Km (aM) k.,/K. 	k,., (s') 	K,,, (jiM) 	k.,/Km 
L-Trp" 	19.5 ± 1.2 114 ± 1 	1.711 (100) 2.86 10. 10 133 ± 7 	0.215(100) 2.6 ± 0.01 197 ± 2 0.132(100) 
6-F-D/L-Trp" 	37.3-+0.6 	186 ± 12 2.005 (117) 	3.78 10. 10 	195 ± 1 0.194 (90) 	3.80 + 0.04 	546 ± 36 	0.070 (53) 
5-F-D/L-Trp" 2.40±0.10 100±6 0.240(14) 0.68±0.14 194±25 0.035(16) 0.80±0.01 183±12 0.044(33) 
6-Me-D/L-Trp" 	41.0 ± 1.2 	975 ± 48 	0.421 (25) 	1.65 ± 0.03 	386 ± 4 	0.0443 (21) 	4.66 ± 0.18 	1980 ± 170 	0.024 (18) 
5-Me-D/L-Tip" 3.59 ± 0.05 357 ± 12 0,101(6) 0.40 ± 0.01 395 ± 20 0.010(5) 1.45 ± 0.01 1302 ± 21 0.011(8) 
"Experiments were performed at 25 °C in 100 mM phosphate buffer, pH 7.5, by varying the concentration of the substrate. It should be noted that 
these rates are determined under normal atomospheric conditions; therefore, the rates determined are "apparent" for k, as oxygen is not present at a 
saturating level. The peak positions of the oxyferrous complex (02-TDO) are at 420, 548, and 578 nm, and 	K,, and Ki are calculated using L-Trp. 
Table 3: Substrate Binding to Oxidized and Reduced X. campestris TDO Wild Type and Mutants" 
TDO WT (Kd) 	 H55A (K,,) 	 H55S (K,,) 
substrate 	Fe3 (mM) 	Fe2 " (UM) 	Fe3  (UM) 	Fe2" (,UM) 	Fe"' (aM) 	Fe2 " (,UM) 
L-Trp 	 3.84 ± 0.14 4.1 ± 0.2 11.8 ± 0.2 3.7 ± 1.3 18.4 ± 3.0 5.3 ± 1.0 
6-F-D/L-Trp 	1.51 ± 0.08 	 165±44 	73 ± 3 	 86 ± 12 	6.2-+0.9 
5-F-D/L-Trp 2.45 + 0.42 <1.00" 	 67 ± 20 9.0 ± 1.7 73 + 5 <5.00" 
"Experiments were performed at 25 "C in 100 mM phosphate buffer, pH 7.5. Absorbance changes upon substrate binding are small (-5---10% of 
initial peak absorbance) but easily quantifiable due to tight substrate binding. "Binding was too tight to be measured. Values quoted represent the 
minimum K,, that can be measured under standard assay conditions. 
substrate Km values, implying a small decrease in the stability 
of the Michaelis complex. The rotation has resulted in the 
displacement of the tryptophan indole ring from the dioxygen 
binding site, thus decreasing overlap of the molecular orbitals 
involved in catalysis. The transition state for the reaction 
will be less stable, thus increasing the activation energy for 
catalysis. This will decrease the turnover rates for both 
mutants compared to WT TDO. 
In WT TDO there is a large increase in the affinity of the 
enzyme for L-Trp for ferrous vs ferric enzyme (Kd(Fe3±) = 
3.8 mM, Kd(Fe2") = 4.1 M) (Table 3). This is in contrast 
to recent findings for human TDO, where there was found 
to be little discrimination of binding between the ferric and 
the ferrous enzymes (27). For both mutant proteins this effect 
is essentially destroyed, with only a small increase shown 
in the affinity of the ferrous enzyme for L-Trp relative to 
ferric (Table 3). This trend in Kd is repeated for other 
substrates. These findings suggest that one role of histidine 
55 is to disfavor substrate binding to the oxidized protein, 
and its removal increases binding affinity by a factor >300. 
It can therefore be hypothesized that histidine 55 is respon-
sible for controlling the binding affinity of the active site 
for L-Trp, effectively gating the binding of substrate to WT 
TDO. In this way histidine 55 greatly disfavors the mecha-
nistically unproductive binding of L-Trp to the oxidized 
enzyme, promoting the productive binding of L-Trp to the 
reduced enzyme. 
Electrochemical Studies. Electrochemical data for WT 
TDO and the H55A mutant are shown in Figure 6, and the 
measured midpoint potentials are displayed in Table 4. There 
is a much smaller shift in the reduction potential upon 
binding of substrate (AEmid H55A = +23 mV) (AEud H55S = 
+57 mV) for the mutant enzymes compared to WT TDO 
(AEmidwT = +136 mV). The shift in reduction potential of 
23 mV for the H55A mutant enzyme almost perfectly 
correlates with the increase in affinity for L-Trp for the 
ferrous vs the ferric form (Kd (Fe(II)) = 3.7 pM vs Kd 
(Fe(Ill)) = 11.8 pM), both giving an estimated AAG of 3.5 
U mol_'. In fact, the difference in these AAG values 
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FIGURE 6: OTTLE potentiometric curves for wild-type TDO (open 
circles), H55A mutant (closed circles), and H55S mutant (open 
triangles) with (right-hand plots) and without (left-hand plots) L-Trp 
substrate present (±t-Trp). Each curve is produced from both 
reduction and oxidation of the layer of interest. 
Table 4: Electrochemical Midpoint Potentials 
potential (mV vs SHE) 
no L-Trp +L-Trp change 
TDO WT 	8±5 144±6 +136 
H55A 64±3 87±2 +23 
H55S 	 44±2 101±2 +57 
rITDO" 100 160 +60 
rhIDO" 	-30 ± 4 16 ± 3 +46 
"See ref 29. "See ref 26. 
approximately 11.5 kJ molt,  within the range of energies 
for a single hydrogen bond. The data are less clear for H55S, 
with a 57 mV shift in the reduction potential on L-Trp 
binding. The increase in affinity for L-Trp to the ferrous H55S 
vs the ferric give an estimated AAG of 5.5 kJ mol-t.  It is 
possible that the lower affinity of oxidized WT TDO for 
substrate may be attributed to subtle changes in the structure 
of the active site (in terms of the hydrogen-bonding pattern) 
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FIGURE 7: Plot of the observed steady-state turnover rate (ka pp) versus 
02 concentration for wild-type TDO (top) and H55A (middle) and 
H55S (bottom) mutant forms. The maximum turnover rate (kmax), 
the Michaelis constant (Kr,), and the inhibition constant (K (for 
oxygen)) are reported. 
accompanies expulsion of solvent from the active site and 
results in the formation of a hydrogen bond between histidine 
55 and the pyrrole nitrogen of the indole i-Trp moiety. 
In the H55A mutant enzyme the alanine side chain is 
unable to form the same hydrogen bonds that histidine 55 
can in WT TDO. Consequently, there may be less rearrange-
ment of the active site hydrogen-bonding interactions neces-
sary to allow L-Trp binding, and the Kd for substrate binding 
to ferric enzyme is correspondingly low. All other amino 
acid interactions binding L-Trp to the active site are 
analogous to WT TDO. Consequently, the absence of 
significant oxidation-state-dependent changes in the active 
site in H55A TDO results in decreased specificity of binding 
to the oxidized or reduced enzyme. 
The case is similar for the H55S mutant enzyme as the 
serine side chain is unable to form the same hydrogen bonds 
that histidine 55 can in WT TDO. It is possible that the serine 
could form a bonding interaction with a nearby solvent 
molecule (water 250), but the data suggest that less rear-
rangement of active site hydrogen-bonding interactions is 
necessary to allow i.-Trp binding than for WT TDO. 
Stability of the Michaelis Complex. Figure 7 shows how 
the observed rate constant for turnover (kapp) is dependent 
300 	 400 	 500 	 600 	 700 
Wavelength (nm) 
FIGURE 8: Production of the wild-type TDO oxyferrous ternary 
complex. The peak positions of the oxyferrous ternary complex 
are at 420, 548, and 578 nm. This decays back to ferrous enzyme 
and product (N-formylkynurcninc, peak position 321 nm). 
on dioxygen concentration, 021,  under saturating L-Trp 
concentrations (25 mM). in phosphate buffer (pH 7.5) at 25 
°C, Km(02) is approximately 120 M and kapp for WT TDO 
is only 60% of maximum; however, in the case of the H55A 
and H55S mutant enzymes, kap1, is nearly maximal (Table 
2). These data seem contrary to the Michaelis model (based 
on steady-state kinetics) that predicts a lower 02 binding 
affinity for the mutant forms. 
WT TDO has an ordered catalytic cycle in which the 
reduced enzyme—substrate complex must be formed prior 
to 02 binding for turnover to occur (11, 28). No fen-ous—oxy 
complex is observed, and addition of oxygen to ferrous WT 
TDO or the mutant forms in the absence of subs-
trate leads to direct decay to the ferric state. This is also the 
case for human TDO (27), suggesting that instability of 
the ferrous—oxy species may be common in TDO species. 
The similar i.-Tip binding affinity of the reduced mutant 
enzymes compared to WT TDO (3.7 and 5.2 1uM versus 4.1 
pM) and similar Km values for substrates (Table 2) show 
that all enzymes can bind substrate and then dioxygen in 
productive ternary complex formation. Structural data indi-
cate that movement of the indole moiety of L-Trp in the 
active site is responsible for the decrease in kca for H55A 
and H55S. The increased L-Trp binding affinity to the 
oxidized H55A and H55S enzymes, compared to WT TDO, 
will lead to a higher probability of nonproductive oxidized 
enzyme—substrate complex formation, possibly decreasing 
kcat, but this effect would be small compared to the effect of 
the destabilized transition state. 
Formation and decay of the oxyferrous ternary species 
generated (Figure 8) for WT TDO show that the (Fe—L-Trp) 
complex displaying a Soret peak at 432 nm binds 02, producing 
(Fe2 —L-Trp-02), with a corresponding shift in the Soret peak 
to 419 nm. This then decays to N-formylkynurenine (shown 
by an increase in absorbance at 321 nm) and ferrous enzyme 
(displaying a Soret peak at 432 nm). This is also observed with 
6-F-Tip as the substrate, but for 5-F-Tip some uncoupling is 
seen, leading to production of the inactive ferric enzyme and 
the superoxide anion (02) and release of the substrate. These 
trends are repeated for H55A and H55S, with uncoupling 
observed only with 5-F-Tip as substrate. However, the initial 
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Table 5: Oxygen Dependence of Steady-State Turnover of L-TryptOphafl 
by X. campestris TDO Wild Type and Mutants 
TDO WT 	H55A 	H55S 
(s) 	35.4 ± 0.9 3.86 ± 0.26 7.88 ± 0.60 
KpM) 119±2 	45.7 ±5.6 	99±16 
KtjeM) 	 1380±140 480±50 
rates of formation of the ternary complexes are slower, with a 
rate constant of approximately 50 s compared to 100 s for 
WT TDO. Oxyferrous decay parallels this with rate constants 
of 0.4 s' and 2 s' for the mutant enzymes and WT 111)0, 
respectively. This indicates that both mutations do not desta-
bilize the ternary complex significantly, but as the rate of decay 
is decreased compared to WT 11)0, this correlates with a higher 
activation energy for catalysis due to the movement of the 
tryptophan indole ring destabilizing the catalytic transition state. 
Substrate inhibition is observed at high oxygen concentrations 
for both mutant forms (Table 5), while none is observed for 
WT TDO. This unexpected result may be plausibly explained 
by the lower rate of decay and subsequent slower expulsion of 
product from the active site by the mutant enzymes. As the 
active site cavity is larger due to the removal of histidine and 
its replacement by alanine or serine in the mutant forms, the 
product, N-formylkynurenine, may be less readily expelled at 
high oxygen concentrations and dioxygen may be able to bind 
before the product has left. This would trap the product in the 
active site, causing inhibition of catalytic activity. 
CONCLUSIONS 
In this study we have investigated whether a putative active 
site base, histidine 55, is necessary for catalytic activity in 
TDO. The data we have presented show that in the mutant 
enzymes H55A and H55S turnover still occurs. This indicates 
clearly that histidine 55 is not an essential base. Instead, a 
different role for histidine 55 in controlling substrate binding 
at the active site has been revealed. On the basis of structural, 
kinetic, and electrochemical data we have proposed that the 
role of histidine 55 is to prevent the formation of the 
nonproductive ferric enzyme—substrate complex. This is 
most likely achieved by histidine 55 controlling the water 
content of the substrate-free active site. 
SUPPORTING INFORMATION AVAILABLE 
A table presenting data on the p1-I dependence of L-Trp 
dioxygenation by wild-type TDO and the H55A and H55S 
mutant forms of the enzyme. This material is available free 
of charge via the Internet at http://pubs.acs.org. 
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FUNCTIONAL CLASS 
Indoleamine 2,3-dioxygenase, E.C. 1.13.11.52; tryptophan 
2,3-dioxygenase, E.C. 1.13.11.11. 
Indoleamine 2,3-dioxygenase (IDO, also known as trypto-
phan pyrrolase) and tryptophan 2,3-dioxygenase (TDO, also 
known as tryptophan oxygenase and L-tryptophan pyrrolase) 
are oxidoreductase enzymes that contain one noncova-
lently bound iron—protoporphyrin IX per monomer. These 
enzymes catalyze the dioxygenation of L-tryptophan (L-Trp) 
to N-formyl-L-kynurenine in the first and rate-limiting step of 
the kynurenine pathway" (Figure 1). 
OCCURRENCE 
IDO and TDO are members of a family of enzymes that also 
includes sIDO from Shewanella oneidensis3 and PrnB, the 
second enzyme in the pyrrolnitrin biosynthesis pathway 
from Pseudomonas fluorescens,4 although dioxygenase 
activity has not been demonstrated for either as yet. 
Recently, a new enzyme with the ability to catalyze L-
tryptophan dioxygenation, INDOLI, was identified. It is 
encoded by a gene adjacent to that for IDO in many 
eukaryotes and is predicted to be closely related to IDO in 
terms of its structure and function.5 
IDO was first isolated from rabbit intestine in 19676 
and is found in many eukaryotes where it is expressed 
throughout the body, except in the liver. 7-9  Its production 
can be induced in many tissues in response to various 
stimuli, and this specific expression in different cellular 
locations suggests a distinct role for IDO.1° Bacteria are 
also believed to use members of this family for the aerobic 
metabolism of L-tryptophan via the kynurenine pathway, 
although prokaryotic IDO-like proteins bear little sequence 
similarity to eukaryotic IDO proteins and very little is yet 
known about them. 
3D Structure The structure of human IDO, comprising two domains. The smaller N-terminal domain is shown in blue and the larger 
domain in cyan. An iron-containing porphyrin shown in red forms the active site. This figure was prepared using PyMOL37 based on 
coordinates from PDB code 2DOT. 
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Figure 1 Reaction catalyzed by IDO and TDO. 
TDO was initially discovered in the 1930s1 ' and is 
found in both eukaryotes (human, 12 rat, 13 and rabbit") 
and prokaryotes (Xanthomonas campestris,3 Raistonia 
metallidurans, and P. fluorescens.' 516 ) Expression of TDO 
in mammals is normally restricted to the liver, but it has 
been identified in the brain and epididymis of some species, 
and, in some tissues, its production can be induced in 
response to stimuli. 
BIOLOGICAL FUNCTION 
IDO and TDO both play a central role in the physiological 
regulation of tryptophan flux in the human body, control-
ling the kynurenine pathway and influencing serotogenic 
regulation.'7 However, many studies have implicated these 
proteins in wide-ranging and seemingly unconnected physi-
ological and pathophysiological conditions. Although both 
enzymes catalyze the same reaction, the compartmentaliza-
tion of IDO and TDO expression is thought to reflect their 
differing biological roles. Production of IDO and TDO 
can be induced in many tissues in response to various 
stimuli, and this specificity of cellular induction suggests 
little crossover of function. 
The kynurenine pathway 
The kynurenine pathway accounts for the processing of 
over 90% of L-tryptophan utilized by humans.13 It is 
important not only as a source of metabolites but also 
because of the effect of IDO/TDO on the local tryptophan 
concentration. The buildup of pathway metabolites due to 
IDO/ TDO induction or poor metabolism further along the 
pathway can lead to numerous conditions.' High levels of 
quinolinic acid and L-kynurenine in cerebrospinal fluid18 
(CSF) may be involved in various neurological disorders 
(e.g. cerebral malaria, ischemic brain injury, multiple scle-
rosis, and acquired immune deficiency syndrome (AIDS)-
related dementia1820). Concentrations of these metabolites 
increase with the severity of neurological dysfunction or 
brain injury under a wide range of inflammatory condi-
tions. For example, the kynurenine pathway metabolites 
3-hydroxyanthranilic acid and 3-hydroxykynurenine are 
LTV filters that can bind to the lens protein in the eye 
and they have been implicated in cataract formation 
when present at high concentrations.21 In addition, some 
kynurenine pathway metabolites are immunomodulatory 
and can consequently contribute to immunosuppressive 
pathways and suppress proliferation (or even cause apop-
tosis) of T cells. 11,22,2' However, the mechanisms of action 
of such metabolites are unknown. 
The local depletion of tryptophan by enzymatic action is 
mainly associated with an antimicrobial response by IDO 
or TDO, or immune regulation by IDO.24 Some pathogens 
are sensitive to tryptophan degradation, including viruses 
(herpes viruses), intracellular bacteria (Chiamydia and 
Rickettsia), and extracellular bacteria (Staphylococci), and 
this may be an effective mechanism for controlling their 
ability to proliferate. 
Immune regulation 
IDO plays an active role in the human body's immune 
response, but there is little evidence to suggest that 
TDO plays a part in this process. Immune regulation 
by IDO is extremely complex and is influenced by many 
factors including tryptophan depletion, the accumulation 
of immunosuppressive metabolites, and interactions with 
signaling or immunoregulatory pathways. 25 
Initially, IDO was associated with peripheral tolerance 
and immunosupression by the immune system. IDO is a 
normal effector of peripheral tolerance in the immunoregu-
latory pathway of tryptophan metabolism and helps create 
a balanced immune response between inflammation and 
tolerance, suppressing excessive immune activation .26 The 
delicate balance between suppression and activation of 
the immune response by the body is not well under-
stood. However, the effects observed when IDO activity 
is disturbed are widespread and suggest that its role is an 
important one. 
IDO is now also thought to play an essential role in 
acquired immune tolerance. Inhibition of DO activity in 
mice has been shown to lead to allogenic fetal rejection '21,21 
and increased IDO activity is thought to be responsible 
for renal allograft rejection .29 In both cases, the body 
must acquire immune tolerance. It has also been discov-
ered that IDO helps tumors induce tolerance from the 
host's immune system by interacting with T cells and 
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Table 1 TDO and IDO proteins characterized by 
crystallography 
Resolution (A) 
Protein 	Organism 	Molecules bound & PDB ID code 
1D030 	Homo sapiens 4-Phenyl imidazole 2.3 2DOT 
Cyanide 3.4 2DOU 
TD03 	Xanthornonas None 2.7 2NW7 
campestris 
L-Tryptophan 1.6 2NW8 
6-Fluoro-tryptophan 1.8 2NW9 
1D015 	Raistonia None 2.4 2NOX 
metallidurans 
depleting L-tryptophan levels.22 Consequently, IDO has 
emerged as an attractive drug target in cancer and trans-
plant treatments.2 
AMINO ACID SEQUENCE INFORMATION 
IDOs and TDOs from a number of eukaryotic species have 
been sequenced and can be found in protein databases. 
Those species whose crystal structures are mentioned in the 
text are described in Table 1. Homology between members 
of this family is apparent from their 3D structures and from 
the conservation of certain amino acids in their active sites, 
but sequence similarity between family members is low and 
sequence alignment based on their structures often gives an 
identity of approximately 10%. 
IDO is monomeric and contains approximately 400 
amino acids, displaying high sequence similarity between 
eukaryotic species. TDO is homotetrameric; eukaryotic 
TDOs contain approximately 400 amino acids, while 
prokaryotic TDOs contain approximately 300 amino acids. 
Sequence identities between prokaryotic and eukaryotic 
TDOs are around 20-30%. 
PROTEIN PRODUCTION, PURIFICATION, 
AND MOLECULAR CHARACTERIZATION 
Both IDO and TDO can be purified directly from 
mammalian sources. Initial studies used these methods of 
preparation. Recent studies into both enzymes have used 
genetic engineering to overproduce the proteins in bacterial 
hosts, thus making it possible to construct site-directed 
mutant forms of the enzymes. The recent examples of 
expression and purification protocols for these enzymes are 
given below. 
Expression of recombinant human IDO 
For the efficient expression of His-tagged recombinant 
human IDO, Raven and coworkers cloned the cDNA 
into a pQE-30 vector previously modified via polymerase 
chain reaction (PCR) to incorporate KpnI and Sal! 
restriction sites and an N-terminal hexa-histidine tag. 
Escherichia co/i BL2I-Gold (DE3) cells were used for 
protein production. The protein was purified using nickel-
affinity chromatography.31  
Expression of Xanthomonas campestris TDO 
Production of full-length X. campestris TDO was achieved 
by cloning the genomic DNA into a pET-21d derivative, 
with a C-terminal hexa-histidine tag, and overexpression in 
F. co/i BL21(DE3) pMGK cells. The protein was purified 
using nickel-affinity and gel-filtration chromatography; the 
details are given in the supplementary material of Forouhar 
et al. 3  
METAL CONTENT AND COFACTORS 
Both IDO and TDO bind one b-type heme (protoporphyrin 
IX) per monomer. This has been confirmed by both UV—vis 
spectrophotometry and pyridine hemochromogen assays on 
active protein samples. Neither protein associates with any 
other metals or cofactors, although IDO may be purified 
with up to 5% of its relative atomic mass as attached 
carbohydrate; this appears to have little or no function. It 
is thought that TDO may possibly bind ligands that act as 
allosteric effectors in vivo,32 but to date none have been 
identified. 
SPECTROSCOPY 
The UV—vis absorbance spectra for this family of proteins 
are characteristic of b-type heme-containing proteins with 
histidine as an axial heme ligand. Spectrochemical data 
are shown in Table 2. EPR (electron paramagnetic reso-
nance) data of the substrate-free and L-tryptophan-bound 
forms of IDO and TDO, in the ferric state, are shown 
in Table 3. Resonance Raman, MCD (magnetic circular 
dichroism), and NMR (nuclear magnetic resonance) spec-
troscopies have also been used to characterize this family of 
proteins, and the results of these studies, along with those 
determined by EPR, are discussed in the section 'Heme Iron 
Coordination'. 
CRYSTAL STRUCTURES 
Crystallization and structure determination 
The crystal structure of recombinant human IDO was 
published in 2006. 1  IDO crystals were obtained using 
the hanging-drop vapor diffusion method at 20'C. 
Hanging drops of 6 uI volume were prepared using 
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Table 2 Absorption spectra maxima 
Enzyme 	 Derivative 	Ferric 	Ferrous 
H. sapiens 1DO31 a 	Substrate-free 404 425 
500, 535/633 527b  558 






H. sapiens TDO 12, 	Substrate-free 406 432 
633 	556 
L-Tryptophan 	433 421 
455 	537,567 
X. campestris 	Substrate-free' 	405 431 
TDO3d 
503,633 555,588 
LTryptophane 	405 	433 
585 555,588 
L-Tryptophan-02 	 420 
548,578 
'Data recorded in pH 7.0 100mM sodium phosphate buffer, 
25°C. 
b  Shoulder. 
Data recorded in pH 7.0 100mMKPj buffer, 25 'C. 
'1 Data recorded in pH 7.5 100 mM KPi buffer, 25 °C. 
SJ Thackray, CG Mowat, SK Chapman, unpublished results.  
(PDB) (Table 1). In addition to this, the structure of the 
IDO cyanide adduct (PDB ID 2DOU; 3.4A resolution) 
was obtained by soaking these crystals in a cryoprotectant 
buffer containing 5 mM KCN for S mm. 
For TDO, the structures of the R. metallidurans15 (PDB 
ID 2NOX; 2.4A resolution) and X. campestris3 (PDB IDs 
2NW7 (2.7A resolution), 2NW8 (1.6 A resolution), 2NW9 
(1.8 A resolution)) enzymes have been published (Table 1). 
The R. metallidurans enzyme was crystallized using a 
construct lacking 18 N-terminal residues (A18TDO). 
Crystals were obtained by vapor diffusion at 22 °C using 
25mgml 1  A18TDO (in SO mM sodium phosphate buffer 
pH 8.0,200 mM imidazole, 300 mM sodium chloride) with 
a well solution comprising 0.8-1.2M tn-sodium citrate 
dihydrate (pH 6.5) supplemented with 1 mM 1-tryptophan. 
For X. campestris TDO, crystals of the reduced enzyme 
were obtained by carrying out crystallization in a glovebox 
under a nitrogen atmosphere. Crystals were obtained 
by the sitting-drop vapor diffusion method with a well 
solution comprising 100mM sodium 2-(N-morpholino) 
ethanesulfonic acid (MES) buffer (pH 6.3), 10-12% PEG 
4000, 60mM MnC12, 10mM sodium dithionite, and 
2mM L-tryptophan. In order to ensure the presence 
of L-tryptophan at the active site, crystals were soaked 
in a cryoprotectant solution supplemented with 50mM 
L-tryptophan. 
Table 3 EPR identification of all species observed in the 
absence or presence of L-tryptophan for IDO and TDO 
Enzyme Species gvalues 
H. sapiens IDO" High spin (H2O) 5.96 and 1.99 
Low spin (N) 2.94, 2.25, and 1.50 
Low spin (OH- )a 2.52 2.19, and 1.86 
H. sapiens TDOb High spin 5.71 and 2.01 
Low spin 2.89, 2.30, and 1.62 
Low spin0 2.63, 2.20, and 1.84 
Pseudomonas High spin 5.8 
ac/do vorans 
TDO (1)330 
Low spina 3.67, 2.20, and 1.80 
a  Only observed in the presence of L-tryptophan. 
b  Basran, S Rafice, N Chauhan, I Efimov, MR Cheesman, 
L Ghamsari and EL Raven.46 
Similar data are observed in the study by Brady et al.34 
a 1:1 ratio of protein (40mgm1 1 in 10mM 2-(N-
morpholino)ethanesulfonic acid buffer (pH 6.5), 25 rrLM 
NaCl, 1 mM 4-PI (4-phenylimidazole)) and the well 
solution.35 The well solution comprised 100mM N-
cyclohexyl-2-aminoethanesulfonic acid buffer (pH 9.0), 
200 mM ammonium acetate, and 10% polyethylene glycol 
(PEG) 8000. Using this method, crystals of IDO in complex 
with the inhibitor 4-phenyl imidazole were obtained, and 
the model has been deposited in the protein data bank 
Overall structure 
lD() 
The structure of human IDO revealed that the enzyme 
is folded into two distinct domains (see 3D Structure). 
The larger (and C terminal) of these is completely helical, 
with 13 a helices and two 310  helices, and belongs to 
the family of IDO-like protein folds,36 while the smaller 
N-terminal domain consists of six a helices, two short 
strands, and three 3 	helices and is similar to the 
C-terminal domain of GST (glutathione S-transferase).36 
The heme is bound within the larger domain, but is close 
to the domain interface. The loop region connecting the 
two domains (residues 250-267) lies above the distal face 
of the heme, close to the active site. The interdomain 
contact is extensive, with a buried surface area of 
3100 A2. 
TDO 
The enzymes from R. metallidurans and X. campestris 
share 47% sequence identity, and their overall structures 
are essentially identical. Indeed, the regions of highest 
sequence conservation are those that are close to the 
active site. For this reason, we limit the discussion of 
the TDO structure to that of the highest resolution 
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Figure 2 The structure of X. campestris TDO. The 'dimer of dimers' arrangement can be seen, with one 'dimer' colored green and 
magenta and the other blue and gray. Heme groups are shown in red and L-tryptophan molecules are in cyan. This figure was prepared 
using PyMOL based on coordinates from PDB code 2NW8. 
structure. This is the 1.6-A-resolution model of the X. 
campestris enzyme in the ferrous form and in complex with 
L-tryptophan.3  
The structure of TDO is an intimately associated 
homotetramer (Figure 2) with approximately 4500 A2 of 
the surface area of each monomer being buried within the 
tetramer interface. The structure of the monomer contains 
12 a helices and no strands and belongs to the family 
of bacterial TDO-like protein folds.36 The tetramer may 
be considered as a dimer of dimers, and the N-terminal 
regions (residues 21-40 of X. campestris TDO) of each 
monomer interact with the adjacent subunit to form part 
Of its L-tryptophan binding site. 
Comparison of IDO and TOO 
With the exception of the smaller N-terminal domain of 
IDO, the structures of IDO and TDO are very similar. 
Indeed, in comparing 201 structurally equivalent Ca 
atoms between TDO and the large domain of IDO, the 
rmsd (root mean square difference) is only 3.1 A. An 
overlay of the structures is shown in Figure 3. The above-
mentioned 'dimeric' arrangement in TDO, which involves 
the N-terminal region of one monomer comprising part 
of the substrate binding site in the adjacent monomer, is 
clearly not possible in monomeric IDO. However, the two 
tyrosine residues in TDO that are proposed to be important 
Figure 3 An overlay of human DO (same coloring as Figure 2) 
with one monomer of X. campestris TDO (in magenta). Also 
shown is the N-terminal region (in green, residues 21-40) of the 
adjacent monomer, which forms part of the active site. The heme 
groups are shown in red. This figure was prepared using PyMOL 
based on coordinates from PDB codes 2DOT and 2NW8. 
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in this arrangement, Tyr24 and Tyr27, are in equivalent 
positions to Tyr126 and Cys129 in IDO. In TDO, the side 
chain of Tyr27 occupies a space that is taken by the side 
chain of Phe164 in IDO. 
The active site 
The active sites of IDO and TDO have several similarities. 
The substrate binding site of TDO is well characterized 
owing to the presence of L-tryptophan in the crystal 
structure (Figure 4). The interactions of the substrate with 
the active site include an electrostatic interaction between 
the side chain of Arg117 and the substrate carboxylate 
group, which is also hydrogen bonded to the phenolic 
oxygen of Tyr113 and the main chain amide group of 
Thr254. The substrate ammonium group is hydrogen 
bonded to the side chain hydroxyl group of Thr254, the 
7-propionate group of the heme, and a water molecule. The 
substrate indole ring is located approximately 3.5 A above 
and is perpendicular to the heme plane. It maintains van der 
Waals interactions with the side chain of PheSl as well as 
those of Tyr24 and Tyr27 from the adjacent monomer. In 
addition to these interactions, there is a hydrogen-bonding 
interaction between the substrate indole nitrogen and one 
of the side chain nitrogen atoms of HisSS. This extensive 
network of enzyme—substrate interactions serves to stabilize 
the active site and control substrate binding and catalysis. 
In contrast to TDO, the structure of IDO is not available 
with any substrate bound, but has been solved with the 
inhibitor 4-PT at the active site (Figure 5). This model shows 
that 4-PI binds to the heme iron as expected, but does 
C 12 






Figure 5 The active Site of human IDO. Potentially important 
active site residues are shown, along with the bound inhibitor 
4-phenylimidazole (4-PI). This figure was prepared using PyMOL 
based on coordinates from PDB code 2DOT. 
not yield any information regarding the mode of substrate 
binding in IDO. Given the similarity between the active sites 
of both dioxygenases, it is perhaps reasonable to assume a 
similar substrate binding mode in IDO. This is supported by 
comparison of the active sites of IDO and TDO (Figure 6). 
Active site bond distances are shown in Table 4. 
For example, it can be seen that Arg117 in TDO is 
equivalent to Arg231 in IDO, while PheSi in TDO is in 
the same position as Phe163 in IDO and Tyr24 in TDO 






Figure 4 The active site of X. campestris TDO. Some of the 
interactions between the bound L-tryptophan and the active site 
residues are shown. This figure was prepared using PyMOL based 
on coordinates from PDB code 2NW8. 
Figure 6 An overlay of the active sites of IDO (cyan) and TDO 
(magenta). This is a composite image of Figures 4 and S with 
the labeling removed for clarity. This figure was prepared using 
PyMOL based on coordinates from PDB codes 2DOT and 2NW8. 
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Table 4 Active site distances and interactions 
Enzyme 	 Atoms 	 Distance (A) 
H. sapiens IDO' NE2 H346 - Fe 2.1 
Fe - N3 4-Fl 2.1 
X. campestris NE2 H240 - Fe 2.3 
TDOb 
Fe — O Wall 3.5 
O Wall - G1 25 amide N 2.8 
O Wall - L-lryptophan 3.0 
i-amino N 
o Wati - L-lryplophan 3.3 
indole N 
NE2 H55 - L-lryptophan 2.6 
indole N 
R. metallidurans NE2 H257 - Fe 2.2 
TDOC 
a PDB ID 2DOT. All distances are ±0.3 A. 
b  PDB ID 2NW8. All distances are ±0.2 A. 
PDB ID 2NOX. All distances are ±0.3 A. In the majority of 
monomers there was found to be no distal water bound to the 
heme iron. 
occupied by Tyr113 in TDO is taken by Phe226 in IDO. 
However, in addition to these similarities, it should be 
noted that the equivalent region in IDO of the loop 
comprising residues 250-260 of TDO is disordered in 
the IDO structure. This region is particularly important in 
TDO because it includes Thr254 that, as mentioned above, 
is involved in binding the ammonium and carboxylate 
moieties of L-tryptophan. It is interesting to note that in the 
absence of L-tryptophan this loop region is also disordered 
in the TDO structure, and that substrate binding is required 
to induce its ordering. This may also be the case for 
IDO, but the possibility exists that there is no equivalent 
interaction between IDO and L-tryptophan. 
Perhaps the most obvious difference between the active 
sites of the two enzymes is the presence of His55 in TDO 
and its equivalent Ser167 in IDO. In TDO, the histidine 
side chain is hydrogen bonded with the indole nitrogen 
atom of i-tryptophan, and the role of HisSS would appear 
to be for regulating substrate binding. The role of Ser167 
in IDO is less clear in the absence of a substrate-bound 
crystal structure, but it is unlikely that this residue plays 
any crucial role in IDO. 
Secondary binding site - allosteric effectors 
In the crystal structure of L-tryptophan-bound X. campes-
tris TDO in the ferrous state, there is a second L-tryptophan 
binding site in the tetramer interface with a well-
defined electron density (Figure 7). It would appear that 
this is a specific interaction with L-tryptophan, and in 
light of reports of allosteric activation of TDO by L-
tryptophan,3839 it could be possible that this site represents 
an allosteric effector site. 
Figure 7 The L-tryptophan binding site in the tetramer 
interface. Each L-tryptophan molecule occupies an identical site 
with respect to the four monomers. This figure was prepared using 
PyMOL based on coordinates from PDB code 2NW8. 
HEME IRON COORDINATION 
UV—vis, EPR, and MCD spectra of ferric human IDO show 
the presence of two distinct species in solution, high-, and 
low-spin heme, in approximately equal population at pH 
6.031 ,40  (Table 3). The two species are shown to be in 
equilibrium, and, on increasing the pH, there is an increase 
in the low-spin component, with a concomitant decrease in 
the high spin component. Histidine is the proximal ligand 
to the heme iron in both species, with a nitrogen—iron 
bond distance of 2.1 A (Table 4). The high-spin species is 
confirmed by MCD and resonance Raman spectroscopy 
as arising from water ligation in the distal position. The 
sixth ligand in the low-spin species is thought to be an as 
yet unidentified nitrogenous ligand, as there is no available 
nitrogen ligand in the active site. The spectra are shown to 
be pH independent - indicating that no ionizable residue 
affects binding, and there is no formation of hydroxide-
bound heme while substrate is absent. 
In the presence of L-tryptophan at pH 8, MCD and EPR 
confirm that there are three distinct species in solution, 
one of which is high spin and the other two are low 
spin. The sixth heme ligand for the additional low-spin 
species is hydroxide, and this is the predominant species 
in solution. The bound L-tryptophan provides a hydrogen 
bond acceptor to stabilize deprotonation of the bound 
water molecule. Ferric substrate-free human IDO does not 
form a hydroxide-bound species as IDO lacks a hydrogen-
bond acceptor to facilitate deprotonation of the bound 
water molecule. In contrast, for the ferric-substrate-bound 
enzyme, the spectra are pH dependent due to an ionizable 
interaction affecting the formation of the hydroxide species 
in the active site. L-Tryptophan is thought to act as a 
proton acceptor, deprotonating the bound water molecule 
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and forming the hydroxide-bound species; this is supported 
by resonance Raman studies. 12  The relation of these studies 
and those above to the active site structure is currently 
limited by the lack of a substrate-bound crystal structure. 
TDO 
The substrate binding site of TDO is well characterized 
due to the presence of L-tryptophan in the crystal structure. 
The active site bond distances are shown in Table 4. EPR 
experiments on human, rat liver, and Pseudomonas TDOs 
in the ferric state have shown the presence of two distinct 
species in solution, a high-spin form and a low-spin form33  
(Table 3). At acidic pH, only the high-spin state has been 
reported, and, on increasing the pH, a transition to a 
mixed-spin state occurs, containing a mixture of the two 
forms. The spin state of the alkaline form of ferric TDO 
is temperature dependent, and the proportion of high-
spin species increases with elevating temperature. Histidine 
occupies the axial coordination position to the heme iron. 
The bond lengths are shown in Table 4. The nature of 
the sixth ligand for the high-spin species is postulated to 
be a water molecule, while that of the low-spin species is 
postulated to be hydroxide. This is possible for substrate-
free TDO as a histidine residue is present in the active site 
to deprotonate a bound water molecule, which is present in 
the X. cam pestris substrate-free active site (PDB ID 2NW7). 
This is in contrast to IDO where no equivalent residue is 
available, but data so far are inconclusive. 
EPR data on rat liver and Pseudomonas enzymes show 
that addition of L-tryptophan to the ferric enzyme causes an 
increase in the low-spin component at neutral pH, with a 
decrease in the high-spin component.34 MCD studies have 
suggested that this high-spin component may be distinct 
from that observed in the substrate-free enzyme, but little 
data are available for analysis at present.41 The spectral 
changes indicate that L-tryptophan binding to the ferric 
protein causes increased deprotonation of the heme bound 
water. L-Tryptophan binding to the ferric enzyme also 
significantly modifies the pH of the spin-state transition, 
decreasing the pH at which this transition occurs by about 
1.6 units. This substrate-induced shift could be caused by 
the bound L-tryptophan, deprotonating the bound water 
molecule, as in IDO, rather than the active site histidine. 
Figure 4 shows that deprotonation of the water by the 
indole nitrogen is possible, as the bond distance is 3.3A 
(Table 4). 
Contrary to the data on the prokaryotic TDO, recent 
EPR analysis has shown that addition of L-tryptophan to 
human TDO causes the creation of an additional low-spin 
species (Table 3). The high-spin and two low-spin species 
observed have g values similar to those of human IDO 
under analogous conditions, and they are proposed to have 
similar ligands in their distal position. This result is clearly 
different from that of the prokaryotic TDO species studied,  
and poses many questions regarding the differences in 
the heme environment and substrate binding interactions 
between TDO enzymes and between IDO and TDO. 
Small molecule binding 
Recent resonance Raman spectra of CO and NO binding to 
ferric, L-tryptophan-bound human TDO and human IDO 
enzymes suggest that in TDO the C2—C3 double bond of 
the tryptophan ring faces the distal diatomic ligand of the 
heme. This is in contrast to IDO, where the indole nitrogen 
appears to hydrogen bond with the diatomic heme ligand.12 
These differences suggest that the two enzymes may 
catalyze the dioxygenation of L-tryptophan via differing 
mechanisms, as deprotonation of the indole nitrogen may 
occur by two distinct processes. These mechanisms are 
discussed further below under 'catalytic mechanism'. 
FUNCTIONAL ASPECTS 
Steady-state kinetics 
Weak catalytic activity by ferric IDO and TDO has 
been reported, but the turnover is generally catalyzed 
by the ferrous protein)2 '42 Reduction of heme iron 
is therefore required to facilitate the observation of 
catalytic activity. Upon reduction, some turnover can be 
observed in the absence of any electron transfer mediators, 
but full catalytic activity is not observed without their 
presence. Ascorbate, catalase, and methylene blue are 
employed in the assay buffer to achieve this. Ascorbate 
and methylene blue are reducing agents, but also react 
with dioxygen to form superoxide and peroxide by-
products, which can bleach the heme and destroy catalytic 
activity. Catalase is therefore present to remove any 
superoxide or peroxide in solution and hence allows an 
efficient turnover of substrate.16 The reaction velocity is 
calculated by monitoring the increase in concentration of 
N-formylkynurenine (or related derivative) at 321 nm, and 
fitting the data to the Michaelis—Menten or Hill equation. 
TDO has been shown to catalyze the dioxygenation 
of L-tryptophan, 6-F-tryptophan, and S-F-tryptophan. D-
Tryptophan is a competitive inhibitor of the enzyme at high 
concentrations.43 IDO displays broader substrate selectivity 
than TDO, catalyzing the dioxygenation of D-tryptophan, 
5-OH-tryptophan, serotonin (5-OH-tryptamine), and tryp-
tamine in addition to those substrates utilized by TDO.' 
Catalytic data is shown in Table S. 
Despite sharing low sequence identity, key active site 
residues are similar in IDO and TDO (Figure 6) and 
they may display the same L-tryptophan binding mode. 
However, IDO may have weaker interactions with the 
ammonium ion and carboxylate group of L-tryptophan 
than TDO. In addition, a histidine residue hydrogen bonds 
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Table 5 Kinetic parameters for substrate dioxygenation 
Enzyme 	 Substrate 	pH 	kcat (s ') 
	
Km (pM) 	kcat/Km (M's") 	Fe" (pM) 	Fe" (ij.M) 
H. sapiens 0031  L-Tryptophan 8.0 1.48 7.1 7.3 x 105 285a nr 
Rabbit ID043,44 L-Tryptopharl 7.0 2.0 13 1.6 x 105 5800 13 
o-Tryptophan 6.0 1.6 7400 220 nc nc 
H. sapiens TD012 L-Tryptophan 7.0 2.1 190 1.3 x 104 nr nr 
H. sapiens TDO' L-Tryptophan 8.0 1.4 220 6300 '-350 -'-'200 
X. campestris TD03 L-Tryptophan 7.5 19 110 1.7 x 105 3800 4.1 
D-Tryptophan 7.5 0.0 16500c nc >50000 nc 
nr, not recorded; nc, no change on binding or no turnover. 
a N Chauhan, J Basran, I Efimov, DA Svistunenko, HE Seward, PCE Moody and EL Raven. 45 
b  Basran, S Rafice, N Chauhan, I Efimov, MR Cheesman, L Ghamsari and EL Raven.46 
Inhibitory constant, K. 
with the indole nitrogen atom of L-tryptophan in TDO, 
providing a precise alignment between the indole ring of 
the substrate and the heme porphyrin (Figure 4). In IDO, 
the analogous residue is serine, which is unable to form a 
hydrogen bond to L-tryptophan. These differences may be 
the reason why IDO cannot completely distinguish among 
the indoleamine substrates, and can therefore catalyze a 
wider range of reactions. 
Binding studies 
The addition of L-tryptophan and related substrates to 
IDO and TDO causes significant changes in their UV—vis 
spectra. Binding affinities are shown in Table 5 and it can 
be seen that L-tryptophan binds to the ferrous enzyme with 
a higher affinity than the ferric enzyme for both IDO and 
TDO. This phenomenon is common in heme enzymes, with 
increased affinity for substrate being attributed to a large 
conformational movement upon reduction of the enzyme. 
When substrate is bound to either enzyme, there is an 
apparent activation toward binding of diatomic ligands 
as evidenced by a decrease in their Kd  values. Previous 
studies have demonstrated that the binding of ligands 
such as oxygen, carbon monoxide, and nitric oxide to 
the ferrous enzyme are greatly augmented by the binding 
of L-tryptophan.47 
Inhibition studies 
The most-studied inhibitor of IDO is 1-methyltryptophan, 
a competitive inhibitor that exists as two stereoisomers. It 
is unclear as to which isomer affects the greatest inhibitory 
response in vitro; many derivatives have been studied 
for their inhibitory properties. 48,49  1-Methyltryptophan is 
ineffective against TDO activity. This can be explained by 
comparison of the active sites of the enzymes (Figure 6). 
In TDO, the Ni atom of tryptophan is directly hydrogen 
bonded to the HisSS side chain and its methylation clearly 
causes a steric clash with this residue. In comparison, 
HisSS is replaced by Ser167 in IDO, which creates a small 
pocket that can accommodate the 1-methyl group, allowing 
binding. IDO is a therapeutic target for the development of 
new anticancer drugs and importance has been given to the 
design of new inhibitors of its action. 
A few potent inhibitors of TDO have been discovered, 
including norharman, a 3-carboline derivative,50'51  and a 
number of 2-(2-pyridylethenyl)indole derivatives.52 
Binding requirements and superoxide 
IDO and TDO must first form a ternary complex 
(substrate—Fe"-02 ) to allow productive substrate turnover, 
and the trapping of this complex for both enzymes confirms 
its formation. 53,54  What is less clear is the order in which 
the substrates bind to the enzyme. 
Studies have shown that TDO must first form the 
ferrous binary enzyme—substrate complex (Fe"—Substrate) 
before dioxygen binding can occur and allow a productive 
turnover. This binding order appears logical as initial 
substrate binding to the ferrous enzyme would prevent 
unproductive coupling of dioxygen to the ferrous enzyme, 
which could lead to the production of superoxide and 
the dead-end ferric complex. However, limited turnover of 
substrate by ferric TDO, possibly utilizing superoxide as 
an electron source, has recently been observed for human 
mo.12 
IDO operates in the same manner, but can also utilize 
superoxide as an oxygen source.43 Ferric and ferrous 
IDO can react with superoxide (02)  to produce the 
ferrous oxygenated enzyme (Fe'1-02 ), which can then bind 
L-tryptophan and effect substrate turnover. It is not known 
if this is important to the biological function of IDO or 
TDO, but research suggests that in vivo utilization of 
superoxide is probably minimal.55 
For IDO, studies have shown that binding of L-
tryptophan to the ferrous enzyme is more favorable or 
similar to the binding of dioxygen. This suggests that initial 
substrate binding may be favored over dioxygen binding 
by IDO, similar to that for TDO. 
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Catalytic mechanism 
The catalytic mechanisms employed by this family of 
enzymes are poorly understood, and little characterization 
of reactive intermediates has been reported. The mechanism 
employed by TDO and IDO for binding and transferring 
dioxygen appears to be very different to that of other heme 
proteins such as hemoglobin and to nonheme dioxygenases 
such as catechol 3,4-dioxygenase. 
The proposed catalytic cycle of tryptophan oxidation 
by TDO and IDO is schematically illustrated in Figure 8. 
Under physiological conditions, the enzymes are likely to 
be in the active ferrous form due to the high reduction 
potential of the heme. Binding of L-tryptophan and oxygen 
to the active site to form the ternary complex (2) is thought, 
in the case of TDO, to occur by substrate binding to form 
the enzyme adduct (1), followed by the binding of dioxygen. 
As described above, formation of the ternary species for 
IDO is more complex. 
In the enzyme active site, 02  coordinates to the ferrous 
heme iron to form the heme-02 complex. This activates 
triplet 02  and allows the otherwise spin-forbidden reaction 
to proceed. Catalysis can then proceed via an ionic or 
radical mechanism, both of which can be shown to undergo 
the same choice of intermediates in product formation. The 
ionic mechanism may be more likely because the radical 
mechanism is thermodynamically unfavorable,56 requiring 
the one-electron oxidation of L-tryptophan; only the ionic 
mechanism is shown in Figure 8. 
In the proposed mechanism, catalysis proceeds via the 
formation of a hydroperoxide intermediate (3) and (6) in 
which addition of 02  to the C3 position of the substrate 
occurs prior to 0-0 bond cleavage. Some studies have 
proposed that this addition could be base catalyzed by 
the loss of the indole proton. This may be possible for 
TDO, which has a histidine residue in the active site 
(Figure 4), although mutation of this histidine residue to 
alanine leads to only a 10-fold loss in kcat3  IDO has no side 
chain available to act as a catalytic base. Figure 8 displays 
a nonbase catalyzed mechanism. Proton abstraction by 
the iron-bound dioxygen is therefore proposed for IDa, 
where the interaction of the indole NH group with the 
proximal oxygen atom weakens the oxygen—oxygen bond. 
It is unclear which route is employed in TDO, but the 
structure of TDO suggests that a precise alignment between 
the indole ring of the substrate and the bound dioxygen is 
necessary for catalysis. This is facilitated by the hydrogen-
bonding interaction with HisSS, and this residue appears 
to play an important role in the active site. Resonance 
Raman data have suggested a clear distinction between the 
mechanisms employed for proton abstraction by IDO and 
TDO. 12 
The hydroperoxide intermediate may undergo one of 
two pathways to form the product. The Criegee rear-
rangement requires an antiperiplanar arrangement of the 
0-0 bond and the indole C2—C3 bond to form an  
intermediate (4), which further rearranges to form the 
product N-formylkynurenine (8). The dioxetane mecha-
nism requires a sin-coplanar configuration of intermediate 
(7), which then undergoes a retro [2 + 2] cycloaddition to 
form the product. The dioxetane mechanism is thought 
to be less favorable owing to the excess endothermicity 
involved in forming the strained dioxetane intermediate 
and the exothermicity of its decomposition to form the 
product. 57 
It is thought that the proximal histidine ligand may play 
a role in determining the bond order of the iron—dioxygen 
(Fe-00) and oxygen—oxygen (FeO-0) bonds. 12  This may 
be important for electron rearrangement in the transition 
state of both IDO and TDO, but the precise nature of 
the mechanisms employed by IDO and TDO needs to be 
further investigated. 
Oxidation/reduction potentials 
Electrochemical midpoint reduction potentials are shown 
in Table 6. Few reduction potentials for either IDO or 
TDO have so far been reported, but those available show 
clear trends. Upon binding of the substrate, there is an 
increase in reduction potential for both IDO and TDO, 
reflecting additional stabilization of the ferrous derivative. 
The increase is larger for TDO proteins (with the exception 
of human TDO), compared to IDO proteins, and the 
shift in reduction potential for X. campestris TDO is 
supported by the almost perfect correlation with the 
increase in affinity for L-tryptophan upon its reduction. 
For both IDO and TDO, it is not clear whether heme 
reduction precedes substrate binding or vice versa, but a 
thermodynamic stabilization of the reduced form would 
clearly favor reduction prior to substrate binding. The 
large positive change in the reduction potential for both 
enzymes suggests that there is a significant stabilization of 
the ferrous form when substrate is bound. This stabilization 
could also play a physiological role in keeping the 
proteins reduced, and therefore active, when L-tryptophan 
is present. 
Allostery 
The recent crystal structure of X. cam pestris TDO showed 
the specific binding of four L-tryptophan residues in the 
interface of the tetramer, as shown in Figure 7. These 
additional binding sites raise the possibility that these 
may be possible allosteric effector sites, where binding of 
substrate changes the conformation of the protein, affecting 
the binding of further molecules. 
When L-tryptophan is bound to TDO, there is an 
apparent activation toward binding of diatomic ligands, 
such as oxygen, carbon monoxide, and nitric oxide, 
as evidenced by dramatically decreased Kd  values.47 In 
addition, there is an increased affinity for oxygen in the 
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Figure 8 Proposed catalytic mechanisms of IDO and TDO. The figure displays ionic, nonbase catalyzed mechanisms of L-tryptophan 
dioxygenation. First, substrate binds to the protein (1), followed by dioxygen binding to form the ternary complex (2). The mechanism 
proceeds by the formation of a hydroperoxide intermediate (3) and (6), which can undergo two different rearrangements to form the 
product, N-formylkynurenine (8), a Criegee rearrangement (4), and (5) or a dioxetane rearrangement (7). The product is then released, 
leaving the protein in the active ferrous state. 
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9 TK Littlejohn, 0 Takikawa, RJW Truscott and MJ Walker, J Biol 
Protein 	Substrate-free Substrate- bounda AEmd Chem, 278, 29525-31 (2003). 
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Abstract 
The haem proteins IDO (tryptophan 2,3-dioxygenase) and IDO (indolearnine 2,3-dioxygenase) are specific 
and powerful oxidation catalysts that insert one molecule of dioxygen into i-tryptophan in the first and rate-
limiting step in the kynurenine pathway. Recent crystallographic and biochemical analyses of TOO and IDO 
have greatly aided our understanding of the mechanisms employed by these enzymes in the binding and 
activation of dioxygen and tryptophan. In the present paper, we briefly discuss the function, structure 
and possible catalytic mechanism of these enzymes. 
Introduction 
Haem-containing proteins have a wide variety of functions 
ranging from oxygen transport, storage and activation to 
simple single-electron transfers. TDO (tryptophan 2,3-
dioxygenase) and IDO (indoleaniine 2,3-dioxygenase) are 
members of a small family of haem enzymes that catalyse the 
aerobic metabolism of L-tryptophan to N-formylkynurenine. 
TDO was initially discovered in the 1930s and is found in 
both eukaryotes and prokaryotes [1]. TDO expression is 
normally restricted to the liver in mammals, although it has 
been identified in the brain and epididymis of some species 
[2,3]. IDO was first isolated from rabbit intestine in 1967 
[4], and is found in many eukaryotes where it is expressed 
ubiquitously throughout the body, except in the liver. Some 
prokaryotic IDO-like proteins from Shewanella species have 
been identified [5], but to date these have no known function. 
Sequence similarity between family members is low, with 
amino acid sequence alignment indicating an identity of 
approx. 10% between family members. Homology is only 
apparent from their three-dimensional structures and the 
conservation of certain amino acids in their active sites. 
Why are TOO and 100 of interest? 
A vital biochemical reaction 
TDO and IDO activate molecular oxygen and catalyse its 
insertion into L-tryptophan to form N-formylkynurenine, in 
the first and rate-limiting step in the kynurenine pathway 
[6]. The kynurcriine pathway processes over 90% of L-tryp-
tophan utilized by humans. Although both enzymes 
catalyse the same reaction, TDO is highly substrate-specific, 
only dioxygenating L-tryptophan and some tryptophan 
Key words haem, iridoleamirie 2,3-dioxyçenase, kynurenine, oxygen, tryptophan 2,3-
dioxygenuse. 
Abbreviations used DO, indotearnine 2,3-dioxygenase; TOO, Horno sapiens 100, TDO, 
tryptophan 23-dioxygenase; IInTOO, Ralston/a metollidurons TOO; xcTDO, Xonthomonas 
compestrrs TOO. 
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derivatives substituted in the 5- and 6-positions. IDO 
displays wider substrate specificity, catalysing the dioxygen-
ation of D-tryptophan, tryptamine and 5-hydroxytryptamine 
(serotonin) in addition to those substrates dioxygenated by 
TDO [7]. 
Tryptophan regulation 
Both TDO and IDO play a central role in the regulation of 
tryptophan in the human body, controlling the kynurenine 
pathway and influencing serotogenic regulation [8]. IDO 
and TDO activity alters local tryptophan concentra-
tion and the build-up of pathway metabolites can lead to 
numerous physiological and pathophysiological conditions. 
These include cataract formation, AIDS-related dementia 
and ischaemic brain injury [6,8-10]. In addition, the local 
depletion of tryptophan by IDO or TDO is associated 
with an antimicrobial response. Some pathogens are sensitive 
to tryptophan degradation, and this may be an effective 
mechanism for controlling their ability to proliferate [II]. 
Immune regulation 
Although both enzymes catalyse the same reaction, compart-
mentalization of IDO and TDO expression is thought to 
reflect their differing biological roles. IDO plays an active 
role in the human body's immune response, but there is 
little evidence to suggest that TDO plays a part in this 
process. Immune regulation by IDO is extremely complex, 
but two major roles have become evident [12,13]. First, 
IDO is a normal effector of peripheral tolerance in the 
immunoregulatory pathway of tryptophan metabolism. It 
helps to create an appropriate immune response, influenc-
ing the balance between tolerance and attack. Secondly, it 
is thought to play an essential role in acquired immune 
tolerance. IDO helps tumours to induce tolerance from 
the host's immune system by interacting with T-cells and 
depleting L-tryptophan levels [13], and it has consequently 
emerged as an attractive drug target in cancer and transplant 
treatments. 
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Figure 11 Structures of (a) xcTDO and (b) hIDO 
(a) Structure of xcWO. r-Iryptophan is shown in red, haem is grey, and separate monomers are shown in cyan, magenta, 
grey and blue. (b) Structure of hIDO. Haem is shown in grey, the smaller N-terminal domain is shown in grey, and the larger 
C-terminal domain is shown in marine. 
TOO and IDO structures? 
Overall structure 
Recent crystallographic studies of xcTDO (Xanthomonas 
campestris TDO) [5], rmTDO (Raistonia metallidurans 
TDO) [14] and hIDO (Homo sapiens IDO) [15] have aided 
our understanding of this family of haem enzymes. The 
crystal structures of xcTDO and rmTDO are essentially 
identical, sharing 47% sequence identity; and are intimately 
associated homotetrameric enzymes (Figure Ia). They are 
perhaps best described as a dimer of dimers because the N-
terminal residues of each monomer form part of the substrate-
binding site in an adjacent monomer. The N-terminal region 
lies above the distal face of the haem, providing part of 
the binding cavity. The proteins are completely helical, and 
a flexible loop (comprising residues 250-260 of xcTDO), 
involved in L-tryptophan binding, is observed just outside 
the haem pocket. This loop is only ordered in crystals grown 
in the presence of L-tryptophan, as substrate binding  appears 
to induce its ordering. 
IDO is a monomeric protein, folded into two distinct do-
mains: a large (C-terminal) domain and a small (N-terminal) 
capping domain (Figure Ib). Contact between these domains 
is extensive, and they are joined by a long loop. The larger 
domain is essentially topologically identical with a monomer 
of TDO, and the structures are readily superposable [5,14,15]. 
The loop region connecting the two domains provides similar 
interactions in the active site to those provided by the N-
terminal arm of TDO, forming part of the active-site cavity. 
A flexible loop exists just outside the haem pocket, like 
that of TDO, but is not fully resolved crystallographically, 
probably due to the lack of bound substrate in the active 
site. 
Active-site environment 
TDO and IDO are b-type haem proteins with histidine 
occupying the axial co-ordination position to the haem iron. 
The only structure available with substrate bound at the 
active site in the catalytically active ferrous state is xcTDO. 
The structure clearly shows the important substrate-binding 
interactions in the active site. The active-site pockets of 
xcTDO with and without L-tryptophan bound and that of 
hIDO are shown in Figure 2. Owing to high similarity 
between the active sites of TDO and IDO, it is reasonable to 
assume a similar substrate-binding mode in IDO. Interactions 
of the substrate with the active site can be split into two cat-
egories: interactions with the carboxy and ammonium groups 
of L-tryptophan, and those with the indole ring system. 
In the structure of xcTDO, the carboxy group of L-
tryptophan interacts with Arg"7, Tyr"' and Thr254. Amino 
acid residues equivalent to Arg117 and Tyr113 are found in 
nearly all TDO and IDO proteins. This carboxy-binding 
motif appears to be essential for substrate binding; arginine 
reorients in the presence of substrate, co-ordinating the 
carboxy group of L-tryptophan with both 'open' and 'closed' 
conformations observed (Figures 2a and 2b). The closed con-
formation is only observed in TDO crystals grown in the 
presence of L-tryptophan. The substrate ammonium group 
is hydrogen-bonded to the side-chain hydroxy group of 
Thr254, the 7-propionate group of the haem, and a water 
molecule. Thr254 is involved in binding both the ammonium 
and carboxy moieties of L-tryptophan and is part of the 
flexible loop, just outside the haem pocket. 
The substrate indole ring binds into a hydrophobic pocket, 
where it interacts with the side chain of Phe5' and several 
other hydrophobic residues, including Tyr 14  and Tyr" from 
the adjacent monomer. Both of these tyrosine residues 
the Authors Journal compilation '2008 Biochemical Society 
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Figure 2 1 Active-site residues of xcTDO and hIDO 
Active-site residues of (a) substrate-free xcTDO, (b) r-tryptophan-bound xcJDO, with t-tryptophan shown in red, and 
(C) hIDO, with 4-phenylimidazole (shown in red) bound. 
(b) xcTDO 	
E59 	
(c) IDO 	E171 




Figure 3 1 Proposed catalytic mechanism of IDO and TDO 
Initial formation of the ternary complex (1) occurs by substrate binding to the ferrous protein, followed by dioxyqen binding. 
The ternary complex activates O and catalysis proceeds via the formation of a hydroperoxide intermediate (2 and 5) that 
undergoes either a Criepee or a dioxetane rearrangement to form the product N-formylkynurenine (7). 
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are hydrogen-bonded to a glutamate residue, linking the 
N-terminal loop of the adjacent monomer to the active site, 
and this Tyr-Glu motif is conserved throughout TDO and 
IDO proteins. 
Perhaps the most obvious difference between the active 
sites of TDO and IDO is the presence of His" in xcTDO 
and its equivalent, Ser'67 in hIDO (Figure 2). In TDO, the 
histidine side chain is hydrogen-bonded with the NH group 
of the indole ring of L-tryptophan, and a role for His" would 
appear to be in regulating substrate binding. In comparison, 
Ser167 in IDO is incapable of forming this bond, and it appears 
unlikely that this residue plays any critical role in substrate 
binding  or catalysis by IDO. 
What is the catalytic mechanism? 
Substrate binding 
The proposed catalytic mechanism employed by this family 
of enzymes is shown in Figure 3. It is thought that the ferrous 
0Th. Authors journal compilation 02008 Biochemical Society 
enzyme is required for catalytic activity and, upon substrate 
binding, there is an increase in the electrochemical midpoint 
potential for both TDO and IDO. This shift in the reduc-
tion potential reflects additional stabilization of the ferrous 
form.Such a thermodynamic stabilization of the reduced form 
would clearly favour reduction before substrate binding 
[5,16-18]. A recent study has suggested that cytochrome b5 
is the electron transfer partner for IDO, providing ferrous 
active protein in vivo, consistent with these results. 
For TDO, the initial formation of the ternary complex 
(Figure 3, 1) occurs by substrate binding followed by 
dioxygen binding to the ferrous protein. For IDO, the order 
of binding events is more complex, but the ternary complex 
must still be formed before the reaction can proceed. The 
ternary complex activates 02 and allows the otherwise spin-
forbidden reaction to proceed. 
Formation of the hydroperoxide intermediate 
It has been proposed that formation of the hydroperoxide 
intermediate (Figure 3, 2 and 5) is catalysed by the loss 
Transition Metals in Biochemistry 	 1123 
of the indole proton. Two mechanisms are thought to be 
probable: base-catalysed deprotonation or proton abstraction 
by bound dioxygen [7]. If the substrate-binding mode 
in IDO is similar to that seen in xcTDO, proton 
abstraction by a proteinaceous base is only possible in 
TDO, with the active-site histidine (His" in xcTDO) 
being the only basic residue in the active site of either 
enzyme (Figure 2). However, catalytic activity is main-
tained upon substitution of alanine for Hi S55  in xcTDO, 
suggesting that base-catalysed deprotonation may not be 
essential for enzymatic activity [5]. Catalysis by the iron-
bound dioxygen is generally proposed for IDO in the absence 
of a base, and seems reasonable from modelling simulations. 
Rearrangement of the hydroperoxide 
intermediate 
The rearrangement of the hydroperoxide intermediate to 
form the product could occur via either a Criegee or a 
dioxetane intermediate [7]. Little biochemical information 
currently exists to discriminate between these two differ-
ing pathways, and all discussion has been based on 
thermodynamic considerations and computer modelling 
simulations [7,14]. Thermodynamic considerations indicate 
that formation of the highly strained dioxetane intermediate 
and its high exothermicity of decomposition make this an 
unlikely route to be employed by an enzyme. In addition, 
no chemiluminescence has been detected on decomposition 
of the dioxetane. These data alone support the Criegee 
rearrangement for both IDO and TDO. However, further 
investigation is necessary to determine the nature of this 
rearrangement. 
Conclusion 
Recent crystallographic and biochemical analyses of TDO 
and IDO have aided our understanding of the mechanisms 
employed for binding and activating dioxygen by allowing 
identification of key active-site residues. Analysis of the 
active-site pockets of TDO and IDO shows that there are dif-
ferences in the choice of residues employed in catalysis. How-
ever, how these changes have an impact on the catalytic 
mechanism and reaction intermediates employed by these 
enzymes is still unclear. Recent studies have led to possible 
future routes of investigation. These include: substitution 
of newly identified key active-site residues to identify their 
roles in catalysis; EPR and ENDOR (electron nuclear double 
resonance) studies of reaction intermediates, and computer 
modelling simulations. 
Note added in proof (received 
23 September 2008) 
In a recent article by Chung et al. [19], density functional 
theory calculations on the catalytic mechanism of TDO 
and IDO have cast doubt on the relevance of the Criegee 
mechanism and raised the possibility of a radical addition 
pathway. 
We thank the Wellcome Trust for financial support. 
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Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- 
dioxygenase (TDO) are heme enzymes that catalyse oxidation 
of L-tryptophan to N-formyl-kynurenine (Scheme I ),'' in a 
mechanism that involves binding of dioxygen to reduced iron. 
The mechanistic details of this oxidation are not yet known, 
but early studies' suggested base-catalysed deprotonation of 
the indole NH group (Scheme 2A). This was based largely on 
the observation that I -methyl-L-tryptophan (I -Me-L-Trp) is an 
inhibitor of dioxygenase activity, and was plausible since 
base-catalysed abstraction is not possible with the methylated 
compound. There are problems with this mechanism, 
however. To begin with, it is inconsistent with the chemistry 
of indoles,4 which typically react by electrophilic addition 
across the C3 position and subsequent formation of a cation at 
Ni . In addition, the structure of human IDO (hIDO)' reveals 
that there is no active-site base close enough for proton 
abstraction at N1. The only polar active site residue is Ser167, 
but this is not essential for activity.56 Although X campestris 
TDO (XcTDO) does contain an active site histidine (His55, 
equivalent to Seri 67 in hIDO)7 which hydrogen bonds to the 
indole N1 , it is not essential for activity.7'5 Together, this led to 
the hypothesis"7 that the bound dioxygen might act as the 
active-site base (Scheme 213), with no involvement from 
active site residues. 
Here, we examine the activity of three heme dioxygenases 
(hIDO. human TDO (hTDO) and XcTD09) with I -Me-L-Trp, 
including a number of site-directed variants focused on the 
His55/Ser167 location. In contrast to previous work,'° we find 
that 1-Me-L-Trp is a slow substrate. These observations are 
inconsistent with current proposals for the mechanism of 
substrate oxidation, and we propose an alternative. 
Sch.m. 1. R clion cataysed by IDO and TOO. 
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To determine if the purified enzymes could utilize I-Me-L-
Trp as a substrate, identification of the methylated product 
was essential.' 1,12 Formation of N-formyl-kynurenine and N-
formyl-methylkynurenine was confirmed at 321 nm (Figure 
S2, solid and dashed line, respectively). The reaction with 1-
Me-L-Trp was repeated in the absence of enzyme (Figure S2, 
dotted line) and no absorbance change at 321 nm was 
observed, confirming that product formation is from 
enzymatic oxidation. LC-MS analysis using selected ion 
monitoring (shown for hIDO, Figure IA) was then carried out. 
For the reaction with L-Trp, this gave an ion with m/z = 237 
(Figure 113, top) which corresponds to the mass of N-formyl- 
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kynurenine (m/z = 236); for the reaction with l-Me-L-Trp, an 
equivalent ion is detected at m/z = 251 (Figure IB, bottom) as 
expected for N-formyl-methylkynurenine (m/z = 250). 
Steady-state kinetic parameters for the oxidation of I -Me-i.-
Trp were also determined .6.1 (Figure S3 and Table 1).13 Clear 
increases in absorbance, corresponding to product formation, 
are observed for hIDO (Figure S3), as well as for the S167A 
variant of hIDO and variants of both hTDO and XcTDO 
(Table J)l3 
These data clearly indicate that formation of N-formyl-
methylkynurenine occurs upon reaction of l-Me-L-Trp with 
hIDO and variants of hIDO, hTDO and XcTDO. However, no 
activity was detected for hTDO and XcTDO with 1 -Me-L-Trp 
in either steady-state or LC-MS analyses. The structure of 
XcTD07 reveals a hydrogen bond (2.6 A) between the indole 
NH of L-Trp and His55, which would be expected to lead to a 
steric clash between His55 and the methyl group of 1-Me-L-
Trp. Indeed, a model of l-Me..L-Trp binding to XcTDO 
(Figure S4) shows a non-bonding distance of -1.5 A between 
the N of His55 and the carbon atom of the Me group on 1-
Me-L-Trp. We propose that binding of I -Me-L-Trp to XcTDO 
is weak as a consequence. Sequence alignments7 indicate that 
hTDO also contains a histidine (His76) in the same position 
(in fact this histidine residue is conserved in all TDOs), so that 
the same steric restrictions apply and thus explain the 
observed inactivity. Substitution of histidine in XcTDO 
(H55A, H55S) and hTDO (H76S) allows accommodation of 
Table 1. Steady-state parameters 	KM) for oxidation of 
I -Me-L-Trp. 
	
Variant 	k,,., (s') 	KM(IIM) 
hIDO 	native 0.027 ± 0.001 150 ± 11 
S167A 0.032±0.002 31±5.0 
native 
hTDO H76S 0.023±0.001 2300±230 
native 	- 
XcTDO H55A 0.048±0.011 59±16 
S 0.052 0.009 	70±11 
the additional methyl group and turnover of 1-Me-L-Trp 
occurs (Table 1). This hypothesis is further supported by the 
fact that hIDO and S167A, which are both able to 
accommodate the bulky Me group in their active sites, are also 
able to oxidise l-Me-L-Trp (Table I). 
Overall, turnover numbers for I -Me-L-Trp are lower than 
for L-Trp.6'5"4 When X=Me (Scheme 2D). the inductive effect 
of the Me group would presumably stabilise the cation 
intermediate. This would not be expected to slow down the 
electrophilic attack but might affect other steps in the 
mechanism that our experiments do not address. A completely 
different binding location/orientation for l-Me-L-Trp (and 
therefore a diffi3rent mechanism) is also possible, but this is 
not supported by inhibition data (Table S  and '°) which show 
I -Me-I. -Trp as a competitive inhibitor for L-Trp. 
Scheme 2. Possible mechanisms for oxidation of Trp (Cu, C. and N, of the substrate are labelled). 
(A) Abstraction of the indole proton by an active site base.vrs (B) Abstraction of the indole proton by 
the hems-bound dioxygen." (C) Direct electrophilic addition. (0) A revised mechanism for product 
formation in hems dioxygenases, where X=H or Me. The conversion to product is proposed to occur 
either by a Cnegee or a dioxetane medlanrem.' 
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Since hIDO and variants of both hTDO and XcTDO can 
oxidise I -Me-L-Trp, deprotonation of the indole NH cannot be 
essential for catalysis. Mechanisms involving abstraction of 
the 	indole proton, either using an active site base 3,15 or 
dioxygen''6 (Schemes 2A. B), are therefore unlikely as they 
cannot proceed with a Me group on N,. 
The chemistry of indoles is very well documented  and does 
not occur by loss of the indole proton. Instead, when an indole 
reacts with an electrophile (e.g. 02) the lone pair on N, 
initiates the process (Scheme 2C) and the electrophile 
becomes attached preferentially at C3 (Scheme 2D).17 We 
propose this as a more likely mechanism for tryptophan 
oxidation in the heme dioxygenases, allowing both L-Trp and 
I -Me-L-Trp to react (Scheme 2D), with the role of the iron 
merely as a donor of the required oxygen molecule. This 
mechanism is compatible with the absence of an active site 
base in IDO, and avoids the need to deprotonate an N, atom 
with a PKa (w17'8) that is out of range.'8 In addition, a recent 
density functional theory study' 9 found that direct electrophilic 
addition has a lower activation energy than a base-catalysed 
deprotonation mechanism, consistent with our observations. 
In conclusion, we report that l-Me-L-Trp is a substrate for 
hDo and variants of hTDO and XcTDO in which the active 
site histidine has been replaced. This shows that deprotonation 
of the indole N, is not essential for catalysis and we propose 
that direct electrophilic addition to dioxygen, facilitated by the 
lone pair on the indole N,, occurs instead. 
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